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INTRODUCTION
Après son administration dans l'organisme tout principe actif est soumis à une multitude de processus
complexes qui vont déterminer sa biodistribution et par conséquent non seulement son efficacité mais
aussi les éventuels effets indésirables et sa toxicité. L’amélioration de l’efficacité des molécules
actives peut être recherchée tant par la voie de la pharmaco-modulation que par celle de la
vectorisation, en les associant à des vecteurs capables de modifier leur distribution et d’améliorer leur
efficacité tout en diminuant leurs effets secondaires. C' est une idée déjà ancienne, proposée il y a plus
de 100 ans par le prix Nobel Paul Ehrlich qui proposa de « cibler » de manière spécifique les cellules
tumorales ou les organismes provocant des maladies. Cette stratégie a donc pour ambition de
restreindre l’effet thérapeutique à un organe ou des cellules pathologiques, c'est-à-dire une
modification de la biodistribution naturelle de la molécule, ce qui permettrait en théorie une
diminution des doses administrées ainsi qu’une réduction des effets secondaires.
Le présent travail s’inscrit pleinement dans le champ de la nanomédecine, un domaine dans lequel on
désire mettre en jeu, à l’échelle nanométrique, des phénomènes variés entre un objet artificiel et
l’organisme d’un patient. Plus précisément, ce travail a consisté à concevoir, préparer et caractériser
des nanoparticules polymères possédant un tropisme pour les tissus osseux, en vue d’améliorer la
distribution des molécules actives vers ces tissus.
Cet objectif nécessite d’être capable de conférer simultanément aux nanoparticules de nombreuses
fonctionnalités différentes, capables d’aider les particules dans leur progression vers leur cible, depuis
leur point d’administration. Dans ce cadre, lors de thèses entreprises au sein de notre équipe [1-3] il a
été montré qu'il était possible de préparer des nanoparticules multifonctionnelles en mélangeant en
proportions variables des polymères dérivés du poly (glutamate de benzyle) et portant différentes
fonctionnalités. De façon intéressante, il a été montré que les propriétés de surface de ces
nanoparticules pouvaient être aisément modulées. En effet, la maîtrise des propriétés de surfaces de
Introduction Générale
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ces particules est indispensable puisque c’est elle qui va induire ou non les phénomènes d’interactions
avec les composants du milieu biologique et qui sont souhaités ou non selon leur nature.
Dans ce contexte, l'objectif de ce travail de recherche a été le développement de nanoparticules
multifonctionnelles polymères préparées à partir de dérivés du poly (glutamate de benzyle) (PBLG)
possédant des propriétés de ciblage des tissus osseux de manière à pouvoir les immobiliser de manière
suffisamment longue et d'assurer la délivrance d’un principe actif qui leur est associé dans les tissus
osseux, de façon contrôlée dans le temps. De cette manière, ces nanoparticules pourraient constituer
des réservoirs de principe actif intéressants en vue d’améliorer le traitement de diverses maladies du
squelette.
Dans ce but, une mini-librairie de copolymères dérivés du PBLG et portant différentes
fonctionnalités a été synthétisée. Ces copolymères, mélangés dans des proportions différentes ont
montré des propriétés d'auto-assemblage pour former des nanoparticules de petite taille, typiquement
inférieures à 80 nm et présentant une morphologie souvent ellipsoïdale. Leurs propriétés d'attachement
aux tissus osseux, conférées par la présentation en surface de différents ligands ostéotropes
(biphosphonates, acide poly(glutamique), ont été évaluées in vitro en utilisant l'hydroxyapatite comme
modèle, puis ex vivo et in vivo.
Le traitement des métastases osseuses a été identifié comme une possible application de ces
nanoparticules ciblées aux tissus osseux. De nombreux cancers ont une forte tendance à métastaser
dans l'os ce qui induit des problèmes majeurs de santé publique, notamment dans le cancer du sein et
de la prostate, en raison de leur incidence élevée. Différentes stratégies ont donc été étudiées visant à
associer à ces nanoparticules des molécules anticancéreuses et à leur conférer ainsi des propriétés
anticancéreuses. Parmi celles étudiées, la complexation du cisplatine aux groupements carboxylates de
nanoparticules formées à partir du copolymère PBLG-PGlu a été retenue puisque de cette manière la
libération du cisplatine peut être contrôlée très efficacement dans le temps, avec une cinétique de
Introduction Générale
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libération compatible avec la stratégie envisagée, où les nanoparticules ciblées aux tissus osseux
constituent réellement des réservoirs de principe actif une fois arrivées à leur cible.
Le travail de thèse présenté se décompose en plusieurs chapitres. Un premier chapitre bibliographique
a tout d’abord été consacré à une revue des différentes stratégies imaginées pour concevoir et préparer
des systèmes d’administration doués d’un tropisme pour l’os. Ce chapitre, qui comprend une
présentation de l’anatomie et de la physiologie osseuse, a pour ambition de déterminer les barrières
actuellement identifiées et que les nanoparticules envisagées devront donc franchir pour rejoindre les
tissus osseux. Une revue des différents systèmes d’administration proposés, particulièrement axée sur
les vecteurs nanoparticules termine cette partie.
Le deuxième chapitre est ainsi consacré à la préparation de nanoparticules décorées avec des
molécules d'alendronate, qui sont des molécules possédant des propriétés osteotropiques et qui sont
utilisées largement dans la thérapeutique de maladies osseuses. L'interaction de ces nanoparticules
avec l'hydroxyapatite et les ions calcium divalents, qui sont en grande partie les responsables de
l'interaction alendronate-hydroxyapatite, a été comparée.
Le troisième chapitre, décrit la préparation de nanoparticules décorées avec le poly(acide glutamique).
Ce ligand confère aux nanoparticules de façon simultanée des propriétés d'attachement à l'os et
d’encapsulation et de contrôle de la libération du cisplatine  grâce à la capacité des groupements
carboxylate de former de complexes réversibles avec le cisplatine. Les propriétés d'interaction,
d’association et de libération du cisplatine ainsi que le maintien d’un effet cytotoxique ont été
explorés.
Le quatrième chapitre est axé sur la mise au point de nanoparticules multifonctionnelles décorées
simultanément avec des chaînes de poly(acide glutamique) et de poly(éthylène glycol). De manière
originale, une technique d'électrochimie a été utilisée comme un outil novateur et complémentaire à
Introduction Générale
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d'autres techniques pour le suivi des différents processus impliquant les nanoparticules chargées en
cisplatine.
Le cinquième chapitre de la thèse présente différents types de nanoparticules multifonctionnelles et
fluorescentes, possédant des propriétés d'attachement aux tissus osseux grâce à leur décoration à l'aide
de l'alendronate ou bien du poly(acide glutamique), ou encore d'une combinaison de deux. La
modulation des propriétés de surface des nanoparticules préparées par une méthode de
nanoprécipitation et plus particulièrement leur capacité d'attachement à l'hydroxyapatite, a été
démontrée uniquement lorsque les particules portent un ligand osteotrope. De plus, leur capacité à
atteindre les tissus minéralisés a été étudiée in vivo par des techniques d'histologie.
Enfin, une discussion générale reprend ces résultats expérimentaux afin de les présenter de manière
synthétique et aussi de façon à les mettre en perspective avec des travaux décrits dans la littérature.
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Résumé
Les maladies squelettiques sont devenus de plus en plus répandues principalement en raison du
vieillissement de la population. Elles sont caractérisées par une morbidité très élevée, impliquant des
complications métaboliques invalidantes et dont la prise en charge est coûteuse. La vectorisation de
principes actifs aux tissus osseux constitue une stratégie prometteuse dans l’objectif d’obtenir des
traitements tout à la fois plus efficaces et dont les effets secondaires seraient moindres.
L'hydroxyapatite, composant très spécifique de l'os, constitue une cible très spécifique pour la
conception de vecteurs nanoparticulaires doués d’un tropisme osseux. Cette revue bibliographique
présente une approche rationnelle de la conception de vecteurs nanoparticulaires en considérant les
barrières biologiques à franchir pour atteindre leur cible et la manière dont les propriétés physico-
chimiques des nanoparticules peuvent être ajustées de manière à favoriser leur franchissement. Enfin,
l’état de la littérature dans le domaine de cette stratégie émergeante est présentée.
Abstract
Skeletal diseases are becoming increasingly important in nowadays society, due mainly to the aging of
the population and are characterised by a high morbidity involving metabolic complications, which
may be quite invalidating for patients and would require costly treatments. The need for safer and
more effective bone therapeutics is thus of major importance. In this way, targeting drugs to bone
would increase therapeutic efficacy while decreasing side effects. In view of bone targeting,
hydroxyapatite, a very specific component to bone, offers a highly specific target to be exploited by
Chapitre I: Bone targeted nanoparticle therapeutics
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nanomedicine. This review deals with a rational approach for bone targeted nanoparticles and discuss
their physicochemical requirements and their relationships with in vivo biological barriers that they
have to overcome from the site of delivery to bone tissues. Finally a review of the scarce literature of
this emerging approach is presented.
Keywords: nanoparticles, bone-targeting, drug-delivery, multivalency, hydroxyapatite, skeletal
diseases.
1- Introduction
Bone diseases such as osteoporosis, Paget's disease, osteopenia, osteogenesis imperfecta or bone
cancer constitute a major public health problem in our society. They are characterised by a high
morbidity involving metabolic complications, pain or fractures. Besides and due primarily to the aging
of the population, age-related bone diseases are to increase: in 2020: more than half of Americans over
50 years old are expected to risk or to actually develop osteoporosis in any part of the skeleton [1].
Moreover, the skeleton is the most common organ for cancers to metastasize, breast and prostate
cancers having the highest incidence of bone metastasis, with 73% and 68% of bone metastases found
respectively at post-mortem studies followed by thyroid and lung cancers [2].
Nanotechnology offers a unique strategy for the development of more effective and safer treatments.
Nanomedicine has revealed a promising approach, more than thirty nanotechnology based products
have been approved by the Food and Drug Administration (FDA) [3]. Nanoparticles offer many
advantages such as improved drug solubility, longer half-life pharmacokinetics, more specific drug
biodistribution or controlled release of the drug. Active targeted nanoparticles involves the specific
drug delivery into a diseased tissue or cell. This will result in safer treatments, with lower therapeutic
dose and less sides effects, derived from the pharmacological action of the drug at other sites. Bone
diseases could benefit from the nanotechnological approach for improved therapeutics.
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Several drug carriers have been designed to target bone tissue as shown in figure 1: drug-conjugates,
polymeric conjugates and nanoparticles. This review will focus on the targeting of bone tissue via the
approach of bone targeted nanoparticles, discussing important characteristics that will determine
optimal targeting and in vivo fate. Drug conjugates and polymeric conjugates are beyond the scope of
this review.
2- Bone targeting systems: approach via bone targeted nanoparticles
Different strategies have been conceived for improving drug delivery to bones as shown in figure 1.
Bone targeting moiety-drug conjugates consist of the chemical coupling between a bone seeking agent
and a therapeutic drug. and they have been extensively reviewed elsewhere [5-7]. As pointed out in
Hirabayashi's review, some of them are under preclinical research. A particular issue is the delivery of
proteins to bone, by chemical conjugation via a spacer to a bone targeting which has been extensively
developed by the group of Uludag [8, 9]. Bone targeted polymer-drug conjugates consist on the
conjugation of drugs and diagnostic tools to a water soluble polymeric backbone. This strategy has
been extensively developed by Kopecek et al. [7, 10]. As pointed out , all this strategies has been
extensively previously reviewed and they are therefore out of the scope of this review.
The bone targeted nanoparticle approach constitutes the scope of this review and it consists of the
building up of nano objects such as micelles or nanoparticles. They can be formed by different
materials depending on the type of nanoparticles. As shown in figure 1, they should bear different
functionalities including a shielding protective layer which is usually formed by the flexible and
hydrophilic poly(ethylene glycol) (PEG) chains. This functionality is mandatory for preventing
premature removal of the nanoparticles by the immune system and favouring long circulating systems
that would allow nanoparticles to attain their target in larger amounts. The bone targeting moiety
should be situated at the surface of nanoparticles, so as to be able to display its targeting efficiency.
The therapeutic drug is usually protected inside nanoparticles and an imaging agent can be associated
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to the nanoparticles. Methods to fabricate multifunctional targeted nanoparticles are beyond the
interest of this review and have been reviewed elsewhere [4].
Figure 1: Bone targeted drug delivery systems
3- The targeted organ: introduction to bone anatomy and physiology
3.1- Bone
Bone is a highly specialized connective tissue that provides all higher vertebrates with an internal
mechanical support thanks to its mineralized extracellular matrix. It is also involved in the
homeostasis of calcium and other ions. Bone is composed of 50-70% mineralized matrix, 20-40%
organic matrix, 5-10% water and 5% of lipids. The organic matrix, is mainly constituted of (~85-90%)
type I collagen and also other collagenous proteins and non collagenous proteins (~10 %), such as
albumin or α2-HS-glycoprotein. The mineralized matrix is mainly constituted by hydroxyapatite
(HAP), Ca10(PO4)6(OH)2, which provides the skeleton with rigidity and strength, maintaining at the
same time a certain degree of elasticity. Morphologically, bone can be cortical and trabecular or
cancellous, whose ratios changes depending on the type of bones. Cortical bone is dense, has an outer
periosteal surface and an inner endosteal surface that surrounds the marrow space. It is formed by
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osteons called Harvesians systems. Trabecular bone consists of a high porous spongy-like network of
trabeculae interspersed in the bone marrow and is formed by osteons called packets. Trabecular bone
is more vascularised and typically more metabolically active.
The cellular elements of bone are osteoblasts, osteoclasts, osteocytes and bone lining cells.
Osteoblasts, osteoclasts and bone lining cells are situated on bone surfaces whereas osteocytes are
embedded in the matrix. Bone lining cells cover inactive trabeculae bone surfaces that are not
undergoing remodellation, whereas osteoblasts and osteoclasts are on active surfaces which are
undergoing modelling and remodelling. Bone remodelling is the process by which bone is renewed in
order to maintain bone strength and homeostasis and it takes place continuously throughout life. Bone
resorption and formation are coupled. Osteoclasts, which are responsible for bone resorption, and bone
forming cells, osteoblasts, constitute basic multicellular units (BMUs), where osteoblasts always trail
behinds osteoclasts, ensuring that the removed bone is replaced by newly formed bone. The triad
receptor activator of nuclear factor κ-B ligand / osteoprotegerin / receptor activator of nuclear factor
κ-B (RANKL/OPG/RANK) is the key regulator in bone metabolism [11].
3.2- Bone marrow
Bone marrow is located in the medullar cavity of the bone, situated next to the endocortical surfaces of
trabecular bone. Bone and bone marrow are highly connected and thus have been suggested to
function as a single unit. Bone marrow and bone blood supply are highly interconnected and age-
related marrow composition changes are known to influence bone remodelling [12]. Bone marrow
contains haematopoietic and non-haematopoietic cells, from which osteoclasts and osteoblasts are
derived, respectively. Mesenchymal stem cells (MSC) are non hematopoietic multipotent cells capable
of multilineage to the majority of marrow stromal cell lineage including osteoblasts, chondroblasts,
bone marrow stromal cells, adipocytes, fibroblasts and dermal and other cells of the connective tissue.
Hematopoietic stem cells (HSC) are pluripotent cells regulated by humoral factors which can
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differentiate into multiple cellular lineages such as erythrocytes, platelets, segmented neutrophils,
monocytes, eosinophils basophils or T and B limphocytes [13]. The HSC have been shown to localize
to specific microenviroments called niches. The HSC osteoblastic niche, situated next to the endosteal
bone surface and regulated partly by osteoblasts, is known to favour quiescence whereas the vascular
one allows differentiation and further mobilization of mature cells, which enter the peripheral
circulation through the endothelial cells. Once in the vascular systems, HSC cells remain in constant
contact with the endothelial cells. Homing of stem cells implies the returning of circulating stem cells
to the bone marrow [14].
3.3- Bone vascularisation
Bone blood supply and flow plays a major role in the delivery of bone targeted nanoparticles to bone.
Figure 2: Vasculature in bone adapted from Williams Hematology, 6th edition [15]
As shown in figure 2, blood is supplied to long bones by six groups of arteries that are interconnected
by a rich network of anastomoses: superior epiphyseal and metaphyseal artery, periosteal arterioles,
dyaphyseal or nutrient arteries, and inferior metaphyseal and epiphyseal artery. The nutrient artery
constitutes the major blood supply and it passes the cortex of long bones and enters the bone marrow
Chapitre I: Bone targeted nanoparticle therapeutics
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
19
as shown in figure 2. Once entered into the marrow cavity, it divides into ascending and descending
branches that will split into smaller vessels in the medullar cavity: mostly capillaries, some of them
arteries and veins that will extend outwards to the cortical bone to form the Harversian and
Volkmann's canals. Plexus venous are formed which then go into the medullar cavity to drain into the
central vein that is parallel to the ascending and descending branches derived from the nutrient artery
in the medullar cavity [16, 17]. The trabecular bone lacks blood vessels unlike the cortical bone, but is
vascularised through the adjacent bone marrow.
Differences in the vasculature will play a major role in the delivery of bone targeted therapeutics.
Intraosseous blood flow varies depending in the type of bone, type of bone marrow and in between
species. It has been determined in all animals and human bones studies that intraosseous blood flow
ranges from 1 mL/min/100 g in the cortical marrow to 20 mL /min/100 g in the cancellous bone while
this value is of 5 mL/min/100 g for cortical bone [18].
Vasculature plays an important role in bone metabolism and remodelling [19]. Red bone marrow, that
is retained mainly in the spine, pelvis, ribs and sternum in the human adult, is highly vascularised and
is the site of large scale transport between the extracellular compartment and blood stream. On the
other hand, fat bone marrow is less vascularised than red bone marrow [20] and its content has been
shown to rise in reduced vascularised states [21].
4- Bone targeting moiety
Attachment of ligands to nanoparticles as a way to improve selective biodistribution into the targeted
organ or cell has attracted much interest in the last few years. The ideal target should be expressed in
the target tissue or cells but not expressed at all in non targets. For example, most of cancer targeting
approaches are based on the overexpressed receptors of tumour vasculature associated to angiogenesis
(vascular endothelial growth factor (VEGF), αv β3-integrin receptors) or up-regulated receptors in
cancer cells associated to cell proliferation markers (transferrin, folate receptors) compared to healthy
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cells [22]. However, receptors do in fact exist in healthy cells and vasculature. αv β3 integrins are
overexpressed in breast cancer bone metastases; however the specificity of this receptor is low since it
is also highly expressed in osteoclasts and it is ubiquitously expressed in diverse cell types, interacting
with the extracellular matrix proteins or with other cells and being involved in different biological
processes. [23]. Due to this limitation, few approaches are based on the targeting of more specific cell
receptors, such as prostate-specific membrane antigen (PSMA) to target prostate cancer cells or CD33
in acute myeloma leucemia. [24]
Bones, thanks to their unique anatomic characteristic, the presence of HAP, (Ca10(PO4)6(OH)2), that is
only present also in teeth and pathological calcifications, offers a unique and highly specific target.
Because of this, it is not surprising that most of the bone targeting approaches are based on HAP
targeting, which is also facilitated by the fact that many aminoacids, proteins and other compounds
have been shown to bind to HAP [25, 26].
Biological HAP in vertebrates is a poorly crystallized, non -stoichiometric HAP that has multiple
deficiencies at all ionic sites and that undergoes multiple substitutions. It is known to contain less
hydroxyl groups than the synthetic HAP and more carbonates groups which substitutes phosphate ions
[27].
There are several moieties that were shown to have HAP affinity such as biphosphonates, acidic
oligopeptides, tetracyclines [28] and tetracycline analogs [29]. For the latter, the tricarbonylmethane of
ring A and the keto-enol function of B and C rings have been suggested to be involved in HAP
binding [30]. Small heterocycles related to the thiadiazole structure were found to bind HAP with a
similar affinity as tetracycline [31] and poly(malonic acids) [32]. In general, these molecules present
groups in their structure that are able to chelate calcium atoms present in the HAP crystallite. Besides,
some metals such as strontium, which is incorporated into the HAP by surface exchange or ionic
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substitution [33], lanthanides or fluorides [34, 35] have shown affinity for bone. To impart
osteotropicity to drugs the most used moieties are biphosphonates and acidic oligopeptides.
Figure 3:Most commonly used bone targeting moieties at physiological pH
Figure 4: Other bone binding moieties
4.1- Biphosphonates
Biphosphonate are commonly used drugs in the treatment of skeletal pathologies. They are analogous
of the endogenous pyrophosphate, where the labile P-O-P linkage has been substituted by the
hydrolysis resistant P-C-P structure. The O-P-C-P-O backbone is responsible for the strong affinity for
calcium ions, the presence of hydroxyl groups in side chains usually enhances the affinity for calcium
ions via a tridentate rather than a bidentade binding. The substituents in the R2 side chains might also
have an effect on the mineral affinity [36]. Biphosphonates show poor oral bioavailability and have a
very short plasma half life due to high renal excretion and high bone uptake [37].
The HAP binding affinity of biphosphonates is of great importance in terms of skeletal distribution
and retention. It was found to be in the range of 106 M-1 whereas with bone powder, affinities were
found to be much lower, in the range of 104 M-1 [38]. Significant differences between biphosphonates
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could be inferred, being the decreasing affinity order as follows: zoledronate > alendronate >
ibandronate > risedronate > etidronate > clodronate [36]. The adsorption isotherm, which is an
equilibrium between HAP adsorbed biphosphonate and free biphosphonates in the bone extracellular
fluid, was found to follow a Langmuir model.
Once administered intravenously, biphosphonates that are not excreted via kidneys are rapidly
distributed to bone. It was found that biphosphonates accumulate in a non homogeneous way,
preferentially at active sites where remodelling process is taking place. This might be due to the fact
that HAP is highly exposed at these areas and is available for biphosphonate adsorption. Indeed, active
surfaces are minoritary, since they are found in less than 10% of the trabecular bone surfaces of the
iliac crest in adult humans [39], although it could vary depending on the type of bone and age.
Besides, biphosphonates distribute preferentially to trabecular bone [40], possibly due to its increased
blood flow and metabolic activity. Studies in rats with radioactive labelled biphosphonates,
alendronate and etidronate showed a dose dependence for skeletal biodistribution, with preferential
binding to bone resorption sites. At much higher doses, however, etidronate was almost equally
distributed although still slightly preferentially accumulated in bone resorption [38, 41].
Once biphosphonates are bound to HAP, they can either be released or become embedded within the
bone matrix as osteoblasts produce osteoid. There are theoretically two release mechanisms for
biphosphonates from bone mineralized surfaces: chemical resorption and osteoclast resorption. The
first one is thought to be relatively more important in the short term after dosing and it is dependent on
the concentration in the extracellular fluid, being desorbed when its concentration in the extracellular
fluid is low. In the long term and being the most relevant in vivo mechanism globally, it is the
osteoclast resorption which will mainly release biphosphonates by the secretion of protons (H+) into
the resorption lacunae. The acidic pH of the resorption lacunae causes the protonation of the
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phosphonate groups, decreasing HAP affinity and provoking its release. Sato et al. have shown in vitro
that at a pH of 3.5 50% of alendronate molecules could be released from bone mineralized tissue [38].
Some of the released biphosphonates could reattach to the bone surface, be eliminated from the bone
organ or be available for internalisation by osteoclasts and other cells and this would depend on the
bone affinity of biphosphonates. Higher rather than lower affinity biphosphonates will be expected to
be soon reattached to the mineralized surfaces. Bone affinity can also provoke different skeletal
distribution of biphosphonates. Higher affinity biphosphonates will expect to diffuse lower through the
osteocyte canalicular network as it was recently shown: lower affinity compounds penetrate deeper
into the bone matrix and thus more osteocytes were in contact with these low affinity compounds [42,
43].
Skeletal retention of biphosphonates is long, although the exact retention time remains controversial.
Some studies have estimated the skeletal retention of alendronate to 10 years in humans, establishing
an intermediate half-life of 6 months, perhaps due to the chemical desorption [44]; pamidronate was
detected in urine in young patients with juvenile osteoporosis up to seven years later [45].
Biphosphonate retention may be also dependent on bone turnover although there is little data on this
issue.
4.2- Acidic oligopeptides
Acidic non collagenous proteins, such as osteonectine and bone sialoproteine, were shown to bind to
HAP with high affinity (binding constants in the range of 106-107 M), preferentially on the (100) face
of HAP crystals [46]. The identification of glutamic-acid rich sequences as possible HAP binding sites
opened the way to the use of acidic oligopeptides as bone targeting moieties [47]. The acidic
oligopeptides containing at least six L-aspartic acid (Asp) and L- glutamic acid (Glu) aminoacids were
shown to be selectively distributed to bone .There were no in vitro bone binding differences between
the two isomeric forms, D and L. However, in vivo L-Asp was eliminated considerably in 7 days,
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attributing this to a possible degradation by peptidases or to the acidic pH present in the bone
microenvironment. The HAP binding affinity constant for both (L-Asp)6 or (L-Glu)6 were in the same
range and were approximately 1.6 105 M-1 [48]. It was suggested that (Asp)6 had a non homogeneous
distribution in bone and that it would accumulate preferentially to the active bone surfaces [49]. It
could be hypothesised from their affinity constant, which is ~100 times lower than that of
biphosphonates, that acidic oligopeptides would chemically desorp more from the mineralized tissue,
would reattach less to the bone, would penetrate deeper into the osteocyte network and would have
shorter skeletal retention.
4.3- Targeting specific sites of bone surfaces
Newly deposited HAP differs substantially from the matured one. Newly deposited HAP has a non-
apatitic domain at the surface of the nanocrystals, that consists of a well developed hydrated layer,
responsible for the high ion exchange reactivity of HAP, where labile phosphates and carbonates
groups are easily and reversibly exchangeable. During maturation, the non-apatitic domain
progressively decreases and the apatitic one increases, evolving towards a highly crystalline phase
involving the relocation of labile phosphate and carbonates and an increase of the phosphate apatite
[50]. In physiological conditions, in normal bone mineral, maturity evolves generally in parallel with
the crystallinity index. However, both have different parameters and their crystallinity index can be
modified by the presence of ionic substitutions in the apatite lattice. Moreover, some pathologies, such
as skeletal fluorosis and osteoporosis, as well as the use of several drugs are known to modify the
degree of crystallinity of HAP [51].
Some bone binding moieties have shown to have specific affinity for either resorption or formation
sites. HPMA targeted to bone by D-(Asp)8 peptide was found to bind preferentially to bone resorption
sites, which are characterised by a higher crystallinity compared to bone formation sites whereas
alendronate bound to both resorption and formation sites. This could be attributed to the lower affinity
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of (Asp)8 for HAP and to a more dependent binding on HAP crystallinity [52] than for the
biphosphonate moiety. Moreover, specific sequences, (Asp-Ser-Ser)n based on dentin
phophoroprotein, one of the major non collagenous protein of dentin extracellular matrix and involved
in nucleation of HAP, have been shown to have a specific binding to calcium phosphates (HA and
amorphous calcium phosphate) and have shown specificity for emerging sites of mineralization such
as dentin. The optimal length has been established to be six, with the maximum affinities values being
for eight repeating sequences [53]. Another specific peptidic binding sequence has been identified
with specific affinity for dental or enamel. Interestingly, such peptidic sequence that binds specifically
with enamel does not contain the known bone binding motifs and is uncharged, which would open
new insights into the mechanisms of interaction with bone surface [54]. Differences in binding
between dentin and enamel might be also due to differences in HAP crystals, as dentin is poorly
mineralized and has smaller and randomly oriented HAP whereas enamel is highly mineralized and
composed of elongated well-oriented HAP crystals.
These findings are of major importance since they open a higher level of bone targeting: the targeting
of specific sites in bone -resorption or formation- according to pathologies and drugs used. In this way,
Zhang et al. showed the sequence (Asp-Ser-Ser)6 binds specifically to bone formation surfaces and
used it as a bone targeting ligand to specifically deliver through liposomes small interfering siRNAs
that silenced bone formation inhibitory genes in osteoblasts [55].
Targeting the bone offers the possibility to concentrate the therapeutic drug in this tissue and thus
minimizing side effects derived from the distribution of the drug in other organs. However, once in the
bone, drug can interact with the different bone cells and thus intra bone side effects cannot be
excluded. Therefore, in a new emerging approach attempts are made to target more precisely
intraskeletal localizations depending on the type of pathological disease to address, which can result in
more specific drug delivering and thus reduced intra-bone side effects.
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5- Biological barriers for nanoparticles to overcome to attain bone mineralised tissue
Biodistribution and clearance of nanoparticles will depend both on the physiological characteristics of
the organism and on their physicochemical characteristics. In order to attain bone mineralised surfaces,
nanoparticles have to overcome numerous barriers, which are discussed below.
5.1- Reticuloendothelial system (RES)
A main parameter that would determine nanoparticle distribution is avoidance by the RES. Long
circulating times are required so that bone-targeted nanoparticles can attain the target bone tissue. The
process of recognition by the RES is the major obstacle to long circulation time and to efficient
targeting. It starts typically by an opsonization process in which opsonins (plasma proteins) bind to
nanoparticles. This leads to the attachment of the phagocytes, principally located in the liver (Kuppfer
cells), spleen and also bone marrow and thus, favouring their accumulation in this tissue and further
ingestion and digestion or accumulation of the phagocytosed material. However, the involved
processes are much more complex since it has been shown that opsonizated sterically stabilized
liposomes may not necessarily induce engulfment by the macrophages [56] and that protein binding
cannot correlate with plasma circulation lifetimes [57]. Opsonin independent mechanisms may be
involved in the recognition by macrophages via scavenger receptors and via direct interactions with
macrophages, where surface characteristics of nanoparticles have shown to play a major role [58, 59].
There are many physicochemical factors that play a role in the clearance and biodistribution of
nanoparticles, such as particle size, shape, composition, surface charge, pegylation and functionality.
Although some generalisations are widely accepted, each nanoparticle system has unique overall
characteristics. It is generally accepted that nanoparticles should be under 100 nm in diameter to be
able to display reduced protein adsorption and enhanced blood circulation [60]. Slightly negative and
neutral nanoparticles are known to have reduced plasma protein adsorption, macrophage uptake and
enhanced target tissue accumulation compared to positive ones [61]. Shape has also proven to have a
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major role in the engulfment of micro and nanoparticles by the macrophages [62, 63], worm-shaped
microparticles exhibiting a very long half life of up to one week [64].
To reduce opsonization and thus to enhance long circulating time in the bloodstream the preferred
method is the PEGylation of nanoparticles, although other materials such as other PEG containing
polymers[65], polysaccharides [66], poly(acrilamide), poly(vinyl alcohol), poly-(N-vinyl pirrolidone)
[67] or poly(aminoacids) have also been used [68]. Recently, a combination of PEG and water soluble
chitosan have shown to synergistically enhance blood half lives [68, 69].The PEGylation provides
nanoparticles with a hydrophilic neutral and flexible shield that reduces hydrophobic interaction with
the RES. However, the exact mechanism of PEG shielding remains largely unknown. PEG can be
linked to nanoparticles through different ways, among which covalent link has shown to be the most
effective. There are many factors affecting the efficacy of the PEG shield in conferring stealth
properties such as the PEG length, conformation and density. The fact that pegylation enhanced blood
circulation time was firstly reported with PLGA-PEG nanoparticles [70]. PEG optimal length varies
depending on other physicochemical parameters of nanoparticles. Some authors found an optimal PEG
length of 5 kDa [71, 72] or longer [60]. A PEG grafting density ranging from approximately 1.4 to 2.2
nm between the PEG chains has shown to reduce protein adsorption [71, 73]. PEG chains can adopt
different conformations depending on the surface coverage. At low surface PEG density, PEG adopts a
mushroom conformation and nanoparticles are prone to opsonization and RES capture. The brush
conformation, where PEG chains are extended at higher surface densities, or the brush-mushroom
intermediate, are more resistant to phagocytosis and activated poorly the human complement system
[74]. The effect of pegylation length and size in poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl
cyanoacrylate nanoparticle on protein adsorption was studied, revealing slower blood clearance for
smaller nanoparticles. This may be due also to a higher surface PEG density exhibited on smaller
nanoparticles [60].
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However, some drawbacks concerning the use of PEG have been reported. In some PEGylated
liposomes and nanoparticles at repeated dose regimens, the accelerated blood clearance (ABC)
phenomena has been described, where a first dose of PEGylated liposomes administered intravenously
would alter the pharmacokinetic properties of a second dose administered within an interval of several
days after the first dose. The second dose presents an accelerated clearance from the blood due to an
enhanced liver and spleen capture [75-77]. There are several factors that can have an influence on the
ABC phenomenon, such as the dose, size and charge of liposomes administered, the PEG density, the
drug encapsulated or the interval between injections [78-81]. In order to reduce this phenomena,
changes in the time interval between consecutive doses [77] as well as the use of other shielding
polymers such as polyvinylpyrrolidone (PVP) as coating for polylactic acid (PLA) nanoparticles have
been proposed [82]. However, this issue still remains a big challenge to overcome in order to have
reproducible pharmacokinetics for multiple dose treatments. Another inconvenient of PEGylation has
been described for gene delivery applications, such as small interfering RNA (siRNA) or plasmid
DNA. In order to be active, they have to attain their intracellular target (cytosol and nucleus,
respectively). However, PEGylation reduces transfection efficiency due to a lower interaction and
uptake by cells [83] and to an inhibition of the endosomal escape of the nucleic acids, being degraded
by the DNAases in the endosome [84]. Therefore, the PEG dilemma refers to the advantageous effect
of PEGylation in terms of prolonged blood residence and improved pharmacokinetics in opposition to
the reduced transfection efficiency inconvenient. To overcome the PEG dilemma, targeting by specific
ligands [85], cleavable PEG from the carrier system in response to intracellular or extracellular
environment [86-88] and the acceleration of membrane fusion or disruption [89] have been proposed.
5.2- Blood-organ barrier
Unlike small molecules, nanoparticulate systems due to their size are dependent on the structure of the
capillary microvasculature to attain the desired tissue. In order to attain longer circulating times,
nanoparticles should avoid renal clearance through excretion as well as hepatic and spleen uptake also
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related to the RES, as previously discussed in section 5.1. Organs with leaky vasculature, such as liver
or spleen will favour an accumulation of nanoparticles in these tissues, whose accumulation is also
related to the RES system capture, and therefore preventing nanoparticles from getting into the
targeted bone organ. Liver capillary microvasculature consists of reticuloendothelial sinusoids with
open fenestrae vessels that allow transvascular flow of nanoparticles up to 180 nm in humans and
rabbits and up to 280 nm in mice and rats. Spleen consists of sinusoidal non reticuloendothelial
microvasculature in the terminal splenic red pulp arterial blood capillary that allows a transvascular
flow of particles up to 5 µm. So as to avoid renal excretion, nanoparticles should be larger than 6 nm
[90, 91]. Pathological conditions such as tumours, which can undergo angiogenesis results in abnormal
leaky vasculature with gap sizes ranging from 100-2µm and present limited lymphatic drainage, which
results in the enhanced permeability effect [22]. Therefore, biodistribution of nanoparticles will be
modified in this disease state and will also tend to accumulate in the organs affected by cancer.
5.3- Blood -bone barrier
Bone targeted nanoparticles will have to extravasate from the bone marrow sinusoids to attain bone
marrow and then bone surfaces. Information regarding extravasation through bone marrow sinusoids
remains controversial in spite of the inter-species differences [92]. Some authors proposed the
existence of pores of around 80 nm, as observed in 7 weeks old chicken [93]. Two ways of
extravasation have been reported: intracellular via endocytosis by the endothelial cells through the
caveolae and bristle coated pits or transcelullar via the diaphragmed fenestrated capillaries of around
80-150 nm [94]. However, a recent review by Sarin establishes that red bone marrow sinusoids are
sinusoidal reticuloendothelial capillaries which are transiently fenestrated for blood cell
transmigration, and these fenestrations are regulated by diverse adhesion molecules and receptors in
the endothelial cells [95] and close rapidly after cells. Under this theory, the transvascular physiologic
upper limit of the pore size is limited to 5 nm. Localization of non endogenous nanoparticles of around
60 nm in the bone marrow is attributed to the phago-endocytic capacity of the endothelial cells
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through the bristle coated pits, which is restricted to a narrow size range of nanoparticles [96]. In any
case, this topic requires deeper research and further understanding in order to explain how
nanoparticles could attain this tissue and if any receptor mediated uptake could be involved. For all
theories of bone microvasculature, the rational approach would be the development of small
nanoparticles (around 60-80 nm) with high stealth properties.
Bone marrow diseases, such as myelofibrosis, have been associated to thickened or continuous
basement membranes. Therefore, delivery to fat bone marrow containing bones or to myelofibrosis
diseased bone marrow might be hampered by nanoparticles and would constitute an additional
challenge. Disease states such as osteoporosis, osteopenia, osteonecrosis or bone infarction, that are
associated with reduced vascularization [97-99] makes the delivery of bone targeted nanocarriers into
the bone more difficult. On the other hand, in other diseases such as bone metastases lesions,
specifically from Walker 256/B cells, an increased vascularization with irregular and increased in
diameter new formed blood vessels have been observed [100], in accordance with the general feature
of tumour related angiogenesis. Besides, a production of enzymes that digest extracellular matrix
[101] could enhance the delivery of the bone targeted nanoparticles and their better diffusion
throughout the bone [102].
5.4- Intra-bone barriers
Once in the bone marrow, bone mineralised surfaces are not readily next to the vessels and there are
still important barriers to overcome as shown in figure 5. To attain the mineralised tissue nanoparticles
will have to overcome a major obstacle: the endocytosis of nanoparticles by the macrophages present
in the bone marrow. Again, as for the biodistribution of nanoparticles into the bone organ, avoidance
of the RES is a major obstacle for nanoparticle to attain bone surfaces. However, macrophages are not
the only obstacle as nanoparticles will be surrounded by a large number of cells, hematopoietic or not,
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that are being differentiated from the HSC and the MSC. As a result, a lesser number of nanoparticles
may attain the mineralized surfaces.
Figure 5: Nanoparticle interaction in the bone microenvironment once attained the bone tissue.
Nanoparticles can interact with different cell types and extracelullar matrix domains present in the bone
microenvironment: 1- bone marrow cells including phagocyting cells; 2- low crystallized HAP
corresponding to bone formation sites; 3- osteoblasts; 4- osteoclasts; 5- highly crystallized HAP
corresponding to bone resorption sites. Once attached to the bone surface nanoparticles could: 6-detach
from it, being available to interact with bone cells, eliminated from bone or reattach to the bone surface; 7-
being resorbed by osteoclasts; 8- being embedded within the osteoid.
If interacting with cells, different general routes for nanoparticles to be endocytosed have been
established: clathrin dependent, caveolae mediated, clathrin and caveolae independent or
macropinocytosis. These distinct pathways determine the post-endocytic trafficking, involving
different type of vesicles with different pH that nanoparticles will encounter. Most nanoparticles have
been shown to use more than one of the pathway to enter cells. Several factors, such as the cell type
and physicochemical characteristics of nanoparticles, including targeting ligands for any of the cell
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surface receptors, will determine the entrance route. The detailed routes have been carefully reviewed
[103-105].
Once the bone marrow space passed, bone surface is heterogeneous as shown by figure 5. Non active
surfaces are covered by a layer of bone lining cells. It is a nearly continuous layer where bone lining
cells are interconnected among them and with osteocytes via gap junctions. Bone binding ligands have
been shown to bind preferentially to active surface, where HAP is more exposed. Thus, in order to
attain bone mineralised tissue, nanoparticles will be more likely to pass around or through osteoclasts
and osteoblasts rather than around or through the nearly continuous layer of quiescent bone lining
cells. If interacting with osteoclasts and osteoblasts, as shown for vinyl phosphonic acid (VPA)
nanoparticles of approximately 200 nm [110] a lesser number will be available for binding to HAP
Then, they will pass a connective tissue layer formed mainly by collagen and the lamina limitans [39]
[106]. To attain mineralized tissue far from vasculature, as bone is a dense tissue and moreover, due to
nanoparticles' size, transport may be hampered in some vascular and extravascular spaces, [107]
Harvesians canals and the lacunocanalicular system could be involved.
Specifically to osteoclasts, they have in addition the ability to phagocytose. Since they are
multinucleated cells of the phagocyte system, which are specialized in internalization and processing
of the degraded bone matrix, they share this ability with the RES cells. Vesicular trafficking is of
major importance in osteoclasts as shown in figure 6. When osteoclasts are active, they are highly
polarised with four different plasma membrane domains. Among the intense vesicular trafficking in
osteoclasts, a transcytotic pathway has been described for the degradation products, which are
endocytosed from the ruffled border and secreted to the functional secretory domain. There are also
endocytic pathways described from the basal plasma membrane to the ruffled border [109].
Polymeric and metallic particles ranging from the submicron up to 10 µm particles have been shown
to be phagocytosed by osteoclasts in vitro [108]. However, no evidence of the mechanism and route
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involved has been described. More insight into these routes would be necessary to fully understand the
endocytic trafficking of actively osteoclast and the entry for nanocarriers.
Figure 6: Actively resorbing osteoclast showing different endocytic pathways, adapted from [111]. (1) RB:
ruffled border; SZ: sealing zones; BL: basolateral membrane; FSD: functional secretory domain.
Biosynthetic pathway from Golgi to basolateral membrane (2) Biosynthetic pathway from Golgi to
endosomal pathway join to form fusion zone of ruffled border. (3) Transcytotic pathway from ruffled
border to functional secretory domain carrying bone degradation products and. (4) Biosynthetic pathway
from Golgi to transcytotic pathway and or to functional secretory domain. (5) Retrieval pathway from
functional secretory domain to ruffled border
6. Bone targeted nanoparticles reported in the literature
The design of the appropriate drug carrier depends on many aspects, one of them being the affinity of
drug carriers for their target. Nanoparticles can display multivalency by conjugation of multiple
targeting units to their surface or the multiassembly of targeted polymers. Multivalent interactions
occur in several processes in nature and are known to be much stronger than their monovalents
interactions [112]. This might be less important for high affinity ligands, such as alendronate [113].
The effective in vivo bone targeting of nanoparticles will be the result of various complex factors, an
essential one being the avoidance of the RES. Indeed, the number of ligands exposed on nanoparticles
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can have an influence on the recognition by the RES and thus an optimal number of ligands with an
optimal bone targeting properties and avoidance of the RES should be established.
Concerning drug release and contrary to the proposed drug controlled release systems discussed in
section 7, up to date no responsive bone targeted nanoparticle systems have been achieved (see table
1); therapeutic drug is physically entrapped and there is no controlled release. More concern regarding
this issue should be devoted, as for drug conjugates and polymer drug conjugates, in order to increase
drug therapeutic efficiency and reduce side effects.
Bone targeted drug delivery by nanoparticles is an emerging field and thus there are still relatively few
papers on this field that are shown in table 1 and discussed below.
6.1- Polymeric nanoparticles
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles
Bone targeted (PLGA) nanoparticles have been employed by several authors. PLGA-alendronate
decorated nanoparticles that showed in vitro HAP affinity were the first bone-targeted nanomedicine
to be reported [114]. Then, PLGA-alendronate nanoparticles loaded with doxorubicin were studied in
terms of biocompatibility and were employed to treat skeletal metastases derived from breast cancers
and for the prevention of osteolytic lesions. The therapeutic effect of alendronate nanoparticle was not
found to be higher than the free doxorrubicin [115, 116].
In another study, PLGA -alendronate nanoparticles containing bortezomir and curcumine showed to
have increased therapeutic efficacy in reducing bone tumor metastasis derived from breast cancer
compared to non targeted nanoparticles and both of them to control vehicle group. Surprisingly and
despite the absence of surface PEGylation of the nanoparticles, biodistribution of bone targeted
nanoparticles was much higher initially (after 0.5 hours), than for control nanoparticles but diminishes
to a very low concentration (the same as for control nanoparticles), after 13 hours. Nanoparticles were
thus rapidly eliminated from bone and hardly accumulated in the bone tissue. This is difficult to
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conciliate with the long term skeletal retention shown by biphosphonates and the involvement of the
bone marrow as a RES organ could account partly for it. [117].
However, PEGylation of nanoparticles is expected (i) to prolong the half life in the bloodstream, and
thus is expected to allow bone delivery of a larger amount of nanoparticles. and (ii) once in the bone,
to avoid the phagocytosis by the macrophages present in the bone marrow. Accumulation of PLGA-
PEG- zoledronate nanoparticles containing docetaxel was enhanced in vivo bone compared to non
targeted PEGylated nanoparticles. Interestingly, these authors evidenced an EPR effect of metastatic
tumour in bone for that model since the delivery of bone targeted PLGA-PEG-zoledronate
nanoparticles to tumour bone was 5 times higher and 3 times higher compared to non-diseased bone
after 1 and 24 hours, respectively [102].
Poly(γ-benzyl-L-glutamate)(PBLG) nanoparticles
Our group reported PBLG-PEG-alendronate nanoparticles that showed an enhanced accumulation in
bone tissue [118].
Poly(butylcyanoacrylate) (PBCA) nanoparticles
PBCA-PEG-zoledronate nanoparticles were shown to enhance biodistribution towards bone
metastasis. Interestingly, they showed that not only the anticancer encapsulated drug but also the
covalently linked zoledronate showed an in vitro pharmacological action. Interestingly, the initially
covalently-linked zoledronate exerted an enhanced pharmacological action (ApppI production)
compared to that of free zoledronate [119].
6.2- Lipid-based nanoparticles
The binding characteristics of nanoparticles to HAP was specifically studied with alendronate-
PEGylated liposomes [120]. In another research, PEGylated liposomes composed of PEG-DPG
encapsulating adriamycin showed significantly increased therapeutic effect in reducing osteosarcome
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growth as well as pulmonary metastases, increasing the survival time compared to the corresponding
control groups [121].
A very interesting approach that selectively delivers siRNAs to bone formation sites was achieved by
means of liposomes decorated with a novel bone targeting moiety (AspSerSer), with enhanced bone
distribution and knockdown efficiency. This enhanced biodistribution might be also the sum up of
different factors, bone affinity and reduced RES capture accounting for this. Some specific unkown
uptake mechanism could also be involved as it has been suggested for modified liposomes [122].
Type of
nanoparticle
Bone targeting
ligand
Therapeutic
drug
Mechanism
of release
Application Ref.
Polymeric- PLGA Alendronate - [114]
Polymeric- PLGA Alendronate Doxorubicin Physically
entrapped
Bone metastases [123]
Polymeric- PLGA Alendronate Bortezomir
Curcumin
Physically
entrapped
Bone metastases [117]
Polymeric-
PLGA-PEG
Zoledronate Docetaxel Physically
entrapped
[102]
Polymeric
PBLG-PEG
Alendronate - [118]
Polymeric
PBCA-PEG
Zoledronate Docetaxel
Zoledronate
Physically
entrapped
Bone metatases [119]
PEGylated
Liposomes
Alendronate - [120]
Liposomes Methylene
diphosphonate
Adriamycin Physically
entrapped
Osteosarcome [121]
Liposomes (Asp-Ser-Ser)6 siRNA Physically
entrapped
Impaired bone
formation
[55]
Composite scaffold
Collagen/HA
Biphosphonate Model drugs
(Doxorubicin,
Physically
entrapped
[124]
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Table 1: Bone targeted nanoparticles reported in the literature
Other types of lipid-based systems have been proposed, such as biphosphonate liposomes [128],
subcutaneous implants formed of scaffolfds of collagen and HAP, containing biphosphonates
liposomes [124, 129], or polyphosphoester ionomer-phospholipid vesicles [125], although there is no
data concerning their biodistribution or bioefficacy.
6.3- Inorganic nanoparticles
The binding characteristics of nanoparticles to HAP has been studied with gold (Au) nanoparticles
presenting three different bone targeting ligands on their surface: alendronate, phosphonate and
glutamate [130]. Gold nanoparticles functionalized with glutamate were suggested as potential
targeted-x-ray contrast agent for damaged tissue after effective results ex vivo [126]. Biphosphonate
decorated fullerenes C60 have also been reported [127].
Conclusive remarks
Some of the researches commented above have reported interesting data concerning nanoparticle
uptake and interactions with cancer cells metastasized to the bone tissue, specifically an enhanced
cellular uptake of nanoparticles decorated with biphosphonate ligands [102, 119]. Enhanced
biodistribution for these bone targeted nanoparticles might partly be due to this enhanced uptake.
Therefore, it would be interesting to know the in vivo fate of nanoparticles in bone diseased state
models. Further, as shown above, most attempts are directed to the targeting of the mineral surfaces.
carboxyfluores-
cein, lysozime)
Phospholipid
vesicles
Poly-
phosphoester
- [125]
Inorganic- Au Alendronate
Phosphonate
Glutamate
- Potential: imaging.
X-ray contrast
[126]
C60 fullerene Biphosphonate - - [127]
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However, the actual contribution of HAP binding by the means of targeting ligands should also be
evaluated in terms of enhanced delivery and efficiency. As an alternative to irreversible HAP
targeting, following bone tissue distribution, nanoparticles can also be designed so as to be transiently
adherent to HAP surfaces and to become available for interaction with different cells types, including
bone cancer cells and others including osteoclasts. It is noteworthy that bone cancer cells and these
specialized phagocytic cells might be active in endocytosing nanoparticles. In summary, once bound
to bone and depending on their affinity for HAP, nanoparticles could either remain bound to the bone
mineralized surface, and in this case the release of the drug might take place in the bone extracellular
microenvironment, by osteoclast-mediated resorption or not, or they could be desorbed and
progressively detached, making them available for further uptake by cells. More insight into the bone
healthy and diseased microenvironment would be necessary so as to predict and to control
nanoparticles in vivo fate in the bone microenvironment.
7- Drug loading and controlled release , a major issue for bone targeted nanoparticles
As discussed above, it is necessary to impart simultaneously various functionalities to bone targeted
nanomedicines and more specifically into nanoparticles. It is not the purpose of this chapter to discuss
these functionalities and the best ways to implement them into bone targeted sytems. Rather, it has
been decided to end this review by considering drug loading and the control of drug release from
nanoparticles designed for bone targeting, as it is a major concern for their efficiency.
As an evidence, nanoparticles should carry a therapeutic drug in a sufficient dose to treat skeletal
diseases. Because the potency of drugs is highly variable, ranging from the need of sufficiently high
concentrations in the vicinity of their pharmacological receptor for many small molecules, to the need
for only few copies in the case of siRNA for example, nanoparticles should be carefully engineered
from this point of view. A broad overview of the literature shows that small drug molecules (typically
under 1,000 Da in molecular weight) can be either physically entrapped in the core of nanoparticles or
chemically linked to one of its components.
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The classical method of encapsulating is based on physical interactions between the drug and the
carrier. However, conventional physically entrapment of drugs into nanoparticles has two major
drawbacks: the generally low (or very low) payloads and the usual lack of controlled release or at least
difficulties to control release kinetics. Indeed, it should be considered that there are strong exigencies
in this area, as release kinetics profiles should ideally ensure drug delivery once at the targeted site and
possibly according to a time prolonged kinetics. Drug release before the target is attained will result in
subsequent side effects, and a redhibitory loss of the payload before attaining the target. On the other
hand, the chemical approach consisting in covalently linking the drug, either directly to nanoparticles
or to the carrier which is further formulated into nanoparticles, with a cleavable bond in physiological
conditions represent an attractive approach so as to maximize the pharmacological activity. In this
approach, not only the drug release should be triggered by the local environment, but also time-
controlled from this moment.
Smart nanoparticles responsive to physio-pathological conditions of the targeting microenvironment is
another promising approach. Here we discuss the advantages and drawbacks of several approaches for
controlling drug loading and release kinetics in bone targeted nanoparticles using triggers in specific
physiological conditions present in the bone microenvironment.
7.1- Acid triggered release
There are several bone conditions where acid triggered drug release could be useful.
First, osteoclasts create an acidic microenvironment for bone resorption. Initially, osteoclasts attach to
the bone surface through integrins and secrete protons and chloride ions through the ruffled border via
direct pumping or by fusions of acidic vesicles extracellularly into the resorption lacunae that will
dissolve the mineral content of the matrix, the HAP. The pH of the resorption lacunae has been
estimated to be about 4.0-4.5 [131]. Although active surfaces are a minority, (found in less than 10%
of the trabecular bone surfaces of the iliac crest in adult humans [39]) bone targeted nanoparticles are
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likely to bind to the active bone sites, where HAP is more exposed and available. Osteoclast resorption
takes only 2-4 weeks in humans to be completed [132] and thus osteoclast mediated drug release from
nanoparticles could be foreseen. However, such a triggering of drug release by acidity could reveal
slow in the case of nanoparticles once they have attained bone formation sites rather than resorption
ones and toxic effects to osteoclast cannot be excluded.
In addition to the osteoclast mediated acidic pH in the resorption lacunae, if nanoparticles are
endocytosed by cells in bone, they will encounter acidic pH in early endosomes where pH ranges from
6.8-6.0, while lysosomes are more acidic (pH 5.2-4.5) [104]. Moreover, if bones are affected by
cancers, tumoral areas could present a mild acidic extracellular pH in the tumour microenvironment.
Cancerous cells, as a result of the increased metabolic activity exports H+ to the extracellular space via
a Na+/H+ exchanger, creating a mild acidic space (pH 6.60-6.98 in various tumours) [133].
Two main approaches in nanoparticulate systems have been used to trigger drug release in response to
acidic conditions, including (i) nanoparticles whose components undergo structural changes or
destabilization resulting in drug release or (ii) the use of an acid cleavable linker between the drug and
the polymer in the case of polymer-drug conjugates that can be further conjugated into nanoparticles
or not.
7.1.1.- Acid induced structural changes or destabilization of micelles
Nanoparticulate systems formed by pH-sensitive polymers, based on their pK properties, such as
carboxylic acid containing polymers or polyhistidine, have been proposed to trigger drug release in
acidic environments. Ionic core-cross linked micelles with enhanced stability against dilution derived
from poly(ethylene oxide)-b-polymethacrylate were achieved in the presence of divalent ions such as
calcium and further crosslinking of carboxylates with 1,2-ethylenediamine. Cores of micelles
presented swelling properties in response to pH. Then, cisplatin was incorporated to the carboxylic
groups of polymethacrylate that could be released in a pH dependent manner, being faster at pH 5.5
Chapitre I: Bone targeted nanoparticle therapeutics
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
41
than 7.4 [115]. Release from micelles derived from polyhistidine show a pH dependency due to the
physical destabilization of micelles at mildly acidic pH caused by the protonation of the histidine
groups, resulting in an enhanced release of their cargos [116].
7.1.2--Acid cleavable linker between the drug and the polymer
Micelles formed by self-assemblying of folate-PEG-poly(aspartic acid) polymer linked to the
adriamicine through hydrazone acid cleavable linkers were shown to selectively release their cargo in
the acidic intracellular compartments [134]. Ulbrich et al also designed pH sensitive micelles formed
by poly(ethylene oxide)-b-poly (allyl glycidyl ether) (PEO-PAGE) which showed faster release of
doxorubicin at pH 5 compared to the physiological pH 7.4, both showing incomplete release due to an
equilibrium between physically entrapped and free doxorubicin [135]. Polymeric micelles formed by
PLA-mPEG were chemically linked to doxorubicin by two acid cleavable linkers: hydrazone and cis-
acotinyl, which present an enhanced release at acidic pH compared to the neutral ones, the hydrazone
linked doxorubicin showing a slower release profile [136]. Prodrugs linked by cis-aconityl have shown
an incomplete release probably due to the formation of a trans isomer that cannot be cleaved [137].
Other acid clevable linkers such as acetals were used. Hydrophobic groups were attached via acetal
groups to the core forming dendrimer copolymer of the micelles, that were charged in doxorubicin.
Upon pH decrease hydrophobic groups were cleaved, rendering copolymers more hydrophilic and
destabilizing micelles and enhancing drug release [138].
7.2 Chloride triggered release
During osteoclast resorption, secretion of protons is accompanied by secretion of chloride anions via
specific chloride channels. In the resorption lacunae, there is a high microconcentration of chloride
due to the secretion of chloride anions via specific chloride channels. Polycarboxylates are known to
form complexes with cisplatin derivates whose release depends mainly in the chloride [139] and to a
lower extent on other nucleophile concentration. Kataoka's group in parallel to Kabanov's group,
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designed cisplatin core cross-linked micelles where cisplatin acted as a crosslinking agent . This
nanomedicines presented a very high loading of cisplatin (almost 40 % w/w) and its release was
dependent mainly on the concentration of chloride anions [140, 141]. Cisplatin carriers involving a
coordinate bond with carboxylate groups could take advantage of the high concentration of chloride
ion present in the resorption lacunae that would enhance the release of cisplatin. The disadvantage of
this approach is that chloride ions are abundant in the bloodstream. Depending on the release kinetics,
drug release could take place in the bloodstream, and thus reducing the percentage of still encapsulated
drug attaining the target tissue, while side effects could occur due to the biodistribution of the free
drug to other organs rather than the bone.
7.3 Enzyme triggered release
During osteoclast resorption, secretion of proteolytic enzymes such as lysosomal cystein proteinases
and matrix metalloproteinases (MMPs) into the resorption lacunae occurs. Among them, cathepsin K
has been shown to play a major role in the degradation of the organic matrix, although other cystein
proteases, such as cathepsin B and L might also be involved [111, 142]. Therefore, peptide sequences
sensitive to these proteolytic enzymes have been proposed as cleavable linkers in bone targeted drug
delivery systems.
7.3.1 - Cathepsin K sensitive spacers
Cathepsin K belongs to the cysteine protease family and is mainly expressed by osteoclasts although
also in other organs to lesser extents, such as ovary, heart and skeletal muscle, lung, testis or small
intestine and colon. It requires an acidic microenvironment for its activity and thus is active in
lysosomes and acidic resorption lacunae. It is secreted into the resorption lacunae where it is
responsible for the degradation of the organic matrix collagen and other non collagenic proteins
including matrix embedded growth factors once they have been released from the matrix by proton
secretion. It is known to cleave collagen at multiple sites within the triple helix of collagen type I and
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II. Deficiency of its activity causes severe bone sclerosing disorder. Cathepsin K inhibitors suppress
degradation of organic matrix while allowing demineralization. Unlike other antiresorptive agents,
bone formation is not suppressed [143, 144].
Specific cleavage sites of cathepsin K are different from those of cathepsin L, in spite of sharing 40 %
of homology, and have been revealed using a peptide containing six sequences Gly-Pro-Z-Gly. The
study revealed three major cleavable sites where Z was Met, Arg and Ser and a minor one where Z is
Gln [145]. An additional specific cleavage sequence Gly-Pro-Z-Gly where Z was Trp was found using
hydrogels, which underwent specific osteoclast degradation [146]. Moreover, Gly-Gly-Pro-Nle
sequence was used to design a HPMA-prostaglandin E1conjugate, whose cleavage was majorly
performed by cathepsin K [147].
7.2.2-Matrix metalloproteinases (MMPs) sensitive spacers
MMPs are a type of endopeptidases. They structurally possess a zinc (Zn) binding catalytic domain.
They are ubiquitously expressed throughout the organism, although substrate specificity differs
depending on the type of MMP. Collagenases are a subfamily of MMPs which have the ability to
degrade fibrilar collagen in its triple helical structure. In type I collagen, the most abundant in bone,
cleavage occurs between Gly775/Ile776 and Gly775/Leu776 of the α 1 (I) and α 2 (I) chain, respectively.
Octapeptides sequences containing similar sequences to the cleavage sites in native type I collagen
have been identified. [148]. However, the degradation of the organic matrix in bone is mainly carried
out by the cathepsin K and the role of MMPs is limited. MMP 13 has been suggested to contribute to
matrix solubilisation in specific areas of the skeleton and in some pathological and developmental
conditions and to play a role in the removal of collagen leftovers at the end of the resorption cycle
[149]. Some types of MMPs have been involved in the skeletal development and in the modulation of
extracellular signals since MMPs can cleave cytokines, growth factors, cell surface molecules or
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matrix molecules [150]. No MMPs specific sequences have been used to trigger drug release; MMPs
are ubiquitously expressed and have a limited role in bone matrix degradation.
8. Conclusions
The development of bone targeted nanomedicines could be an interesting approach considering the
bone disease state and the associated pathological characteristics. It is also a very complex issue,
because of the complexity of the barriers to overcome before reaching bone mineralized tissue,
including bone marrow, which is an hematopoietic organ with numerous cell types and also a RES
organ. Although being an emerging field, bone targeted nanoparticles have already shown
considerable therapeutic improvements in the treatment of cancers and delivery of nucleic acids. More
insight into the mechanisms by which nanoparticles can overcome barriers, such as blood capillaries
extravasation in physiological and specific disease state or microdistribution pattern in the bone
marrow environment, would be really useful to optimise the nanomedicine approach. Further, more
detailed studies are necessary to understand the actual contribution and efficacy of active targeting
approaches using specific ligands in order to challenge this strategy and conclude about its pertinence.
Finally, toxicological concerns equally have  to be considered. The seek for specific cell targeting and
not only HAP surfaces, should be considered and may constitute a valuable approach for efficient intra
bone targeting.
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Résumé
Le ciblage des nanoparticules aux tissus osseux est une étape importante dans la thérapeutique de
maladies squelettiques. L'hydroxyapatite est un composant très spécifique de l'os et donc constitue la
cible principale pour conférer des propriétés d' osteotropicité. Des nanoparticules de PBLG10-PEG-
alendronate (~75 nm) sont préparées par une méthode simple de nanoprécipitation. L'affinité pour les
ions calcium (KCa+2=1.8x104 M-1) est évaluée au moyen de la technique de titration calorimétrique
isotherme. Leur interaction avec les surfaces de hydroxyapatite (KHAP) est étudiée par fluorescence et
estimée à 1.1x1010 M-1, ce qui est 4000 fois plus fort que l'interaction monovalente entre l'alendronate
et les surfaces de hydroxyapatite préalablement décrit dans la littérature. Les études de modélisation
moléculaire suggèrent que le nombre de sites d'union disponibles sur la surface d'hydroxyapatite est en
large excès par rapport à ceux qui sont nécessaires pour le recouvrement total de la surface par les
nanoparticules décorées avec l'alendronate. L'affinité plus faible envers les ions calcium
comparativement à celle envers les surfaces d'hydroxyapatite permettrait aux nanoparticles liées aux
ions calcium d'interagir avec l'hydroxyapatite. Cela apporte une compréhension plus profonde des
nanoparticules ciblées aux tissus osseux et pourrait potentiellement améliorer leurs propriétés de
ciblage.
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Abstract
Hydroxyapatite (HAP), a highly specific component of bone tissue, is the main target in order to
impart osteotropicity. Bone targeted nanoparticles can increase the strength of the interaction with
HAP through multivalency and thus constitute a valuable strategy in the therapeutics of skeletal
diseases. PBLG10k-b-PEG6k-alendronate nanoparticles (~75 nm) were prepared by a simple
nanoprecipitation method. The calcium affinity (KCa+2=1.8x104 M-1) of these nanoparticles was
evaluated using isothermal titration calorimetry. The multivalent interaction with HAP surfaces (KHAP)
was studied by fluorescence and was estimated to be 1.1x1010 M-1, which is more than 4000 times
stronger than the reported monovalent interaction between alendronate and HAP surfaces. Molecular
modeling suggests that the number of binding sites available at the HAP surface is in large excess than
what is required for the whole surface coverage by alendronate decorated nanoparticles. The lower
calcium affinity of these nanoparticles than for HAP allows calcium bound nanoparticles to interact
with HAP, which yields a deeper understanding of bone targeted carriers and could potentially
improve their bone targeting properties.
Table of contents graphic
Targeting nanoparticles to bone tissue is an important issue in the therapeutics of skeletal diseases.
Hydroxyapatite, a highly specific component of bone tissue is the main target used so as to impart
osteotropicity. The aim of this study was to prepare bone targeted nanoparticles derived from poly (γ-
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benzyl-glutamate), PBLG10-PEG-alendronate, and to evaluate their binding affinity to calcium ions
and hydroxyapatite surfaces.
Keywords: bone targeting, nanoparticles, isothermal titration calorimetry, adsorption
1- Introduction
Multivalent interactions, simultaneous binding of multiple ligands into one biological entity are
involved in many different biological processes. Once the recognition has been established, the
binding strength will depend on the possible number of individual interactions and will be enhanced
compared to a single monovalent interaction (Mammen et al., 1998 ). As a result, site specific drug
delivery is expected to increase therapeutic concentrations locally, simultaneously minimizing dose
and side effects. For this purpose, nanoparticles can display multivalency through the conjugation of a
discrete number of targeting ligands to their surface in order to enhance their target affinity (Carlson et
al., 2007; Kiessling et al., 2000).
The design of bone targeted systems is of great importance in the therapeutics of skeletal diseases.
HAP, (Ca10(PO4)6(OH)2), is specific to bone -except for teeth and pathological calcifications and thus
constitutes an ideal target for the design of osteotropic systems. Biphosphonates as well as other
molecules such as acidic oligopeptides or tetracyclines have shown to bind effectively to HAP (Wang
et al., 2005). Biphosphonate structure presents two phosphonate groups sharing a common carbon
atom (P-C-P), which are responsible for the high affinity for HAP; the most important interactions
involving the calcium ions of HAP. For a systemically administered system to attain the bone
mineralized tissue, it has to cross the blood-bone barrier (Shea and Miller, 2005) including the
fenestrated capillaries with pore sizes up to 80 nm (Howlett et al., 1984; Shea and Miller, 2005).
Biphosphonates have been largely used to confer osteotropic properties to drugs by conjugation to
small molecules (Hirabayashi et al., 2001), to linear macromolecular carriers (Wang et al., 2005), to
proteins (Gittens et al., 2005) or to nanoparticles (Park et al., 2003; Ross and Roeder, 2011 ).
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However, only little research on the binding affinities of these systems with bone tissue or HAP has
been conducted so far.
In this work we present nanoparticles prepared from poly (γ-benzyl-L-glutamate) (PBLG), a
synthetic polypeptide that can adopt rigid α-helix structures and shows biocompatibility and good
biodegradability due to the degradable amide bond in its polymeric structure (Oh et al., 1995).
Homopolymers and amphiphilic copolymers of PBLG can assemble into small nanoparticles (less than
80 nm in diameter) by a simple nanoprecipitation method as it has been shown in our group (Barbosa
et al., 2007).
The aim of this study was to prepare bone targeted nanoparticles under 80 nm derived from PBLG,
PBLG10k-b-PEG6k-alendronate nanoparticles, and to evaluate their binding affinity with HAP crystals
and with calcium ions, which are mostly responsible for the interaction with HAP, deepening into the
interaction of alendronate with HAP.
2- Materials and Methods
2.1- Materials
DMF extradry Acroseal (99.8 %)  and benzylamine Acroseal (+99.5 %) and BLG-NCA were
purchased from Acros, and IsoChem respectively and were used as received. TFA (99%) was
purchased from Sigma Aldrich. All other regeants were of analytical grade and used directly. MeO-
PEG5k-NH2 (MW PEG= 5000 g/mol) and α,ω-Bis-NHS-PEG6k (MW PEG= 6000 g/mol) were purchased
from Iris Biotech GmbH. Alendronate was purchased from Chemos GmbH. DCTB and CF3COOK
were purchased from Sigma Aldrich.
Methods
2.2.- Synthesis of PBLG-polymers
Different derivatives of PBLG were synthesized by ring opening polymerization of BLG-NCA:
PBLG25k-bnz , PBLG10k-bnz, PBLG40k-b-PEG5k, PBLG40k-b-PEG6k-alendronate, PBLG10k-b-PEG6k -
alendronate and PBLG40k-FITC. Briefly, n milimoles of BLG-NCA were weighed in a glove box
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under inert atmosphere (argon) and were dissolved in DMF at a concentration of 0.5 M. The solution
was stirred for 10 minutes and the initiator, a solution in DMF of benzylamine or previously dried
MeO-PEG5k-NH2 in the case of PBLG40k-b-PEG5k, was added with an argon-purged syringe. The
solution was stirred at 30 °C and bubbled with argon several times during 5 - 7 days. Polymers were
obtained by precipitation in cold DEE and dried under vacuum. The evolution of the reaction was
controlled by infrared spectroscopy, by following the disappearance of BLG-NCA peaks and the
appearance of those of PBLG. A second purification step, consisting of dissolving the precipitate in
THF, reprecipitating in cold DEE and drying under vacuum, was performed. For copolymers
containing the hydrophilic PEG block or the FITC fluorophore, the purification step also included
washing the precipitates three times with MeOH in order to eliminate the excess of unreacted PEG or
FITC.
The synthesis of PBLG-b-PEG6k-alendronate copolymer was achieved based on a slightly modified
carbodiimide chemistry approach (Ozcan et al., 2011) and it is detailed in SI. α,ω-Bis-NHS-PEG6k was
dissolved in DMSO and reacted with a solution of alendronate in water with 3.5 equivalents of TEA at
a ratio of 1/1.5 overnight at 40 °C (reaction medium DMSO/water 60/40). The reaction was
precipitated in a mixture of EtOH/DEE, dialyzed with a membrane of a molecular cut-off of 3500 Da
during 72 hours to eliminate unreacted alendronate and lyophilized. A further activation of the COOH
groups was conducted in anhydrous DMF, in presence of DCC (5 equivalents) and NHS (5
equivalents), overnight under argon atmosphere at 25°C. After filtration with 0.45 µm filters, it was
precipitated in DEE and dried under vacuum. Next, reaction between NHS-PEG-alendronate and the
amine groups of the PBLG block, synthesized using the benzylamine as initiator molecule as
described above, at a [NHS-PEG-alendronate] /[PBLG] molar ratio of 1.5 was performed in anhydrous
DMF at 40 °C for 24 hours. The product was purified by precipitating in DEE and washed three times
with MeOH to eliminate the any unreacted PEG. (Figure 1)
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Figure 1: Structure of the PBLG-b-PEG6k-alendronate copolymer
For the PBLG-FITC polymers, close to the end of the reaction, a solution containing three times
more moles of FITC than of the initiator (benzylamine) was added and after 24 h, PBLG-FITC
polymer was obtained by precipitation as described above (Segura-Sanchez et al., 2010) (see SI).
2.3- Characterization of PBLG polymers
2.3.1- Fourier transform infrared spectroscopy (FTIR)
Infrared measurements were performed on a Fourier Transform Perkin-Elmer 1750 infrared
spectrometer using the ATR system to confirm the absence of NCA auto-polymerization, to follow the
evolution of the polymerization reactions and to determine the secondary structure of the polymers.
2.3.2- Nuclear Magnetic Resonance (NMR)
1H NMR spectra were recorded on a Bruker AC 300 spectrometer. 1H NMR spectra of the polymers
were recorded in CDCl3 + 15 % TFA. For the PBLG40k-b-PEG5k block copolymer, where
polymerization initiator was the mPEG-NH2, the molar mass of the polymer could be determined by
integration of the benzyl protons belonging to the PBLG block and the ethylene protons of the PEG
block and taking into account the mass of the initiator. For the PBLG-b-PEG6k-alendronate
copolymers, the efficacy of the reaction between the two blocks could be determined. Phosphorus
nuclear magnetic resonance (31P NMR) spectra were recorded on a Bruker AC 300 spectrometer for
the PEG-alendronate to quantify the alendronate using KH2PO4 as an internal standard.
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2.3.3- Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry
A Voyager DE-STR MALDI-TOF mass spectrometer (AB Sciex, Les Ulis, France), equipped with
a 337-nm pulsed nitrogen laser (20 Hz) and an Acqiris® 2 GHz digitizer board, was used for all
experiments. Mass spectra were obtained in linear positive ion mode with the following settings:
accelerating voltage 20 kV, grid voltage 75 % of accelerating voltage, extraction delay time of 150 ns.
The laser intensity was set just above the ion generation threshold to obtain peaks with the highest
possible signal-to-noise (S/N) ratio without significant peak broadening. All data were processed using
the Data Explorer software package (AB Sciex). DCTB was used as the matrix for MALDI-TOF
experiments and CF3COOK was used as the cationizing agent.
2.4- Nanoparticle preparation and characterization
Nanoparticles were prepared following a modified nanoprecipitation method previously described
(Barbosa et al., 2007). Briefly, 5 mL THF solutions of the pure or mixtures of PBLG derivatives were
added dropwise to 10 mL water and stirred for 10 minutes. Solvents were evaporated by a
standardized protocol under vacuum in the rotavapor at 40 °C. Nanoparticles size and zeta potential
were determined by DLS using a Zetasizer 4, Malvern Instruments. Experiments and measurements
were always made in triplicate. Nanoparticles were observed by means of TEM at 120 KV with
negative staining.
For the alendronate decorated fluorescently labelled nanoparticles, the number of PBLG α-helices
forming a nanoparticle was calculated as the ratio between the nanoparticle volume and PBLG α-helix
volume. Nanoparticles were considered to be spheres and PBLG α-helices were considered to be rods,
whose lengths were calculated by taking into account the projected segment length of a single
aminoacid unit (= 0.15 nm), the number of residues, and the diameter of 1.6 nm (Klok et al., 2000).
αhelix/np = 	 np(	 . 	 αhelixA	 αhelixA 	 . 	 αhelixB	 αhelixB ) (1)
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where	 np is the radius of nanoparticles obtained from TEM measurements from 100 nanoparticles,
αhelixA and ℎαhelixA are the radius and the length of the PBLG-b-PEG-alendronate helices
respectively, and	 rαhelixB, ℎ helixB are those for the PBLG-FITC helices.
2.5- Multivalent binding affinity for HAP surfaces
2.5.1- In vitro HAP binding assay
The multivalent interactions of PBLG10k-b-PEG6k-alendronate nanoparticles and PBLG40k-PEG6k-
alendronate nanoparticles with HAP were studied by means of fluorescence. Multifunctional
nanoparticles containing a PBLG-derivate and a fluorescent one, PBLG-FITC, at a ratio of 3:1 wt in
0.1 % of poloxamer Pluronic® F 68 were incubated in a HAP suspension in PBS at a pH of 7.4 during
1 and 18 hours. The suspensions were centrifuged at 3000 rpm and were observed under UV light ( =
365 nm). Pellets were washed three times with 1% poloxamer in PBS at pH 7.4. Supernatants were
quantified by a Perkin Elmer Luminescence spectrometer LS 50B at room temperature (λ excitation=495
nm, λ emission =525 nm) in order to determine the amount of nanoparticles bound to HAP. A calibration
curve was plotted for each type of nanoparticle.
2.5.2- Binding isotherms
Different concentrations of multifunctional nanoparticles containing PBLG10k-b-PEG6k-alendronate
or PBLG10k-bnz, and PBLG40k-FITC in 0.1 % of Pluronic® F 68 were incubated in a HAP powder
suspension in PBS at a pH of 7.4 during 18 hours and proceeded as described above. Binding
isotherms of PBLG10k-b-PEG6k-alendronate in the presence and absence of CaCl2 (10 equivalents of
CaCl2 per equivalent of alendronate, pre-incubated for 3 hours prior to the assay) were plotted as the
mass of nanoparticles per mass of HAP added versus the initial nanoparticle concentration. PBLG10k-
bnz nanoparticles were used as a negative control. Binding isotherms could be described by Langmuir
isotherm. Langmuir isotherm assumes an ideal model where adsorption takes place at specific
homogenous sites within the adsorbent, no interactions existing between adsorbed molecules and only
a monolayer is formed at the maximum adsorption, molecules of adsorbate being only adsorbed on the
Chapitre II: PBLG-PEG-alendronate multivalent nanoparticles for bone targeting.
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
61
free surface of the adsorbant (Langmuir, 1916). The binding data were plotted and expressed in
concentration as a function of alendronate, PBLG10k-b-PEG6k-alendronate copolymer and number of
nanoparticles considered as multivalent objects, since a single nanoparticle could present
simultaneously many alendronate molecules, all of them being available for interaction with HAP.
Data was fitted by the Langmuir linear regression method, as follows:= + 	 (2)
where Q is the mass of alendronate or PBLG10-PEG-alendronate copolymer or number of
nanoparticles bound per mass of HAP, Q is the maximum surface binding, 	is the multivalent
equilibrium binding constant (M-1) and C the initial concentration of nanoparticles. The plot of 1/Q vs
1/C allowed to determine the Q and the , expressed either in alendronate, in PBLG10k-b-
PEG6k-alendronate copolymer or in PBLG10k-PEG6k-alendronate nanoparticles. The concentration of
alendronate available in nanoparticles was calculated taking into account the amount of alendronate
estimated by NMR.
When binding data were expressed as a function of the number of particles, the latter was calculated
assuming that nanoparticles were spheres and the density of PBLG lyophases available in the literature
was taken into account (1.271 g/cm3) (Shiau and Labes, 1989) as follows:
np = PBLGPBLG 	 (3)
where PBLG is the molecular weight of PBLG estimated by MALDI-TOF, PBLG is the density
of PBLG and is the hydrodynamic radio of PBLG10k-b-PEG6k-alendronate nanoparticles measured
by dynamic light scattering. To calculate the affinity constant (KHAP) in M-1 expressed in nanoparticles,
the number of Avogadro (NA) was used.
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2.6- Binding affinity for calcium ions
The interaction of alendronate displayed by PBLG10k-b-PEG6k-alendronate nanoparticles with
calcium ions was studied by ITC (Microcal Inc., USA). The cell (1.2 mL) was loaded with the
nanoparticle suspension and stirred at 264 rpm by a rotating syringe, which was filled with a 4 mM
solution of CaCl2, PBLG10k-b-PEG6k-alendronate nanoparticle suspensions at 0.3 mM concentration of
polymer corresponding to 0.075 mM concentration of alendronate were prepared. The concentration of
alendronate in nanoparticles was calculated taking into account the amount of alendronate estimated
by NMR. The titration of PBLG10k-b-PEG6k-alendronate nanoparticles involved 30 injections of 10 µL
of the calcium solution during 200 s at an interval of every 600 seconds. Experiments were carried out
at 25 °C. Blank nanoparticles, i.e. not containing alendronate groups, were prepared from PBLG10k-
bnz and PBLG40k-b-PEG5k and were used as a negative control. A positive control was made with an
aqueous solution of PEG-alendronate. As the interaction with calcium ions is a monovalent
interaction,  the affinity constant was assumed to remain the same for PEG6k-alendronate in solution
and when PEG6k-alendronate was inserted at the surface of PBLG10k-b-PEG6k-alendronate
nanoparticles. The affinity constant determined in the PEG-alendronate ITC experiment was obtained
constraining the stoichiometry to 1 and it was used to determine the effective stoichiometry of the
PBLG10k-b-PEG6k-alendronate nanoparticles and calcium ions interaction. Additionally, the interaction
of an aqueous solution of alendronate with calcium ions was performed and used as a reference.
2.7- Molecular Modeling
The three-dimensional structure of HAP (as a .cif file) was downloaded from the Inorganic Crystal
Structure Database (Leventouri et al., 2003) (ICSD, http://icsd.ill.eu/icsd/index.html, code
icsd_98873) and manually curated. Packing structures were created with Mercury 3.0 (Macrae et al.,
2008) with sizes of 10x10x10 and visualized within Maestro interface from Schrodinger Suite
(Schrödinger, 2011).
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The three-dimensional structures of alendronate were generated using CORINA v3.44, (CORINA,
version 3.44) as individual entities. Alendronates were modeled as zwitterionic molecules, with one
negative charge on each phosphonate group and one positive charge on the protonated amino group. A
stochastic conformational search, based on Monte Carlo sampling, was employed to generate various
conformations, using the Mixed torsional/Low-Mode sampling method in the MacroModel module
(Macromodel, 2011) of Schrodinger Suite with improved setup options as follows: the maximum
number of steps was set to 10 000, all calculations used 1 000 steps per rotatable bond and an energy
cut-off of 42 kJ/mol above the global energy minimum. Redundant conformers were eliminated by
imposing a root mean square deviation (RMSD) cutoff of 2.0 Å. Unless otherwise noted, only the
lowest energy conformation for each compound was retained. The searches were done using the water
continuum model, with standard settings as below: OPLS_2005 force field with supplied charges,
dielectric constant 1.0, van der Waals cut-off 8.0 Å, electrostatic cut-off 20.0 Å, and hydrogen bond
cut-off 4.0 Å. The conformational search produced a number of 24 unique conformers, for which all
possible distances between two oxygen atoms belonging to the bisphosphonate group were measured.
Similar oxygen-oxygen distance measurements were carried out on the exterior surfaces of HAP.
The comparison of these two distance data sets showed that four values (4.12 Å, 4.75 Å, 4.80 Å and
5.02 Å) were common to both HAP surfaces and alendronate conformers.
Selected alendronate conformers were inserted on the HAP surface using the matching oxygen-
oxygen distances identified earlier, the biphosphonate moiety facing the HAP surface and the amino-
containing positive end stretched in the opposite direction. Various HAP-alendronate complexes were
designed, in accordance with the global symmetry of the HAP exterior surfaces and with the
biphosphonate coordination states in alendronate. Steric clashes within the complexes were removed
by energy minimization using Schrödinger’s Maestro framework, with all HAP atoms frozen in order
to keep the intact crystal structure. Visual inspection of the resulting HAP-alendronate complexes
using PyMol (DeLano, 2006) showed that the amino-alkyl substituent in alendronate is mainly
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oriented vertically on the HAP surface. Larger HAP-alendronate complexes (10 x 10 x 10) were then
built by extending the crystal network on both surfaces using symmetry rules.
3- Results
3-1 Synthesis and characterization of PBLG polymers
Polymerization reactions were followed by FTIR. The complete disappearance of the anhydride
signals at ~1850 cm-1,~1775 cm-1 ,~920 cm-1 corresponding respectively to the C5=O and C2= O and
C–O–C of the anhydride confirms the completion of the polymerization reaction (see SI). Polymers
were characterized by NMR, FTIR, and MALDI-TOF. FTIR spectra of all polymers show an α-helix
secondary structure, characterized by the amide I, amide II, and amide III at ~1655 cm-1 ,~1550 cm-1
and ~1260 cm-1 respectively (Barbosa et al., 2007; Cauchois et al., 2013; Segura-Sanchez et al., 2010).
A critical DPn of 18 was established above which the α-helix structure is increasingly favored versus
the β-sheet secondary structure (Papadopoulos et al., 2004). In the present study, the minimal DPn of
the synthesized polymers was 38, and as a result they were only composed of α helical secondary
structures (Table 1).
Table 1:Molar mass of the polymers determined by 1H NMR and MALDI-TOF
PBLG-polymers DPna DPn b Mn (g/mol) PIc
PBLG25k-bnz 136 106c 23407c 1.13
PBLG10k-bnz 45 38c 8431c 1.16
PBLG40k-b-PEG5k 228 156c
235d
39366c
56465d
1.23
PBLG40k-b-PEG6k -alendronate 228 190c 42415c 1.17
PBLG10k-b-PEG6k -alendronate 45 38c 8711e -
PBLG40k-FITC 228 163c 36155c 1.14
(a) theoretical;  (b) of the PBLG block;  (c)determined by Maldi-TOF; (d) determined by NMR; (e)
determined from the PBLG10k-bnz
Differences between theoretical and the experimental DPn determined by the MALDI-TOF
technique and between DPn established for PBLG40k-PEG5k by NMR and MALDI-TOF, suggest that
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MALDI-TOF technique underestimated the molar mass of polymers, probably due to the molar mass
discrimination effect (Favier et al., 2004). Alendronate content in PBLG-b-PEG-alendronate was
estimated by 31P NMR (see SI) and 1H NMR, quantifying the efficacy of the reactions. It was found
that 3.6 % of PBLG40k-PEG6k-alendronate copolymer chains contained a molecule of alendronate
whereas that of 5.3 % for the PBLG10k- PEG6k-alendronate copolymer chains.
3.2- Characterization of nanoparticles
Nanoparticles prepared from one or from a mixture of different PBLG derivates could be easily
obtained by a simple nanoprecipitation method without the use of any additional surfactants. In all
cases, nanoparticles were characterized by a size under 80 nm with a narrow size distribution and thus
nanoparticles were likely to pass through the bone-blood barrier and reach the bone tissue. They all
showed a negative zeta potential, which varied depending on the polymer or polymer mixtures. The
more negative zeta potential of PBLG10k-b-PEG6k-alendronate nanoparticles could be attributed to the
presence of alendronate, which holds two negative charges at pH 7.9. (Table 2)
Table 2: Size and Zeta potential of nanoparticles determined by DLS
Nanoparticles Size (nm)
± SD a
Polydispersity
Index
ζ Potential
(meV) ± SD
PBLG25k-bnz 58 ±0.4 0.14 -29 ± 1.3
PBLG10k-bnz 70 ± 0.3 0.13 -23 ± 1.4
PBLG40k-b-PEG5k 52 ± 2.8 0.15 -24 ± 0.5
PBLG40k-b-PEG6k-alendronate 57 ± 1.7 0.16 -27 ± 0.8
PBLG10k-b-PEG6k-alendronate 76 ± 1.3 0.17 -34 ± 1.2
PBLG25k-bnz: PBLG40k-FITC 3:1 68 ± 2.1 0.17 -18 ± 1.3
PBLG10k-bnz: PBLG40k-FITC 3:1 56 ± 1.2 0.16 -17 ± 0.9
PBLG40k-b-PEG5k: PBLG40k-FITC 3:1 52 ±1.1 0.13 -20 ± 1.0
PBLG40k-b-PEG6k-alendronate:
PBLG40k-FITC 3:1
63 ± 1.3 0.12 -20 ± 1.6
PBLG10k-b-PEG6k-alendronate:
PBLG40k-FITC 3:1
69 ± 0.5 0.15 -38 ± 1.2
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PBLG10k-b-PEG6k-alendronate: PBLG40k-
FITC 3:1 pre-incubated with CaCl2
70 ± 0.8 0.18 -16 ± 1.2
Nanoparticles prepared from the PBLG10k-bnz and PBLG10k-b-PEG6k-alendronate, and their
mixtures with PBLG40k-FITC in a 3:1 proportion, presented rather a spherical form, as revealed by the
TEM images, whereas it can be observed that nanoparticle shape became increasingly ellipsoidal as
the molar mass of the PBLG increased (Cauchois et al., 2013), as shown also for PBLG25k-bnz
nanoparticles and PBLG40k-b-PEG6k-alendronate (see SI).
Calculations suggested that on an average each individual fluorescently labelled PBLG10k-b-PEG6k -
alendronate nanoparticle could be formed by the self-assembly of approximately 1100 α-helix chains
and thus, approximately 60 molecules of alendronate were present on each nanoparticle. For
fluorescently labelled PBLG40k-b-PEG6k -alendronate nanoparticles, each individual nanoparticle could
contain approximately 190 α-helix chains and thus the number of alendronate molecules per
nanoparticle was estimated to be around 7. Thus, it is observed that the molecular weight of the PBLG
block had a considerable influence in the number of ligands theoretically available for interactions
with HAP. Both the high solubility of alendronate in water combined with the rigidity of the auto-
assembling PBLG blocks favors the localization of the alendronate molecules on the nanoparticle
surface.
3.3- Multivalent binding affinity for HAP
In vitro HAP binding assay
The multivalent interaction of PBLG10k-b-PEG6k -alendronate nanoparticles with HAP was studied
by means of fluorescence to determine if alendronate decorated nanoparticles could bind to HAP
surfaces. It is a multivalent interaction because each nanoparticle is decorated with multiple
alendronate molecules on its surface, which interact at multiple sites with one HAP surface with
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various calcium ions available on its structure. This assay revealed the effective binding of alendronate
nanoparticles to HAP (Figure 2).
Figure 2: Degree of binding expressed in percentage of nanoparticles bound to HAP for PBLG40k-b-PEG6k
-alendronate nanoparticles and PBLG10k-b-PEG6k-alendronate nanoparticles after 1 and 18 hours compared
to PBLG25k-bnz and PBLG40k-b-PEG5k nanoparticles. Nanoparticles at a concentration of 1.5 mg/mL in 0.1
% Pluronic® F 68 were incubated with 0.4 g of HAP suspension in PBS buffer.
PBLG10k-b-PEG6k-alendronate nanoparticles, decorated with approximately 60 molecules of
alendronate per nanoparticle, could bind totally to HAP after 18 hours whereas for PBLG40k-b-PEG6k-
alendronate nanoparticles, which contained around 7 molecules of alendronate per nanoparticle, HAP
bound particles were of about 80%. Control nanoparticles showed no binding in the case of PBLG25k-
bnz nanoparticles. In the case of PBLG40k-b-PEG5k nanoparticles, a non specific interaction was
observed, as shown by the 20 % of HAP bound nanoparticles after 18 hours.
The binding of alendronate decorated nanoparticles to HAP was a kinetic process, as described already
for alendronate (Leu et al., 2006) and other molecules (Kandori et al., 2000; Moreno et al., 1984; Rill
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et al., 2009), Indeed it was a rapid process since 85 % of PBLG10k-b-PEG6k-alendronate nanoparticles
were already bound after one hour, which was similar but slightly quicker than previously observed
for biphosphonate-tagged gold nanoparticles (Ross and Roeder, 2011).
Binding Isotherms
The multivalent interaction between PBLG10k-b-PEG6k-alendronate nanoparticles and HAP was
estimated from binding isotherms experiments. Binding isotherms of PBLG10k-b-PEG6k-alendronate
and calcium pre-incubated PBLG10k-b-PEG6k-alendronate nanoparticles were studied and compared to
PBLG10k-bnz nanoparticles, used as a negative control.
No differences were observed between the binding isotherm for PBLG10k-b-PEG6k-alendronate in
presence or in absence of calcium ions (Figure 3).
Both followed the Langmuir model. This could suggest that calcium ions in solution could be easily
exchanged with calcium ions belonging to the HAP structure. The plot of C/Q vs C expressed in
alendronate, in polymer and in nanoparticles using a Langmuir model exhibited correlation
coefficients R2 of 0.99, where Qmax and KHAP could be determined and are shown in table 4. (Table 3)
Figure 3: Binding isotherms of PBLG10k-b-PEG6k-alendronate nanoparticles and calcium pre-incubated
PBLG10k-b-PEG6k-alendronate nanoparticles with HAP in PBS pH 7.4 vs PBLG10k-bnz nanoparticles.
Experimental data were fitted to a Langmuir model using the equation 1.
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Table 3: The binding parameters of PBLG10k-b-PEG6k-alendronate nanoparticles for HAP determined by
the Langmuir model using the Langmuir linear regression method
Np PBLG10k-b-PEG6k-alendronate R2 Qmax (moles/g HA) KHAP (M-1)
Expressed in alendronate 0.99 4.4x10-9 1.6x107
Expressed in polymer PBLG10k-b-PEG6k-
alendronate
0.99 7.1x10-9 9.6x107
Expressed in nanoparticles 0.99 6.4x10-12 1.1x1010
Not surprisingly, calcium pre-incubated PBLG10k-b-PEG6k-alendronate nanoparticles had a less
negative zeta potential (from -26.7 meV to -16.2 meV), which did not affect nanoparticle interaction
with HAP. This supports the fact that the interaction of nanoparticles were driven by the alendronate
targeting moiety, and not by the zeta potential.
3.4- Binding affinity for calcium ions by isothermal titration calorimetry
ITC experiments were carried out to determine the affinity of the interaction between the alendronate
molecules in PBLG10k-b-PEG6k-alendronate nanoparticles and calcium ions, as it is the most important
interaction involved in the interaction of alendronate with HAP. PBLG10k-b-PEG6k-alendronate
nanoparticles clearly showed a specific interaction with calcium ions that was not seen for negative
control nanoparticles. Such interaction resulted in exponentially decreasing heats of interactions while
adding calcium ions to the nanoparticle suspension. A positive control with PEG6k-alendronate in
solution was performed so as to mimic the type of interaction occurring with nanoparticles, since
alendronate conjugation with PEG chains (see figure 1) was likely to differ from that observed with
free alendronate molecules. Alendronate on its zwitteronic form is known to form 2:1 complexes with
calcium ions (Fernandez et al., 2003). However, alendronate moiety in PEG6k-alendronate in solution
or exposed on nanoparticle surface had two negative charges, where it could be depicted that
interaction with Ca2+ would form a 1:1 complex. Interactions between alendronate, PEG6k-alendronate
in solution and PBLG10k-b-PEG6k-alendronate nanoparticles with calcium ions had similar
thermodynamic parameters (ΔH and ΔS), which confirmed that the interaction involved was likely to
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be similar. All interactions were entropically driven and could be described by a one-site model.
(Figure 4)
Figure 4: Typical ITC integrated heat data proﬁles obtained from the binding interaction of CaCl2 with: (a)
(up-left) Nanoparticles (Np) PBLG10k-b-PEG6k-alendronate vs Np PBLG25k-bnz and Np PBLG40k-b-PEG6k;
(b) (up-right) Np PBLG10k-b-PEG6k-alendronate (c) (down-left) PEG6k-alendronate solution (d) (down-
right)alendronate solution.
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Interactions were strong, as suggested by the binding constants (KCa+2), and slightly stronger for the
1:1 complex alendronate calcium (in PEG6k-alendronate and PBLG10k-b-PEG6k-alendronate
nanoparticles) than for the 2:1 complex (in calcium- alendronate solution). The heat signal variations
were weaker in the case of the titration of PBLG10k-b-PEG6k-alendronate nanoparticles due to the
limited concentration of alendronate, but were still exploitable. The stoichiometry for PBLG10k-b-
PEG6k-alendronate nanoparticles and calcium interaction was found to be 1,04 indicating that all
molecules of alendronate were exposed on the nanoparticle surface and available to interact with
calcium ions. (Table 4)
Table 4 : Binding parameters for PBLG10k-b-PEG6k-alendronate nanoparticles and for PEG6k-alendronate
and alendronate in solution with calcium ions determined by isothermal titration calorimetry.
Alendronate PEG6k-alendronate PBLG10k-b-PEG6k-alendronatenanoparticles
Chi2/DoF 99 90 238
Stoichiometry, N 0.5a 1.0a 1.0 ± 0,05b
KCa+2(M-1)c 1.8x104 ± 7 x102 1,8x104 ± 1.7x103 1,8x104
ΔH (kcal mol 1) 11x102 ± 34 16x102 ± 36 13x102 ± 57
ΔS (cal deg-1 mol-1) 23 25 24
aimposed stoichiometry for calculations. bcalculated stoichiometry using the experimental affinity constant
determined for PEG6k-alendronate in solution. cexpressed in alendronate concentration.
3.5- Analysis of alendronate complexation at HAP-surfaces by molecular modeling
Molecular modeling has been used to investigate the possibilities of interactions of alendronate
moieties with the two surfaces of HAP crystals. Four modes of interaction of alendronate molecules
with HAP surfaces 1 and 2 were identified as shown in figure 5. The alendronate interacts with HAP
not only by chelation of calcium ions but also by hydrogen bonds with oxygen atoms from the
crystalline structure. The distances between the oxygen atoms of alendronate in the selected
conformers are compatible with the same distances in the HAP structure, which allows for an optimal
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interaction between these two entities. These oxygen-oxygen interatomic distances are of 4.12, 4.80
and 5.02 Å respectively for Models 1, 2 and 3 on Face 1, and of 4.75 Å for Model 4 on Face 2 (Figure
5).
Figure 5: HAP-Alendronate complexes on face 1 (Model 1, 2, 3) and on face 2 (Model 4)
For Model 1, two calcium atoms coordinated by oxygen are situated at 2.48 and 2.83 Å from the first
atom and respectively at 2.52 and 2.83 Å from the second oxygen on HAP surface. For Model 2,
distances of 2.81 Å are measured between the oxygen atoms responsible for binding and the common
calcium ion. Two others calcium ions coordinate these oxygen atoms and are found at 2.33 Å.
According to Model 3, the binding of alendronate is mediated by two calcium ions that coordinate
oxygen, within distances of 2.32 and 2.74 Å for the first oxygen and 2.58 and 2.89 Å for the second.
Alendronate coordination on HAP’s face 2 involves oxygen atoms positioned at a distance of 4.75 Å.
These atoms are coordinated with two calcium ions, positioned at 2.50 and 2.30 Å from the first, and
at 2.50 Å from the second oxygen.
The alendronate interaction with HAP is enhanced by the interaction between the three -OH groups
of alendronate with the crystalline structure: two hydrogen bonds for Model 2 and three hydrogen
bonds for the other models. The areas of external surfaces of HAP were measured in order to
determine the specific surface for the interaction with alendronate and for comparison with the
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experimental data. The HAP structure that we generated contains 1000 units (10x10x10 units from the
crystal cell) with areas of 9427 Å² for the first surface (face 1) and 7544 Å² for the second (face 2) (see
SI). According to our models, a number of 121 to 132 alendronate molecules can theoretically interact
with the first face (corresponding to interatomic oxygen-oxygen distances of 4.80 Å, 5.02 Å and 4.12
Å). Similarly, up to 110 alendronate molecules can interact with the second surface (face 2),
corresponding to the oxygen-oxygen distance of 4.75 Å (see SI).
4- Discussion
The design of efficient bone targeted delivery systems depends on many aspects, an important one
being the affinity of the drug carriers to their target. Self-assembly of amphiphilic copolymers to form
nanoparticles represents a convenient way to display multiple targeting units to their surface, likely to
result in multivalent interactions with their targets. Multivalent interactions occur frequently in nature
and are known to be much more stronger than corresponding monovalents interactions (Mammen et
al., 1998).
PBLG copolymers have been selected for preparing bone targeted nanoparticles due to an attractive
set of other characteristics including their biocompatibility and degradability. Ring opening
polymerization was found to be convenient to obtain copolymers with low polymolarity index (PI
<1.3). In order to attain bone, HAP targeting has been the selected strategy as it is highly specific of
bone tissue, existing only also in teeth and pathological calcifications. Alendronate has been
successfully coupled to PBLG copolymers which could self-assemble to form small nanoparticles so
as to impart bone osteotropicity.
For bone-targeted nanoparticles to reach bone tissue, a prolonged time of circulation is required.
The small hydrodynamic diameter of the nanoparticles (50-75 nm, depending on the composition) was
likely to favor a prolonged bloodstream circulation (Alexis et al., 2008). In order to avoid premature
clearance by the reticuloendothelial system, pegylation of nanoparticles is a preferred method (Owens
I and Peppas, 2006). The hydrophilicity and flexibility of the surface PEG chains is widely used to
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prevent the adsorption of opsonins and the subsequent phagocytosis and clearance by the
reticuloendothelial system. Thus, a PEG above 5 kDa, MeO-PEG5k-NH2,was selected to synthesize
PBLG40k-b-PEG5k block copolymer. To ensure that molecules of alendronate could be exposed and
available on the surface, NHS-PEG6k-NHS was chosen for the synthesis of the bone-targeting
copolymer both as a spacer and to confer stealth properties to the bone-targeted nanoparticles.
As previously reported by our group, PBLG blocks adopt α-helix structures resulting in quite rigid
rods able to self-assemble and to form the core of nanoparticles. Nanoparticles made from PBLG-b-
PEG6k-alendronate copolymers had a core-shell structure, where the flexible PEG chains would form
an external flexible hydrophilic shell, while the rigidity of the hydrophobic PBLG block would
mechanically favor alendronate presentation on the particle surface.
First, the ability of alendronate decorated nanoparticle to effectively bind to HAP was checked by a
fluorescence method. The possibility of assembling different PBLG-derivates to form multifunctional
nanoparticles was previously reported by our group (Martinez-Barbosa et al., 2009) and it was
confirmed with this assay, where each PBLG10k-b-PEG6k-alendronate nanoparticle displayed at the
same time its fluorescent and its bone binding property. It can be inferred from this experiment that the
binding between PBLG10k-b-PEG6k-alendronate nanoparticles and PBLG40k-b-PEG6k-alendronate
nanoparticles with HAP is a specific interaction, not driven by the negative zeta potential of
nanoparticles. The absence of binding for PBLG10k-bnz nanoparticles allowed us to conclude that the
affinity of PBLG10k-b-PEG6k-alendronate nanoparticles for HAP is due to the alendronate moiety and
to exclude the differences in shape, evidenced by the TEM.
Next, the affinity between PBLG10k-b-PEG6k-alendronate nanoparticles and the HAP surface was
studied by adsorption isotherms. Multivalent interactions are known to enhance the affinity compared
to its corresponding monovalent interaction (Kiessling et al., 2006; Mammen et al., 1998). The
multivalent affinity constant for PBLG10k-b-PEG6k-alendronate nanoparticles (KHAP) expressed in
alendronate was more than 5 times stronger compared to  the monovalent interaction between
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alendronate and HAP reported value in the literature (Nancollas et al., 2006). It was almost 4000 times
more if the multivalent affinity constant was expressed in terms of nanoparticle concentrations. This is
in agreement with the previous works which showed that multivalent interactions are 4 to 9500 times
stronger than the corresponding monovalent ones, the highest enhancements seen for weaker intrinsic
affinities (Tassa et al., 2010).
Affinity binding was also studied in presence of calcium ions in solution since the main interaction
between the alendronate and HAP is known to involve the calcium ions of the HAP crystalline
stucture. Interestingly, it was shown that calcium-bound nanoparticles could still bind to HAP
structures with the same affinity as in absence of calcium ions.
Then, interaction of PBLG10k-b-PEG6k-alendronate nanoparticles with calcium ions was studied by
ITC. The interaction with calcium ions, KCa+2 , determined by ITC was of 1.8x104 M-1 which is 900
times weaker than the multivalent interaction of PBLG10k-b-PEG6k-alendronate nanoparticles with
HAP (KHAP =1.6x107 M-1) estimated from binding isotherm. This enhanced affinity of alendronate
nanoparticles for HAP in comparison with calcium ions in solution explains why calcium pre-
incubated PBLG10k-b-PEG6k-alendronate nanoparticles can still bind to HAP surfaces, this being a
competition which is favorable to HAP. After intravenous administration of nanoparticles, they are
confronted to physiological concentrations of calcium ions in the blood. Interestingly, this would
imply that even if nanoparticles could interact with calcium ions present in the bloodstream or
physiological fluids, this would be reversible and would not affect their interaction with the mineral
matrix of the bone tissue due to higher affinity to HAP.
Finally, molecular modelling studies were performed so as to determine the interactions involving
alendronate and HAP. Although the most important interactions between alendronate and HAP
involves the coordination of the calcium ions of HAP, the interactions involving alendronate/calcium
ions and alendronate/ HAP crystalline structure were not the same since in addition hydrogen bonding
involving the alendronate and the HAP structure are established (see figure 5). The theoretical models
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developed in this work for the interaction of alendronate with the HAP surface are important in
evidencing the detailed structural determinants of this interaction, at atomic level, and allow the
rational analysis of the experimental data showing a good affinity of PBLG nanoparticles for the bone
tissue. According to molecular modeling data, the theoretical number of free alendronate molecules
that can interact with a HAP surface unit of 95 nm2 or 75 nm2 was of 132 and 110 respectively,
depending on the crystal face. Experimentally, depending on the molecular weight of the PBLG block,
the number of alendronate decorating molecules could be considerably varied. However, irrespective
of the situation, binding sites available at HAP surface were in excess compared to the number of
alendronate available at nanoparticle surface. For example, in the case of the PBLG10k-b-PEG6k-
alendronate nanoparticles (about 60 alendronate per nanoparticle) only a reduced fraction of these
alendronate moieties was likely to interact with HAP surface due to nanoparticle size (ranging from 52
to 76 nm in size). Therefore, it could be concluded that numerous sites at the surface of HAP crystals
were available for interactions with alendronate molecules compared to the number of interactions
necessary in the case of alendronate decorated nanoparticles, which is obviously favorable for their
binding to HAP crystals included in bone matrix.
5- Conclusion
Bone-targeted multifunctional alendronate nanoparticles which showed strong affinity for HAP, one
major component of bone extracellular matrix, could be easily prepared. The binding isotherm for
PBLG10k-PEG6k-alendronate nanoparticles with HAP surfaces suggested that multivalency of the
nanoparticles resulted in 4000 fold stronger interactions with HAP compared the monovalent
interaction with free alendronate molecules. The molecular modeling studies yielded a deep insight
into the possible interactions of alendronate with HAP. These interactions could be considerably
enhanced by the ability of the nanoparticles to develop specific multivalent interactions with HAP, via
calcium binding as well as hydrogen bonding. In this case, it was suggested that steric hindrance due
to the size of the nanoparticles resulted in a very number of HAP binding sites involved in the
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interaction, which favors a very strong interaction between alendronate and HAP. Finally, the 900 fold
lower affinity of the nanoparticles for free calcium ions compared to HAP allowed calcium bound
nanoparticle to interact with HAP. This is favorable to maintain the targeting specificity of the
nanoparticles and yields a deeper understanding of bone targeted nanoparticle in the body.
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1. Chemical synthesis of PBLG-PEG6k-alendronate
Figure S1: Chemical pathway for the synthesis of PBLG-PEG6k-alendronate
2. Chemical synthesis of PBLG40k -FITC
Figure S2: Chemical pathway for the synthesis of PBLG40k-FITC
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3. Typical FTIR spectrum of a PBLG derivate polymerization
Figure S3: Typical infrared spectrum of a PBLG derivate polymerization after 1.5 hours (below) and 5 days
(above)
4. 31P NMR quantification of alendronate in PEG6k -alendronate
Figure S4: 31P NMR quantification of alendronate contained in PEG6k-alendronate in D2O using a solution of
KH2PO4 in D2O as a reference standard
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5. 1H NMR spectrum of PBLG-PEG6k-alendronate
Figure S5: 1H NMR spectrum of PBLG-PEG6k-alendronate in CDCl3 15 % TFA
6. Typical MALDI-TOF spectrum of a PBLG-derivate
Figure S6: Typical MALDI-TOF spectrum of a PBLG-derivate, here shown for PBLG25k-bnz
Chapitre II: PBLG-PEG-alendronate multivalent nanoparticles for bone targeting.
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
85
7. TEM images of different PBLG derivate nanoparticles
Figure S7: TEM images of different PBLG derivate nanoparticles
PBLG25k-bnz
PBLG40k-PEG6k-alendronate/ PBLG40k-FITC
PBLG10k-PEG6k-alendronate
PBLG10k-bnz/PBLG40k-FITC
PBLG10k-PEG6k-alendronate/PBLG40k-FITC
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6. Analysis of alendronate complexation at HAP-surfaces by molecular modeling
The analysis of HAP edifices(fig. 6.1) reveals the existence of two dissimilar surfaces, the first having a
rhomb shape (Face1) and the latter having a parallelepiped shape that correspond to the two lateral external
surfaces (Face2). Modifications were made on both surfaces by removing the external layer containing
calcium atoms, in order to make the oxygen atoms from the crystal structure available for direct interaction
with alendronate bisphosphonates. Relative distances between all oxygen atoms on HAP surface were
measured and compared with the corresponding distances in alendronate conformers.
Figure S8: HAP building block showing the two dissimilar surfaces: face 1 and face 2 having a rhomb and a
parallelepiped shape, respectively.
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Figure S9: Conformational search protocol and building of HAP-alendronate complexes
The areas of external surfaces of HAP were measured, in order to determine the specific surface for the
interaction with alendronate and for comparison with experimental data. The HAP structure that we generated
contains 1000 units (10x10x10 units from the crystal cell) with areas of 9427 Å² for the first surface (face 1)
and 7544 Å² for the second (face 2). According to our models, a number of 121 to 132 alendronate molecules
can theoretically interact with the first face (corresponding to interatomic oxygen-oxygen distances of 4.80 Å,
5.02 Å and 4.12 Å). Similarly, up to 110 alendronate molecules can interact with the second surface (face 2),
corresponding to the oxygen-oxygen distance of 4.75 Å as shown in fig. 6.3.
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Figure S10: Alendronate interaction with HAP surfaces
Face 2
Face 1
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Graphical Abstract
Resumé
Les cancers de la prostate et du sein ont une tendance élevée à métastaser dans l'os et représentent
deux causes majeures de mortalité par cancer. Des nanoparticules ciblées aux tissus osseux ayant une
taille ~50 nm et des propriétés anticancéreuses ont été préparées à partir du copolymère amphiphile
poly (glutamate de benzyle)-poly (acide glutamique) (PBLG-b-PGlu) par une méthode simple de
nanoprécipitation. Les nanoparticules PBLG-b-PGlu ont permis la complexation du cisplatine avec un
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taux d'association élevé de 6.2 ± 0.23 % (p/p). La libération du cisplatine était déclenchée par des
concentrations physiologiques d' ions chlorures et était parfaitement maîtrisée durant une période de
14 jours selon un cinétique d'ordre quasi zéro. Les nanoparticules cisplatine PBLG-b-PGlu ont montré
de façon simultanée des propriétés in vitro de ciblage osseux par des chaînes PGlu, mises en évidence
dans une expérience in vitro avec de l'hydroxyapatite et des nanoparticules fluorescentes. Finalement,
elles ont montré un effet cytotoxique dans trois lignées cellulaires de cancer de la prostate pouvant
potentiellement métastaser dans l'os. Ces propriétés suggèrent une utilité potentielle des nanoparticules
cisplatine PBLG-b-PGlu comme vecteurs pour le traitement de métastases osseuses dérivées de
cancer de la prostate.
Abstract
Prostate and breast cancers, two of the leading causes of death by cancer, have a high tendency to
metastasize to bone. Bone targeted nanoparticles of ~50 nm in size with anticancer properties were
successfully prepared from the amphiphilic copolymer poly(γ-benzyl-glutamate)-poly(glutamic acid)
(PBLG-b-PGlu ) by a simple nanoprecipitation method. PBLG-b-PGlu nanoparticles could complex
cisplatin with a high drug loading content of 6.2 ± 0.23 % (w/w). Cisplatin release was triggered by
physiological concentrations of chloride ions and was perfectly controlled during a 14 day period
according to an almost zero order kinetics. Simultaneously, cisplatin-loaded PBLG-b-PGlu
nanoparticles showed in vitro bone targeting properties mediated by the poly(glutamic acid) (PGlu)
moiety, as evidenced in an in vitro hydroxyapatite binding assay using fluorescent nanoparticles.
Finally, they were shown to exert a cytotoxic effect in three prostate cancer cell lines that potentially
metastasize to bone. These properties suggest the potential utility of cisplatin-loaded PBLG-b-PGlu
nanoparticles as carrier systems for the treatment of bone metastases derived from prostate cancer.
Keywords: bone targeting, cisplatin, cancer, nanoparticles, poly(benzylglutamate), poly(glutamic
acid)
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1- Introduction
The skeleton is the preferred metastatic site for breast and prostate cancers, which constitute the
second leading causes of cancer death in women and in men [1]. Many other cancers, such as lung,
renal, melanoma and multiple myeloma can also develop skeletal metastasis. Metastatic bone disease
results in metabolic complications such as hypercalcaemia, fractures, bone pain and spinal cord
compression and it is associated with a bad prognosis of the disease [2]. Chemotherapy is generally
poorly efficient and therapeutic alternatives, including chirurgical removal of metastasis, can be
foreseen in some situations, although it is not possible in many patients due to their general health
conditions and/or multiple dissemination.
Cisplatin is used for the treatment of different types of cancer, such as ovarian, testicular, bladder,
cervical, head and neck, small cell lung cancer and esophageal [3]. It is also used in combined
chemotherapy for advanced prostate cancer. However, its biodistribution properties should be
improved: cisplatin has a very short half life in the bloodstream due to glomerular excretion [4] and its
use is limited due to several side effects, the most threatening ones being neurotoxicity, nephrotoxicity
and ototoxicity [4, 5]. Moreover, cisplatin has showed minimal efficacy against some types of cancer
due to the development of resistances [6, 7].
To increase cisplatin therapeutic efficacy and to circumvent side effects, much research has been
focused on the development of targeted polymeric drug delivery systems [8]. Cisplatin has two
chloride groups that can be replaced by a variety of groups, such as carboxylates in low chloride
concentration medium. The good leaving property of carboxylates makes the metal complex
reversible, such property being used for the design of drug carrier systems. Therefore, much research
has been devoted to the development of macromolecular systems containing carboxylate groups so as
to form reversible complexes with cisplatin including polymer systems [9-11] and micellar forming
copolymers [9-13].
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Site specific drug delivery would allow to attain therapeutic concentrations locally, therefore reducing
side effects and the dose administered. Nanomedicine plays a major role in tissue specific drug
delivering. A lot of research has been focused on active targeting of cancer cells as a way of improving
treatment. Bone targeting drug delivery approach is a promising way of enhancing drug time of
residence within the bone affected by cancer and thus of increasing its therapeutic effect.
Herein, we report the preparation of bone targeted nanoparticles derived from an amphiphilic PBLG-
b-PGlu copolymer that can self-assemble into nanoparticles by a simple nanoprecipitation method.
Preformed PBLG-b-PGlu nanoparticles can then easily associate cisplatin via a coordinate bond and
show good bone targeting properties using hydroxyapatite (HAP) as an in vitro model. Cisplatin
(CDDP) from PBLG-b-PGlu nanoparticles is released in a sustained manner in a phosphate buffer
saline (PBS) medium to induce a cytotoxic effect on prostate cancer cell lines that constitute cellular
models for bone metastases [14].
2-Materials and Methods
2.1-Materials
Dimethylformamide (DMF) (99.8 %) Extradry Acroseal and cisplatin (CDDP) were purchased from
Acros, γ-benzyl-L-glutamate-N-carboxylic anhydride (BLG-NCA) was provided by IsoChem and
used as received. Hexylamine (puriss ≥99.5%), trifluoroacetic acid (TFA) (99 %), palladium on carbon
(Pd/C), deuterated chloroform (CDCl3) and blue trypan were provided by Sigma Aldrich. Dialysis
membranes were purchased from Carlroth, (Spectra Por). 1 mL microdialyzers used for in vitro drug
release experiments were bought from Orange Scientific. PGlu3000 and PGlu30000 were purchased from
Alamanda Polymers. PC-3 were kindly provided by the Institut Curie (Paris, France) and LNCaP and
DU-145 were obtained from American Type Culture Collection (ATCC). CellTiter 96® aqueous one
solution cell ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 sulfophenyl)-2H-
tetrazolium, inner salt) (MTS) proliferation assay was purchased from Promega. Double stranded
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deoxyribonucleic acid sodium salt from salmon testes (ds-DNA) was purchased for Sigma Aldrich and
used as received.
2.2- Synthesis of PBLG-b-PGlu copolymer
A poly(γ-benzyl-L-glutamate)-block-poly(glutamic acid) (PBLG-b-Pglu) copolymer was synthesized
by a modified method previously described [15]. Briefly, the synthetic approach consisted of
preparing a hydrophilic PGlu derivate, which was further used as a macroinitiator for the synthesis of
the hydrophobic PBLG block. The synthetic approach for the synthesis of this copolymer is shown in
Figure 1.
Figure 1: Synthetic scheme for PBLG-b-PGlu copolymer
2.2.1- Synthesis of hexyl-PBLG
Firstly, PBLG3000 polymer was synthesized by ring opening polymerization of γ-benzyl-L-glutamate-
N-carboxylic anhydride (BLG-NCA). Briefly, 3.9 g of BLG-NCA were weighed in a glove box under
inert atmosphere (argon) and were dissolved in DMF at a concentration of 0.5 M. The solution was
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stirred for 10 minutes and the initiator, a DMF solution of hexylamine at a concentration of 0.037 M,
was added with an argon-purged syringe. The solution was stirred at 30 °C during 5 days. Then, the
mixture was poured into a large excess of cold diethyl ether (DEE) and the precipitate filtered and
dried under vacuum. The extent of the reaction was controlled by infrared analysis, by checking the
disappearance of BLG-NCA bands and the appearance of the PBLG ones. A second purification step,
dissolving the precipitate in tetrahydrofuran (THF) and reprecipitating in DEE and drying it under
vacuum was made. This polymer was analyzed by proton nuclear magnetic resonance (1H NMR) in
CDCl3 + 15 % TFA and its molecular weight could be determined in function of the relative intensities
of the benzyl groups of the PBLG and of the methylene protons belonging to the hexylamine.
2.2.2- Debenzylation of hexyl-PBLG
The benzyl groups of the hexyl-PBLG polymer were eliminated by catalytic hydrogenation. Briefly,
1.6 g of hexyl-PBLG were dissolved in 27 mL of anhydrous DMF and 10 % of Pd/C was added to the
solution. After purging three times with argon, the reaction mixture was stirred for 3 days at room
temperature under overpressure of hydrogen (4 mbar). Then, the solution was centrifuged at 25°C,
4000 rpm for 10 minutes and was further filtered over 0.22 µm filters in order to eliminate the Pd/C
(black). It was then precipitated into a large excess of DEE, filtered and the precipitate dried under
vacuum at 40°C overnight. The reaction product was analyzed by 1H NMR in deuterated dimethyl
sulfoxide (DMSO (d6)).
2.2.3- Ring opening polymerization of BLG-NCA using hexyl-PGlu as a macroinitiator
Secondly, synthesis of PBLG-b-PGlu was achieved by ring opening polymerization of BLG-NCA.
Briefly, 1.8 g of BLG-NCA mg were dissolved in anhydrous DMF at a concentration of 0.5 M. The
solution was stirred for 10 minutes and the initiator, a DMF solution of hexyl-PGlu at a concentration
of 0.0031 M, was added with an argon-purged syringe. The solution was stirred at 30 °C during 7
days. Then, the mixture was poured into a large excess of cold DEE and the precipitate filtered and
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dried over vacuum. A second purification step, involving dissolution in THF/MeOH 75/25 and
reprecipitation into cold DEE, filtration and drying over vacuum was made. The evolution of the
reaction was controlled by infrared analysis, by checking the disappaerance of BLG-NCA bands and
the appearance of the PBLG ones. This polymer was analyzed by
1H NMR in CDCl3 + 15 % TFA and its molecular weight was determined by size exclusion
chromatography (SEC).
2.3- Synthesis of other PBLG derivates
PBLG-bnz and PBLG-dansyl were synthesized by a ring opening polymerization of BLG-NCA in the
conditions described above using benzylamine and dansylcadaverine respectively as initiators. For the
PBLG-dansyl, purification also included a washing step with methanol (MeOH).
2.4- Characterization of PBLG copolymers
2.4.1- Fourier transform infrared spectroscopy (FTIR)
FTIR spectra of the polymers were performed on a Fourier Transform Perkin-Elmer 1750
spectrometer using the attenuated total reflection system (ATR) to confirm the absence of NCA auto-
polymerization, to follow the evolution of the polymerization reactions and to study the secondary
structure of the polymers.
2.4.2- Proton nuclear magnetic resonance (1H NMR)
1H NMR spectra of polymers were recorded on a Bruker AC 300 MHz spectrometer in CDCl3 +15%
TFA for PBLG polymers and in deuterated dymethylsufoxide (DMSO d6). The role of the TFA is to
disrupt α-helix that PBLG polymers adopt in chloroform, rendering them in a random coil
conformation [16].
2.4.3- Size exclusion chromatography (SEC)
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SEC was used to determine the molecular weight of PBLG-b-PGlu. The SEC system was equipped
with two PLgel 5µm MIXED-D (7,5mm ID x 30,0cm L) and a PLgel 5µm guard column (guard
column 7,5mm ID x 5,0 cm L), a refractive index detector (Jasco 1530-RI) and a UV detector (Jasco
875-UV). DMF with 1g/L of lithium bromide (LiBr) was used as a diluent at a flow of 0.8 ml/min at
80°C and linear polystyrene samples were used as calibration standards.
2.5- Nanoparticle preparation
PBLG-b-PGlu nanoparticles were prepared following a novel nanoprecipitation method. Briefly,7.5
mg of the PBLG-b-PGlu copolymer were dissolved in THF/MeOH 75/25 at 40 °C at a concentration
of 0.1 nM without magnetic stirring. Once dissolved, they were added by dripping to an aqueous
solution containing two equivalents of sodium hydroxyde (NaOH) per equivalent of COOH and stirred
for 10 minutes. Solvents were eliminated by a standardized protocol under vacuum in the rotavapor at
40 °C. Nanoparticles size and ζ potential were determined by dynamic light scattering (DLS) at 25 °C
(Zetasizer 4, Malvern Instruments) after dialysis with a SpectraPor membrane (molecular weight cut
off 3000 Da) during 24 hours to eliminate the NaOH. PBLG-b-PGlu nanoparticle size and ζ potential
were measured before and after cisplatin association. Nanoparticles were observed by means of a
Transmission Electron Microscopy (TEM) at 120 KV (MET JEOL 1400) with phosphotungstic acid as
a negative coloration agent. Measurements of the longitudinal and axial radius of 100 nanoparticles
were made on TEM photos using Image J.
2.6- PBLG-b-PGlu nanoparticle interaction with cisplatin by isothermal titration calorimetry
(ITC)
Interaction of PBLG-b-PGlu nanoparticles with cisplatin was studied by ITC (Microcal.Inc.USA). The
cell was loaded with PBLG-b-PGlu nanoparticles at a molar concentration of polymer of 0.042 mM
and a molar concentration of COO- groups of 0.68 mM. The nanoparticle suspension was placed in the
measurement cell (approx. 1.3 mL) and stirred at 112 rpm by the syringe, which was filled with an
aqueous solution of cisplatin at a concentration of 0.8 mM. The titration of PBLG-b-PGlu
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nanoparticles involved a first injection of 5 µL followed by 27 injections of 10 µL during 20 s each
300 seconds. Experiments were carried out at 37 °C. PBLG-bnz nanoparticles, not containing COO-
groups, were used as a negative control.
2.7- Cisplatin association to PBLG nanoparticles
Cisplatin was dissolved in water at a concentration of 1 mg/mL and reacted with silver nitrate
(AgNO3) in a 1/1 [AgNO3/CDDP] molar ratio to form the aqueous complex. The solution was kept in
dark overnight at room temperature under gentle stirring. The presence of AgCl precipitates confirmed
the reaction [9, 11, 17]. Next, centrifugation of the reaction mixture at 10000 rpm for 10 minutes and
supernatant filtration over 0.22 µm filters was made in order to eliminate AgCl precipitates. The
content of cisplatin was measured by atomic absorption spectroscopy (AAS) (Varian® SpectrAA
220Z) as detailed in Supplementary Data (SD).
A first approach consisting of encapsulating the aqueous soluble poly(glutamic acid)-cisplatin
complex (PGlu-CDDP) in PBLG-bnz nanoparticles was assayed. PGlu-CDDP complex was obtained
after reaction of PGlu with aqueous cisplatin at a [CDDP/ COO-] ratio of 0.2, in dark for 48 hours at
25°C, under gentle stirring. Unreacted cisplatin was purified by a further dialysis (SpectraPor
membrane, molecular weight cut off 1000 Da) during 24 hours and cisplatin content measured by
AAS. Two different molecular weight of PGlu were assayed:3000 g/mol and 30000 g/mol. Next, the
PGlu-CDDP complex was encapsulated in PBLG-bnz nanoparticles by the nanoprecipitation method
described above, where the aqueous complex was dissolved in the aqueous phase. PBLG-bnz
nanoparticles were further filtered with 1µm filter and centrifuged at 20000 rpm for 1 hour at 4°C.
Cisplatin loading content was quantified by AAS as the difference between total cisplatin and
remaining cisplatin in the filter and supernatant.
A second approach consisting of complexing aqueous cisplatin to the carboxylate groups of the
preformed PBLG-b-PGlu nanoparticles was assayed. Firstly, the kinetics of the reaction of cisplatin
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with PBLG-b-PGlu nanoparticles at a [CDDP/COO-] ratio of 1.25 was followed over time. A
purification step by dialysis with a SpectraPor membrane (molecular weight cut off 3000 Da) was
performed during 24 hours. The cisplatin content in the nanoparticles was determined by AAS.
Secondly, PBLG-b-PGlu nanoparticles at a [COO-] of 0.86 mM were incubated under gentle stirring
with the cisplatin aqueous complex solution at different [CDDP/ COO-] feed ratios ranging from 0 to
1.56 and reacted for 60 hours in dark to form the complex between the hydrophilic chains of PGlu and
CDDP. Purification and analysis were made as described above. Cisplatin-loaded PBLG-b-PGlu
nanoparticles were prepared at a ratio [CDDP/ COO-] = 1.25 as described above for further
experiments. Drug loading content (mg of loaded cisplatin/mg of polymer * 100) and association
efficiency (mg of loaded cisplatin/mg of initial cisplatin * 100) were determined by AAS and
expressed in percentage.
2.8- In vitro cisplatin release
In vitro cisplatin release from the cisplatin-loaded PBLG-b-PGlu nanoparticles was studied by the
dialysis method in a 0.01 M phosphate buffer saline (PBS pH 7.4) containing 0.138 M of NaCl and in
distilled MilliQ water at 37 °C. Briefly, 0.950 mL of a PBLG-b-PGlu nanoparticle suspension at a
concentration of 0.75 mg/mL and containing 0.1 % of Pluronic F 68 were introduced in the 1 mL
microdialyzers and dialyzed against 15 mL of medium using dialysis membranes with a molecular
weight cut off of 3500 Da. The solution outside the microdialyzers was sampled at defined periods and
replaced with fresh medium. Cisplatin release was measured by AAS. Experiments were carried out
by triplicate. Control release experiments with a cisplatin solution in the conditions described above
were also carried out.
2.9- In vitro hydroxyapatite (HAP) binding assay
Multifunctional nanoparticles containing the fluorescent PBLG-dansyl polymer and the osteotropic
PBLG-b-PGlu copolymer, loaded with cisplatin at a ratio [CDDP]/[COO-]= 1.25 and containing 0.1 %
of poloxamer (Pluronic® F68, BASF) were incubated in a HAP (0.4 g/mL) suspension in PBS at a pH
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of 7.4 at 25 °C during 24 hours. The suspensions were centrifuged at 5000 rpm for 5 minutes, washed
three times with poloxamer 1% in PBS 7.4 and observed under UV light at 365 nm. Supernatants were
quantified by a Perkin Elmer Luminescence spectrometer LS 50B at room temperature ( λ excitation =340
nm . λ emission= 472 nm) so as to determine the amount of nanoparticles not bound to HAP.
2.10- Interaction of cisplatin released from PBLG-b-PGlu nanoparticles with DNA
The capability of cisplatin released from nanoparticles to interact with DNA has been evidenced by
electrochemistry. 2 mL of a cisplatin loaded PBLG-b-PGlu nanoparticle suspension at a concentration
of 1.5 mg/mL were incubated in PBS (pH 7.4) during 1 week in the presence of an excess of double
stranded DNA (dsDNA). A positive control was performed with a 0.2 mM cisplatin solution.
Electrochemical experiments were performed at 298±1 K in a thermostated cell with a CH I660
equipment. A BAS MF2012 glassy carbon working electrode (GCE) (geometrical area 0.071 cm2), a
platinum wire auxiliary electrode and an Ag/AgCl (3M NaCl) reference electrode were used in a
conventional three-electrode arrangement. 0.10 M potassium phosphate buffer (pH 7.0) and PBS (pH
7.4), deaerated by argon bubbling during 15 min, were used as supporting electrolytes.
2.11- In vitro cytotoxicity studies
The cytotoxic effect of free cisplatin, PBLG-b-PGlu nanoparticles and cisplatin-loaded PBLG-b-PGlu
nanoparticles was studied in three different prostate cancer cell lines, PC-3, DU-145 and LNCaP by
the MTS cell viability assay 48 and 72 hours after exposure. PC-3, DU-145 and LNCaP were grown in
RPMI 1640 (BE 12−702 F, Lonza) supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(Lonza), penicillin (100 UI/mL), and streptomycin (100 μg/mL). Cells were maintained in a 95%
humidified atmosphere of 5% CO2 at 37 °C. Cells were seeded in 96-well plates (5.5 103 cells per
well) and were pre-incubated during 48 hours. Then, cisplatin, PBLG-b-PGlu nanoparticles and
cisplatin-loaded PBLG-b-PGlu nanoparticles at different concentrations were added and after 48 or 72
hours 20 µL of MTS solution per well were added. Viable cells were quantified by recording the UV
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absorbance at 492 nm using a plate reader multi-well scanning spectrophotometer (Labsystems
Multiskan MS). Cytotoxicity was also followed by the blue trypan exclusion assay. Briefly, fresh
media was replaced by trypsine 0.25 % EDTA and once cells were in suspension trypan blue was
added. Cells were counted through a hemacytometer (Kova slides).
3- Results and discussion
3.1-Synthesis and characterization of PBLG polymers
Characteristic peaks were identified for hexyl-PBLG polymer in 1H NMR (see SD). The degree of
polymerization (DPn) could be determined in function of the relative intensities of the benzyl groups of
the PBLG and of the methylene protons belonging to the hexylamine and it was found to be 16 (see
SD). The debenzylation reaction is driven to completion as confirmed by the absence of the benzyl and
aromatic protons peaks (see SD). 1H NMR spectrum of the PBLG-b-PGlu copolymer is shown below
(figure 2).
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Figure 2: 1H NMR spectrum of PBLG-b-PGlu in CDCl3 + 15% TFA
Infrared study of PGlu polymer, which presented a DPn of 16, revealed a majority of α-helices with a
minor existence of β-sheets, evidenced by a shoulder at 1628 cm-1 (see SD). This is in coherence with
the reported secondary structures for PBLG polymers with a DPn <18 [18] and for PGlu oligomers
(see SD) [19]. Carboxylic acids from PGlu were in the protonated state as evidenced by the band at
1710 cm-1. PBLG-b-PGlu copolymer presented an α-helix structure, as shown by the amide I amide II
and amide III bands at ~1655cm-1, ~1550 cm-1 and ~1260 cm-1 respectively and the ester C=O band at
~1735 cm-1 (see SD) [20-22].
Table 1: Experimental molecular weights of the PBLG polymers determined by SEC. (a) DPn of the PBLG
block
3.2- Nanoparticle preparation
The preparation of novel PBLG-b-PGlu nanoparticles was achieved by a new nanoprecipitation
method, modified from a previously described one [20]. The use of NaOH was essential for
nanoparticle preparation since it ionized the carboxylate groups of the hydrophilic PGlu block,
avoiding nanoparticle aggregation. DLS measurements suggested that the nanoparticles had a
hydrodynamic diameter in the range of 50 nm and a very negative ζ potential, as a result of the ionised
carboxylate groups, which enhanced the nanoparticle stability. Accurate size measurements from TEM
images revealed that nanoparticles presented an ellipsoidal form with an aspect ratio of 1.33 and an
actual size of 37 ± 7 nm x 27 ± 6 nm, with no significant changes in the morphology and size after
cisplatin coordination.
PBLG polymers Mn (g/mol) PI
PBLG-b-PGlu 24436 1.7
PBLG-bnz 31727 1.1
PBLG-dansyl 25944 1.1
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Table 2: Size and ζ potential determined by DLS of PBLG-derivate and PBLG-b-PGlu nanoparticles
prepared at different [CDDP]/[COO-] ratios
a (n=3) b CDDP content determined by AAS expressed as mass of associated CDDP per mass of
nanoparticles (% w/w)
Nanoparticles might exhibit a core-shell structure, where the inner hydrophobic core is formed by the
stacking of quite rigid α-helices of the PBLG blocks and the outer shell by the hydrophilic PGlu
chains. PGlu chain conformation is known to be dependent on pH. At acidic pH (<4.3-4.9) the side
chains are protonated [23] and can adopt an α-helix conformation whereas when side chains are
charged (pH>5), electrostatical repulsion between the side chains induces a random coil conformation
[24-26]. The pH of nanoparticle suspensions was 7.9, above the pK for PGlu and thus carboxylate
groups were ionized, which avoided nanoparticle aggregation. Therefore, PGlu should adopt a random
coil conformation and should be forming the outer hydrophilic flexible shell. Metal interactions can
have a significant impact on the secondary structures of PGlu [27]. Cisplatin coordination to the COO-
Nanoparticles Size (nm) ±
SD a
Polydispersity
Index ± SD a
ζ Potential
(meV) ± SD a
Drug loading
contentb
(w/w%)
PBLG-bnz
PBLG-dansyl
57 ± 1.1
58 ± 0.91
0.17 ± 0.073
0.12 ± 0.0077
-37 ± 2.5
-45 ± 1.5
0
PBLG-b-PGlu
nanoparticles
53 ± 0.11 0.13 ± 0.010 -37 ± 2.4 0
After CDDP loading at
[CDDP]/[COO-] ratio
0.3 52 ± 0.61 0.22 ± 0.075 -36 ± 2.5 0.36
0.5 49 ± 1.1 0.15 ± 0.049 -34 ± 0.3 0.62
0.8 49 ± 0.12 0.17 ± 0.0071 -34 ± 0.81 2.3
1.0 51 ± 0.53 0.12 ± 0.0089 -32 ± 2.2 5.3
1.2 50 ± 0.31 0.12 ± 0.0077 -35 ± 0.74 5.9
1.6 51 ± 0.33 0.15 ± 0.0084 -33 ± 1.3 8.3
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groups could lead to an enhancement of the α-helical conformation, as it has been previously reported
for other metals [28]. However, infrared spectroscopy and circular dichroism studies showed an α-
helical conformation, with absence of random coils. Further studies should be necessary to fully
understand the conformation adopted by the PGlu block in the PBLG-b-PGlu copolymer and
nanoparticles and the influence of pH and cisplatin coordination.
3.3- Cisplatin association to PBLG nanoparticles
Once PBLG-b-PGlu colloidal suspensions were obtained, cisplatin was associated to the preformed
PBLG-b-PGlu nanoparticles through incubation with an aqueous cisplatin solution, which is most
appropriate for complex formation due to better leaving group properties of hydroxide/water
molecules compared to chloride ions.
Figure 3: [CDDP]/[COO-] incorporated ratio to the PBLG-b-PGlu nanoparticles at different
[CDDP]/[COO-] feed ratios.
DLS measurements showed that nanoparticles size remained constant (~50 nm) before and after
cisplatin association. As shown in figure 3, the incorporated ratio increased almost linearly when the
[CDDP]/[COO-] feed ratio increased from 0.6 to 1.6, suggesting no saturation in this range of
concentration ratios. It can be estimated that the core-shell structure was maintained for cisplatin-
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loaded PBLG-b-PGlu nanoparticles, since remaining negative electric charges could still exist on the
PGlu chains after cisplatin coordination as shown by figure 3.
However, shell cross-linking could be foreseen considering that cisplatin can bind up to two COO-
groups born by two adjacent PGlu chains. Cisplatin can form complexes with poly(carboxylates)
groups where one or two carboxylates could be complexed to cisplatin. The 1.25 [CDDP]/[COO-] feed
ratio was chosen for further experiments where the [CDDP]/[COO-] incorporated ratio was of 0.27,
which was considered to be a good balance between cisplatin loading and nanoparticle stability. At the
0.27 incorporated ratio, free COO- groups which are not coordinated to cisplatin remained ionized and
enhanced the colloidal stability of nanoparticle suspension.
Figure 4: Kinetics of the reaction of PBLG-b-PGlu nanoparticles with aqueous cisplatin at a
[CDDP]/[COO-] ratio of 1.25.
Therefore, nanoparticle suspensions were stable for a prolonged period of time (up to several months)
and did not exhibit aggregation or precipitation behaviour. The kinetics of the reaction of the
carboxylates on the outer shell of the PBLG-b-PGlu nanoparticles and aqueous cisplatin was followed
(figure 4). Although usual reaction times to form cisplatin-polycarboxylate complex have been
reported as 24 hours [30], 48 hours and 72 hours (for cisplatin-P(Asp or Glu)-PEG micelles whose
formation is driven by the formation of cisplatin-polymer complexes), reaction of PBLG-b-PGlu
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nanoparticles with aqueous cisplatin was much more rapid and was almost completed in few hours.
These results are in coherence with the reaction kinetics of cisplatin with PEG-P(Asp) copolymer
shown for similar poly(glutamic acid) chain lengths [12].
3.4- PBLG-b-PGlu nanoparticle interaction with cisplatin by ITC
ITC experiments were conducted to study the interaction between PBLG-b-PGlu nanoparticles and
cisplatin.
Figure 5: Typical ITC raw data and integrated heat data proﬁles obtained from the interaction of cisplatin
at 0.8 mM with PBLG-b-PGlu nanoparticles at [COO-] of 0.68 mM and compared to the negative control
PBLG-bnz nanoparticles.
As shown in figure 5, an interaction that did not exist for control PBLG-bnz nanoparticles, which
could be considered as the core of the PBLG-b-PGlu nanoparticles, was found. The effect of the 1.5 %
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of NaOH used for nanoparticle preparation was checked and was found to be negligible. Heats
measured during ITC experiments are the sum of different processes implied during cisplatin
association to nanoparticles, including possible polymer conformation changes [31].
Cisplatin contains two chloride ligands that can be replaced by the carboxylate groups belonging to the
PBLG-b-PGlu nanoparticle shells. At low [CDDP]/[COO-] ratios, as in the conditions of the
experiment, a stoichiometry of two COO- per CDDP could be favoured. Carboxylate-metal complexes
could occur between cisplatin and carboxylate groups belonging to the same or an adjacent PGlu
chain, inducing conformational changes that could induce heat variations. Therefore, the heat
measured included both cisplatin binding to the carboxylate groups and possible conformation changes
of the PGlu chains induced by it.
3.5- Cisplatin loading content
Since cisplatin is a water soluble and hydrophilic molecule, direct cisplatin encapsulation into the
PBLG nanoparticles was not assayed. PBLG-b-PGlu complex encapsulation in PBLG-bnz
nanoparticles using two different molecular weights of PGlu, 3000 g/mol and 30000 g/mol, was found
to be negligible, with drug loadings of 0.066 ± 0.11 % and of 0.18 ± 0.30 % respectively and drug
encapsulation efficiencies of 1.9 ± 3.4 % and 6.4 ± 9.8 %. Since PGlu has a polypeptide backbone as
the nanoparticle forming PBLG-bnz polymer, interactions between these two similar chains could
have been expected. However, this was not the case. As explained above, the approach implying the
complexation of cisplatin to the carboxylate groups of preformed PBLG-b-PGlu nanoparticles was
much more successful and revealed to be simple in view of scaling up the preparation process. The
initial ratio [CDDP/COO-] was adjusted to 1.25 to have an optimal balance between stability and
cisplatin association. In these conditions, drug loading content was found to be 6.2 ± 0.23 % with a
drug association efficacy of 16 ± 0.58 %.
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3.6- In vitro cisplatin release
Cisplatin release was triggered by chloride ions. In presence of chloride ions, cisplatin-loaded PBLG-
b-PGlu nanoparticles released cisplatin in a sustained manner with a remarkable absence of initial
burst under physiological conditions (figure 6). The absence of a burst effect suggests that cisplatin
was mainly associated to nanoparticles through complexation to the carboxylate groups and not
physically entrapped. An almost linear release profile was obtained suggesting an almost zero order
kinetics on the whole range. Remarkably, cisplatin was completely released from the PBLG-b-PGlu
nanoparticles, more than 90 % was released after 14 days. Cisplatin release from nanoparticles was
slow; less than 10 % and 50% of cisplatin was released after 24 hours and 7 days respectively. It is
striking to compare cisplatin association and release kinetics from the PBLG-b-PGlu nanoparticles, the
latter being much slower. These differences can be attributed to the fact that cisplatin association to
PGlu and cisplatin release in presence of chloride ions are two distinct chemical reactions.
Figure 6: In vitro cisplatin release from a cisplatin solution and from cisplatin-loaded PBLG-b-PGlu
nanoparticles in 0.01 M PBS (pH 7.4) containing 0.138 M of NaCl and in water.
As previously reported in the literature, the presence of chloride ions is essential for cisplatin release
due to a ligand exchange reaction where chloride ions would substitute the Glu residues from the
PBLG-b-PGlu nanoparticle, due to good leaving properties of Glu residues [12]. Other ions such as
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acetates or phosphates can also play a minor role in the release of cisplatin. An enhanced cisplatin
release from carboxylate complex at mild acidic pH involving the protons has also been reported [32].
However, contrarily to what has been previously described in the literature for cisplatin-carboxylate
complexes [9, 11, 17] and cisplatin-loaded micelles [12, 13], release of cisplatin in distilled water
medium did take place, although it was considerably reduced, since less than 2 % and only 20 % of the
initial dose was released after 48 hours and 14 days respectively.
3.7- In vitro HAP binding assay
An in vitro HAP binding assay showed a total binding for cisplatin-loaded PBLG-b-PGlu and
fluorescently labelled (33% of PBLG-dansyl and 66% of PBLG-b-PGlu) nanoparticles (figure 7).
HAP binding property was driven by the PGlu block polymer and not by the PBLG or dansyl moiety
as evidenced by the absence of binding of the negative control PBLG-dansyl nanoparticles.
Figure 7: Degree of HAP binding expressed in percentage of nanoparticles bound to HAP. PBLG-dansyl
nanoparticles and cisplatin-loaded PBLG-b-PGlu/PBLG-dansyl nanoparticles at a concentration of 1.5
mg/mL in 0.1 % poloxamer were incubated with 0.4 g of HAP suspension in PBS during 1 hour.
Indeed, oligomers of glutamic acid have been shown to have both in vitro and in vivo affinity to bone
matrix and HAP respectively [33] and it has been used to provide drugs with osteotropic properties
[34]. In the case of cisplatin-loaded PBLG-b-PGlu nanoparticles, the complexation of cisplatin to
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carboxylate groups at a [CDDP]/[COO-] ratio of 1.25 did not affect their bone binding properties,
likely due to the free carboxylate groups remaining available for interactions. Besides, cisplatin could
also be involved in HAP binding [35].
3.8- Interaction of cisplatin released from PBLG-b-PGlu nanoparticles with DNA
Adduct formation between DNA and platinum derivates is responsible for their cytotoxic activity. An
electrochemical technique has been used in order to assess the capability of platinum species to
interact with DNA after being progressively released from cisplatin-loaded PBLG-b-PGlu
nanoparticles. Indeed, electrochemical detection techniques can be conveniently used to monitor
cisplatin interactions with DNA [36]. Voltammograms for cisplatin-loaded PBLG-b-PGlu
nanoparticles incubated with PBS in presence and absence of a DNA solution were different (figure
8).
Figure 8: Square wave voltammetry (SWVs) for a) cisplatin solutions in phosphate buffer (pH 7.0); b)
cisplatin-loaded PBLG-b-PGlu nanoparticles in phosphate buffer; c) free cisplatin diluted in PBS (pH 7.4)
and incubated with DNA for 24 hours d) cisplatin loaded PBLG-b-PGlu nanoparticles previously
incubated in PBS for 5 days and with DNA for 24 hours. Potential scan initiated at +0.4 V in the negative
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direction; potential step increment 4 mV; square wave amplitude 25 mV; frequency 5 Hz. Arrows indicate
the DNA-bound cisplatin signal.
The response of free cisplatin with DNA in phosphate buffer was performed as a positive control. The
voltammograms in figure 8 showed intense peaks at -1.10 V, corresponding to the interaction of free
cisplatin with DNA. The peak observed at -0.45 V in the case of free cisplatin (figure 8a and 8b) could
be attributed to the adsorption of cisplatin to the electrode surface. Further voltamogramms in figure
8c and 8d suggested that the cisplatin released from the cisplatin-loaded PBLG-b-PGlu nanoparticles
during PBS incubation was able to interact with the DNA strands similarly to free cisplatin.
3.9- In vitro cytotoxicity assay
The in vitro cytotoxic activity of cisplatin-loaded PBLG-b-PGlu nanoparticles has been determined in
three different prostate cancer cell lines that have the potential to metastasize to bone [14]. As inferred
from figure 9, which corresponds to the MTS assay, PBLG-b-PGlu nanoparticles exhibited no or very
low toxicity for PC-3 and DU 145 cell lines whereas for LNCaP cell line they were not toxic under 25
µM. The MTS assay revealed a dose-dependent response on all three cell lines. Lower cytotoxicity
was observed for cisplatin-loaded PBLG-b-PGlu nanoparticles than for free cisplatin, which was also
confirmed by the blue trypan assay (see SD). This might be related to the fact that cisplatin is
coordinated to PBLG-b-PGlu nanoparticles and is slowly released. This lower cytotoxicity has already
been reported for other cisplatin carboxylate coordination complexes within a wide range of cancer
cell lines. Therein, their IC50 values were between 6-15 times higher than those of free cisplatin, this
low toxicity not compromising the antitumour activity [11, 28]. Cytotoxicity of cisplatin-loaded
PBLG-b-PGlu nanoparticles appeared to be enhanced with time as suggested by the 48 and 72 hours
IC50 values. This suggests an elapsed time for nanoparticles to be cytotoxic either through cell
internalisation or cisplatin release in the vicinity. Once distributed to bone and due to the bone binding
properties of the PGlu ligand, nanoparticles could remain in the bone tumour vicinity, and thus they
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could constitute drug reservoirs for sustained cisplatin release for the treatment of skeletal
malignancies.
Figure 9: In vitro cytotoxicity profiles of free cisplatin, cisplatin-loaded PBLG-b-PGlu nanoparticles
and PBLG-b-PGlu nanoparticles after 48 and 72 hours after exposure determined by the MTS assay.
cisplatin 48 hours;  cisplatin 72 hours;▲ PBLG-b-PGlu np 48 hours;▼ PBLG-b-PGlu np 72
hours; ◄ PBLG-b-PGlu -CDDP np 48 hours; ► PBLG-b-PGlu-CDDP np 72 hours.
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Table 3: IC50 values for free cisplatin and cisplatin-loaded PBLG-b-PGlu nanoparticles after 48 and 72
hours after exposure determined by the MTS assay
4- Conclusion
We report the synthesis of novel PBLG-b-PGlu nanoparticles with the dual functionality of bone
targeting and efficient cisplatin loading and controlled release. PBLG-b-PGlu nanoparticles could
complex high cisplatin payloads (6.2 % w/w) without affecting stability and released it in a very
sustained way, triggered by chloride ions, in order to produce cytotoxic effects in three different
prostate cancer cell lines that could potentially metastasize to bone.
Simultaneously, cisplatin-loaded PBLG-b-PGlu nanoparticles showed very efficient hydroxyapatite
binding suggesting potential for in vivo bone targeting. Therefore, in vivo drug residence time into or
in the vicinity of the bone tumour could be potentially enhanced. Favourably, sustained cisplatin
release from these nanoparticles may help to prolong cytotoxic effects, making them promising
carriers for the treatment of bone metastases derived from prostate cancers.
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1. 1H NMR spectra of polymers
Figure 1: 1H NMR spectrum of hexyl-PBLG polymer
Figure 2:1H NMR spectrum of hexyl-PGlu polymer
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2. FTIR spectra of polymers
Figure 3: FTIR spectrum of solid-state hexyl-PGlu polymer
Figure 4: FTIR spectrum of solid-state PBLG-b-PGlu copolymer
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3. TEM images of PBLG-b-PGlu nanoparticles
Figure 5: TEM images at 120 kV of PBLG-b-PGlu nanoparticles using 1% phosphotungstic acid as
negative coloration; left: before cisplatin loading; right: after cisplatin loading
4. AAS for cisplatin determination
Table 1: Detailed procedure of the GFAAS heating program
Step Furnace
Temperature(°C)
Ramp Time (s) Hold Time (s) Internal Gas Flow
(L.min-1)
1 40 0 0.1 3 Drying
2 120 55 0 3
3 600 10 5 3
4 1300 5 5 3
Ashing
5 1300 0 0.5 0
6 2700 0.9 2 0 Atomizing
7 2850 1 0 3
Cleaning
8 40 22 0 3
The instrument used for AAS was a Varian® SpectrAA graphic furnace AA spectrophotometer
(model 200Z) (GFAAS) (Australia) with Zeeman background correction and equipped with an
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adapted autosampler, an ultrAA® platinum lamp and a pyrolytically coated graphite tube
(Varian® partition tubes (coated)-GTA). A platinum hollow-cathode lamp was used as radiation
source at 265.9 nm with a slit width of 0.5 nm. Lamp current was set at 10.0 mA. Volume of
automatic sample injection was 20 μL; internal Ar flow rate was 3 L.min-1 and was stopped during
atomizing. Details of the GFAAS heating program are listed in table 1.
5. Blue trypan exclusion assay
Figure 6: In vitro cytotoxicity profiles obtained by the blue trypan exclusion assay of free cisplatin,
cisplatin-loaded PBLG-b-PGlu nanoparticles and PBLG-b-PGlu nanoparticles after 48 and 72 hours
after exposure determined by the MTS assay. cisplatin 48 hours;  cisplatin 72 hours;▲ PBLG-b-
PGlu np 48 hours;▼ PBLG-b-PGlu np 72 hours; ◄ PBLG-b-PGlu-CDDP np 48 hours; ► PBLG-b-
PGlu-CDDP np 72 hours.
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Résumé
La voltammétrie a été mise en œuvre afin de caractériser à pH voisin de la neutralité et en présence
d’ions des nanoparticules multifonctionnelles de poly(L-glutamate de γ-benzyle)-poly(acide
glutamique) conçues pour le ciblage des tissus osseux. L’affinité de ces nanoparticules pour
l'hydroxyapatite, c'est-à-dire la composante minérale majoritaire de l'os, a été réalisée grâce à la
décoration de la surface des particules par des chaînes de poly(acide glutamique). Des signaux
voltammétriques significativement différents ont permis de mettre en évidence l'association du
cisplatine aux nanoparticules et d’établir sa cinétique de libération, en concordance avec les
expériences de spectroscopie d'absorption atomique. La fixation des nanoparticules à l'hydroxyapatite
a été évaluée par marquage en fluorescence des nanoparticules et a été confirmée par la technique
d'électrochimie. En conclusion, la méthode électrochimique permet de confirmer les données obtenues
par les méthodes de caractérisation par absorption atomique et fluorescence, tout en apportant des
informations complémentaires
Abstract
The voltammetric response of different processes concerning cisplatin-complexed (γ-benzyl-L-
glutamate)-b-poly(glutamic acid) derivate nanoparticles with bone targeting properties was studied in
aqueous electrolytes and at biological pH. Bone targeting properties were achieved by targeting
hydroxyapatite, the major mineral component of bone, by decorating the nanoparticles with poly
(glutamic acid) chains. Significant differences in the cisplatin-centered voltammetric signals allowed
to monitor cisplatin association to nanoparticles as well as release kinetics from them, in agreement
with the data generated by atomic absorption spectroscopy experiments. In vitro hydroxyapatite
binding assay was performed by using fluorescencently labelled nanoparticles and was further
confirmed by electrochemistry, using the voltammetry method previously developed for microspheres.
Electrochemistry revealed as a very useful tool which provides with complementary information to
that obtained by atomic absorption spectroscopy and fluorescence techniques.
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1- Introduction
Cisplatin is a cytotoxic metallodrug used for the treatment of different types of cancers, such as
ovarian, testicular, bladder, cervical, small cell lung cancer, esophageal, head and neck [1]. The main
target accounting for the cytotoxic action of cisplatin is DNA [2], although other non-DNA targets are
also involved [3]. However, its use is highly limited due to several strong side effects, the most
threatening ones being neurotoxicity, nephrotoxicity and ototoxicity [4, 5].
In order to circumvent side effects and to increase the therapeutic activity, research has been focused
in the development of cisplatin targeted nanoparticle carrier systems. Cisplatin structure allows
chemical modifications, due to the presence of two chlorides that can be replaced by a wide variety of
chemical groups, such as carboxylate units and such property being used for the design of drug carrier
systems [6, 7]. The good leaving properties of carboxylate group converts the metal complex
reversible, allowing the release of cisplatin from the carrier.
Electrochemical methods are very sensitive, easy to handle and inexpensive tools for drug detection.
In the cisplatin (cis-dichlorodiamineplatinum (II), [PtII(NH3)2Cl2]), the platinum can be
electrochemically reduced to Pt0 and this voltammetric response can be employed to determine its
concentration, complexation and to monitor its role in biochemical processes [8-10].
In this work, multifunctional cisplatin-complexed poly(γ-benzyl-L-glutamate) block poly(glutamic
acid) (PBLG-b-PGlu) derivate nanoparticles where the metallodrug is coordinated to the carboxylate
groups of the poly(glutamic acid) and possessing bone targeting properties were prepared. Bone
targeting properties were achieved by targeting hydroxyapatite (HAP), the major mineral component
of bone. Poly(glutamic acid) (PGlu) block was used to target HAP, since acidic oligopeptides have
shown in vitro and in vivo bone affinity and they have been used to provide drugs with osteotropic
properties [11]. Association of cisplatin to PBLG-b-PGlu derivate nanoparticles, cisplatin release from
them and bone targeting properties were studied. A multiple electrochemical approach combining
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conventional solution-phase voltammetry and voltammetry of microparticles approaches [12-14],
allowed to monitor these three processes. Electrochemical tools are proposed as innovative tools for
monitoring properties of active targeting metal containing nanoparticles providing complementary
information to the results obtained by other techniques.
2- Materials and Methods
2.1- Materials
Cisplatin, phosphate buffer saline (PBS) and hydroxyapatite (HAP) were purchased from Acros and
Sigma, respectively. All reagents were of analytical grade and used directly. Dialysis membranes were
purchased from Carlroth, (Spectra Por). 1 mL microdialyzers used for in vitro drug release
experiments were bought from Orange Scientific. The glassy carbon working electrode (GCE) was
purchased to BAS MF2012.
2.2- Atomic absorption spectroscopy (AAS) detection
Cisplatin content of the nanoparticles was quantified by AAS. Details of the instrument and heating
program used are found in Supplementary Information (SI).
2.3- Electrochemical detection
Electrochemical experiments were performed at 298±1 K in a thermostated cell with CH I660
equipment. A BAS MF2012 glassy carbon working electrode (GCE) (geometrical area 0.071 cm2), a
platinum wire auxiliary electrode and an Ag/AgCl (3M NaCl) reference electrode were used in a
conventional three-electrode arrangement. 0.10 M aqueous potassium phosphate buffer (pH 7.0) and PBS
(pH 7.4), optionally dearated by bubbling Argon during 15 min, were used as supporting electrolytes.
Blank experiments were conducted in ca. 1 mM cisplatin solutions. For in vitro HAP binding assay, a
different electrochemical strategy, previously developed for microspheres has been adaptated to
nanoparticles such as described in section 2.7.
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2.4- Preparation of multifunctional poly(γ-benzyl-L-glutamate) (PBLG) nanoparticles
PBLG copolymers were obtained by a ring opening polymerization (ROP) procedure previously
described. Multifunctional nanoparticles based either only on PBLG-b-PGlu copolymer or from a
mixture of this and poly(γ-benzyl-L-glutamate) block poly(ethylene glycol) (PBLG-b-PEG) were
prepared following a novel nanoprecipitation method. Briefly, different proportions of the copolymer
PBLG-b-PGlu and PBLG-b-PEG were dissolved in tetrahydrofuran/methanol 75/25 (THF/MeOH) at
40 °C at a concentration of 0.1 nM without magnetic stirring. Once dissolved, they were added by
dripping to an aqueous solution containing two equivalents of sodium hydroxide (NaOH) per
equivalent of carboxylic acid (COOH) contained in the PGlu block and stirred for 10 min. Solvents
were eliminated by a standardized protocol under vacuum in the rotavapor at 40 °C. Nanoparticles size
and ζ potential before and after incubation with cisplatin were determined by dynamic light scattering
(DLS) at 25 °C (Zetasizer 4, Malvern Instruments). Morphological characterization of nanoparticles
was performed by means of transmission electron microscopy (TEM) at 120 kV (TEM JEOL 1400)
after negative coloration with phosphotungstic acid 1% w/w. Measurements of the longitudinal and
axial diameter of 100 nanoparticles of each type were made on TEM photos using Image J.
2.5- Cisplatin association to PBLG-b-PGlu and PBLG-b-PGlu/PBLG-b-PEG nanoparticles
Cisplatin was associated to preformed nanoparticles prepared from PBLG-b-PGlu or PBLG-b-PEG or
from a mixture of them at different proportions. Cisplatin-complexed PBLG-b-PGlu/PBLG-b-PEG
nanoparticles were prepared at [CDDP/COO-] ratios of 0.8 and 1 and reacted for 60 h in dark to form
the complex between the carboxylate groups of PGlu block and cisplatin. A purification step by
dialysis (membrane of a molecular weight cut off size of 3000 Da, SpectraPor) was performed during
24 h. The cisplatin content in the nanoparticles was determined by AAS.
The electrochemical response of cisplatin and cisplatin-complexed PBLG-b-PGlu/PBLG-b-PEG
nanoparticles was studied. PBLG-b-PGlu/ PBLG-b-PEG nanoparticles were incubated with cisplatin
at a ratio of [CDDP/COO-] = 1 in the conditions described above. A cisplatin solution of 4 mM was
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used as a positive control. PBLG-benzyl (PBLG-bnz) nanoparticles, not containing COO- substituents,
were incubated with cisplatin as described and used as a negative control. No purification step was
done. The electrochemical response was achieved diluting each sample in 1 mL of aqueous phosphate
buffer (pH=7).
2.6- In vitro drug release from cisplatin-complexed PBLG-b-PGlu nanoparticles
In vitro cisplatin release from the PBLG-b-PGlu nanoparticles was studied by the dialysis method in a
0.01 M PBS at pH 7.4 containing 0.138 M of NaCl and in distilled MilliQ water at 37 °C. Briefly,
0.950 mL of nanoparticles at a concentration of 0.75 mg/mL containing 0.1% of Pluronic® F 68 were
introduced in 1 mL microdialyzers and dialyzed against 15 mL of medium using dialysis membranes
with a molecular weight cut off of 3500 Da. The solution outside the microdialyzers was sampled at
defined periods and replaced with fresh medium. The release of cisplatin was measured by AAS.
The cisplatin loading content is expressed as the mg of loaded cisplatin with respect to 100 mg of the
PBLG-b-PGlu nanoparticle forming copolymer.
The electrochemical response of cisplatin-complexed PBLG-b-PGlu nanoparticles in aqueous
phosphate buffer (pH=7) was studied diluting 1 mL of the nanoparticles solution with 1 mL of PBS
(pH=7.4) and 1 mL of water respectively for 5 days.
2.7- In vitro HAP binding assay
Fluorescently-labelled bone targeted nanoparticles containing the fluorescent PBLG-dansyl, and an
osteotropic PBLG derivate, PBLG-b-PGlu copolymer in 0.1 % of Pluronic® F 68 were incubated in 3
mL of PBS containing 0.4 g of HAP at a pH of 7.4 during 24 hours at 25°C. The suspensions were
centrifuged at 5000 rpm for 5 minutes, washed three times with Pluronic® F 68 1% / PBS 7.4 1/1 and
observed under UV light at 365 nm. Supernatants were quantified by a Perkin Elmer Luminescence
spectrometer LS 50B at room temperature ( λ excitation = 340 nm . λ emission = 472 nm) to determine the
amount of nanoparticles not bound to HAP.
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For the electrochemical detection, a different strategy, based on a voltammetric methodology
originally proposed for microparticles was used [12, 15]. This methodology has been previously used
to study nanoparticle systems [16]. Microparticulate deposits of HAP on GCE were prepared by
evaporation of suspensions (1 mg/mL) of the solid in ethanol (EtOH). Blank experiments were
performed with HAP. Briefly, 1 ml of monofunctional cisplatin-complexed PBLG-b-PGlu
nanoparticles were diluted in 1 ml of phosphate buffer and their electrochemical responses were
studied.
3- Results and discussion
3.1- Nanoparticle characterization
Different osteotropic monofunctional and multifunctional nanoparticles were prepared, as well as
other non osteotropic ones that were used as controls.
Table 1:Morphological characterization of multifunctional PBLG nanoparticles by TEM
Nanoparticles D longitudinal
(nm) ± SD a
Daxial
(nm) ± SDa
Aspect
ratio
Dequivalent
(nm)
PBLG25-bnz 34 ± 8.8 26 ± 5.7 1.6 39
PBLG-b-PGlu/PBLG-b-PEG 100/0 37 ± 7.4 27 ± 5.9 1.3 34
PBLG-b-PGlu/ PBLG-b-PEG 80/20 41 ± 6.4 26 ± 5.3 1.6 35
PBLG-b-PGlu/ PBLG-b-PEG 60/40 40 ± 7.8 24 ± 5.1 1.5 35
PBLG-b-PGlu/ PBLG-b-PEG 40/60 40 ± 6.6 28 ± 5.1 1.4 36
PBLG-b-PGlu/ PBLG-b-PEG 20/80 36 ± 7.42 23 ± 4.3 1.6 31
PBLG-b-PEG 39.6 ± 2.6 23 ± 2.6 1.7 29
After CDDP association
PBLG-b-PGlu/PBLG-b-PEG 100/0 39 ± 8.1 28 ± 5.9 1.3 35
PBLG-b-PGlu/ PBLG-b-PEG 80/20 48 ± 6.7 34 ± 5.5 1.4 43
PBLG-b-PGlu/ PBLG-b-PEG 60/40 40 ± 7.8 27 ± 4.8 1.6 34
PBLG-b-PGlu/ PBLG-b-PEG 40/60 41 ± 5.2 27 ± 5.2 1.5 36
PBLG-b-PGlu/ PBLG-b-PEG 20/80 37 ± 5.2 26 ± 4.6 1.4 33
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The nanoprecipitation method using previously synthesised PBLG copolymers allowed the preparation
of nanoparticles of with an oblate morphology and a relatively small size, with an equivalent diameter
less than ~40 nm and an aspect ratio of 1.3 to 1.7 as evidenced by the TEM measurements. No
significant changes in size were seen after cisplatin association to the nanoparticles. DLS experiments
were routinely performed to confirm nanoparticle formation during the preparation process (see
Supplementary Information).
3.2- Association of cisplatin to PBLG-b-PGlu and PBLG-b-PGlu/PBLG-b-PEG nanoparticles
Cisplatin association experiments showed the capability of multifunctional nanoparticles prepared
from mixtures of PBLG-b-PGlu/PBLG-b-PEG copolymers in different proportions to associate
cisplatin (Figure 1).
Figure 1: Cisplatin loading content related to PBLG-b-PGlu copolymer of different PBLG-b-PGlu/PBLG-
b-PEG nanoparticles incubated at [CDDP/COO-] ratios of 0.8 and 1.
Cisplatin association has been tested at two [CDDP/COO-] ratios, but cisplatin loading contents trends
were similar. Interestingly, there was an important increase of nearly three times in the cisplatin
loading content when the proportion of the nanoparticle forming polymer PBLG-b-PGlu passed from
Chapitre IV: Bone targeted cisplatin-complexed PBLG-b-PGlu
nanoparticles: an electrochemical approach
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
131
40% to 60% w/w in the final composition of the nanoparticles. Indeed, cisplatin was more efficiently
associated when the proportion of the PBLG-b-PGlu copolymer was predominant (beyond 60% w/w)
over the PBLG-b-PEG one. This could be related to the arrangements of the PGlu and PEG chains
within the nanoparticles or to a possible steric hindrance of PGlu chains in presence of other PEG
chains.
The electrochemical experiments were performed with cisplatin-complexed PBLG-b-PGlu
nanoparticles using cisplatin and PBLG-bnz nanoparticles as positive and negative controls,
respectively. Figure 2 shows such voltammetric responses for cisplatin solutions and cisplatin-
complexed PBLG-b-PGlu nanoparticles in phosphate buffer (pH 7.0).
Figure 2. Voltammograms of: a) cisplatin; b) cisplatin-complexed PBLG-b-PGlu nanoparticles; c, d)
PBLG-bnz nanoparticles in phosphate buffer (pH 7.0). a, b ,d) Square wave voltammograms initiated at
+1.25 V in the negative direction; potential step increment 4 mV; square wave amplitude 25 mV; frequency
5 Hz. c) Cyclic voltammogram, potential scan rate 20 mV/s.
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For cisplatin, two cathodic waves at 0.20 and 0.80 V vs. Ag/AgCl were recorded. For cisplatin-
complexed PBLG-b-PGlu nanoparticles, the response was similar but both signals became enhanced
in height and slightly shifted towards more negative potentials (0.40 and 0.85 V), the second wave
now defining a sharp-shaped peak. As frequently occurring for nanoparticles functionalized with
electroactive motifs, the voltammetric response was dominated by the signals of such species anchored
to the nanoparticles [17, 18]. The peak potential shift suggested that cisplatin was coordinated to the
PBLG-b-PGlu copolymer while the peak current enhancement could be attributed to the increase of
the effective concentration of cisplatin due to its association to the nanoparticle system. In the case of
PBLG-bnz nanoparticles similar features to free cisplatin were obtained, confirming the absence of
interaction between the cisplatin and PBLG-bnz nanoparticles. Experiments for monofunctional
cisplatin-complexed PBLG-b-PGlu nanoparticles (see figure 3a), produced voltammograms with a
cathodic peak at 0.75 V, which could be attributed to cisplatin reduction involving prior de-
complexation from PBLG-b-PGlu nanoparticles. Experiments for the multifunctional cisplatin-
complexed PBLG-b-PGlu /PBLG-b-PEG nanoparticles at a proportion of 40/60 yielded a similar
voltammetric response (see figure 3b), but the signal became significantly decreased (notice the
different current scale in figures 3a,b) while an additional wave at 0.20 V appeared. This wave
increased linearly on increasing frequency, a characteristic of adsorption-mediated voltammetric
signals [18-20] and also increased with decreasing PBLG-b-PGlu/PBLG-b-PEG ratios. These features
suggested that cisplatin was effectively bound to PGlu and, under this binding situation, was available
for electrochemical reduction. For multifunctional PBLG-b-PGlu/PBLG-b-PEG nanoparticles, the
presence of PEG was responsible for adsorption-mediated peak at 0.20 V, cisplatin was indeed
coordinated to the PGlu block although to a much lesser extent, as evidenced by the significantly
decreased signal at 0.75 V. These results confirmed the more effective coordination of cisplatin to
PBLG-b-PGlu nanoparticles compared to PBLG-b-PGlu/PBLG-b-PEG nanoparticles 40/60 in
coherence with the AAS measurements.
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Figure 3. Square wave voltammograms of: a) cisplatin-complexed PBLG-b-PGlu (100% PBLG-b-PGlu)
nanoparticles and b) cisplatin-complexed PBLG-b-PGlu/PBLG-b-PEG nanoparticles 40/60 in phosphate
buffer (pH 7.0). Potential scan initiated at +1.25 V in the negative direction; potential step increment 4 mV;
square wave amplitude 25 mV; frequency 5 Hz.
3.3- In vitro cisplatin release from PBLG-b-PGlu nanoparticles
In vitro cisplatin release from PBLG-b-PGlu nanoparticles was studied by the dialysis method during
15 days. After 5 days, cisplatin release in PBS medium was incomplete and significantly higher than
in water medium as shown by figure 4. Indeed, chloride ions are known to play a major role in
cisplatin release from PBLG-b-PGlu nanoparticles since they act as nucleophile groups that would
replace carboxylate groups via ligand exchange reaction and due to the good leaving properties of
carboxylates[7]. Acidic pH has also shown to play a role in cisplatin release [21]. This role of chloride
ions accounted for the enhanced cisplatin release in PBS medium compared to water medium. These
Chapitre IV: Bone targeted cisplatin-complexed PBLG-b-PGlu
nanoparticles: an electrochemical approach
134 Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
results are in coherence with other cisplatin-carboxylate complexes and micelles previously
reported[6, 7, 22].
Figure 4. In vitro cisplatin release after 5 days from cisplatin-complexed PBLG-b-PGlu nanoparticles in
water and in 0.01 M PBS medium (pH 7.4) containing 0.138 M of NaCl. The in vitro release is expressed
as area under the cisplatin release curve related with the time (% * h).
The voltammetric responses obtained for cisplatin-complexed PBLG-b-PGlu release experiments in
water and in PBS were different as shown in figure 5. In PBS release medium, two peaks at 0.60 and
1.20 V appeared. The first one could be attributed to the released cisplatin and the second one to the
reduction of cisplatin associated to PBLG-b-PGlu nanoparticles, respectively. In water, only one
cathodic peak at 0.85 V was recorded. This peak was attributable to the reduction of cisplatin
associated to the PBLG-b-PGlu nanoparticle and thus no cisplatin was released in these conditions
(figure 5). These results confirmed the effective cisplatin release from the PBLG-b-PGlu nanoparticles
induced by the PBS medium in contrast with the absence of significant cisplatin release when the
experiment is conducted in water. Although PBS medium introduces an electrostatic barrier
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disfavouring the cisplatin reduction, there is no inhibition of the electrochemical activity of the drug,
and cisplatin release is promoted by the PBS.
Figure 5. a, b) square wave voltammograms and c, d) their respective deconvolution of: a, c) cisplatin-
complexed PBLG-b-PGlu and incubated with a PBS (pH 7.4) solution, b, d) cisplatin-complexed PBLG-b-
PGlu and incubated with phosphate buffer (pH 7.0). Potential scan initiated at +1.25 V in the negative
direction; potential step increment 4 mV; square wave amplitude 25 mV; frequency 5 Hz.
3.4- In vitro HAP binding assay
HAP is the major mineral component of bone and accounts for 50-70 % of the bone extracellular
matrix. The in vitro HAP binding assay showed a total binding for fluorescently labelled cisplatin-
complexed PBLG-b-PGlu nanoparticles as shown in figure 6. This HAP binding property was driven
by the PGlu block and not by the PBLG or dansyl moiety as evidenced by the absence of binding of
PBLG-dansyl nanoparticles. Moreover, cisplatin could also be involved in the adsorption onto HAP,
as it has been previously reported [23]. There are several osteotropic moieties such as biphosphonates,
acidic oligopeptides and tetracycline analogs [24]. The discovery that acidic non collagenous salivary
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proteins could bind HAP with high affinity [25] and the identification of glutamic acid rich sequences
as the responsible moieties for this binding opened the way to the use of acidic oligopeptides as bone
targeting moieties. Indeed, oligoglutamic acid such as oligoaspartates and oligoglutamates have been
shown to have affinity to HAP in vitro and to bone in vivo and they have been used to provide drugs
with osteotropic properties [11].
Figure 6: Degree of binding expressed in percentage of nanoparticles bound to HAP for PBLG-dansyl and
cisplatin-complexed PBLG-b-PGlu/PBLG-dansyl 2/1 nanoparticles after 18 h. Nanoparticles at a
concentration of 1.5 mg/mL in 0.1% Pluronic® F 68 were incubated in 3 mL of PBS containing 0.4 g of
HAP at 25 °C.
Electrochemical monitoring of in vitro HAP binding assay was performed using the voltammetry of
microparticles approach, a solid-state electrochemical methodology developed by Scholz et al. which
provides information on solid materials attached to inert electrodes in contact with suitable electrolytes
[12, 13]. Using this technique, previously used for nanoparticulate system studies [16], the
voltammetric response of fluorescently-labelled cisplatin-complexed PBLG-b-PGlu nanoparticles
Chapitre IV: Bone targeted cisplatin-complexed PBLG-b-PGlu
nanoparticles: an electrochemical approach
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
137
attached to HAP was studied. Square wave voltammetry was used as a detection mode because of the
inherently high sensitivity of this technique and its reluctance to undergo capacitive distortions [18].
Voltammograms for cisplatin-complexed PBLG-b-PGlu associated to HAP showed two main cathodic
peaks at 0.90 and 1.40 V, as can be seen in Fig. 7a. The peak at 0.90 V can be assigned to the
reduction of cisplatin directly released from the PBLG-b-PGlu nanoparticles due to the use of the PBS
medium and the peak at 1.40 corresponds to the reduction of cisplatin complexed to the PBLG-b-
PGlu nanoparticles that are bound to the HAP. Such peaks are slightly shifted to more negative
potentials relative to those recorded at PBLG-b-PGlu nanoparticles solution. It appears that attachment
to HAP results in negative potential shifts, in particular, for the reduction of released cisplatin,
possibly due to the formation of cisplatin adsorbates on the HAP.
Figure 7. Square wave voltammograms for films on GCE of NPs associated to HAP using: cisplatin-
complexed PBLG-b-PGlu nanoparticles and immersed in 0.10 M phosphate buffer (pH 7.0) after
subtraction of the blank voltammogram for HAP-modified GCE. Potential scan initiated at +1.25 V in the
negative direction; potential step increment 4 mV; square wave amplitude 25 mV; frequency 5 Hz
These results can be interpreted combining the theoretical model proposed by Lovric, Scholz, Oldham et
al. [26-29] on the electrochemistry of ion-insertion solids with modelling for complexes associated to
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microporous and mesoporous inorganic supports [30-34] The essential idea is that the observed
electrochemical signals results from the superposition of the processes due to different topological redox
isomers; i.e., electroactive guest molecules located in different sites of the inorganic host. This is
schematized in figure 8, where at least four different electrochemical pathways can be associated to the
previously described voltammetric features: reduction of ‘free’ cisplatin adsorbed on the electrode surface
(A), reduction of cisplatin-complexed to PBLG-b-PGlu derivate nanoparticles (B), reduction of HAP-
adsorbed cisplatin-complexed to PBLG-b-PGlu nanoparticles (C) and reduction of HAP-adsorbed
cisplatin (D).
Figure 8. Scheme for the different electrochemical processes involved in the voltammetry of cisplatin-
complexed PBLG-b-PGlu nanoparticles and associated or not to HAP.
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According to the above set of results, voltammetric techniques not only confirmed the interaction of
cisplatin-complexed PBLG-b-PGlu nanoparticles with the HAP but provided further information,
being able to distinguish free cisplatin from cisplatin associated to the PBLG-b-PGlu nanoparticle and
bound to the HAP.
4- Conclusion
In this work, multifunctional bone targeted nanoparticles derived from PBLG-b-PGlu and PBLG-b-
PEG copolymers were prepared. The cisplatin association, release and bone targeting properties were
studied by AAS and fluorescence techniques and were confirmed by electrochemical methodologies.
Interestingly, cisplatin association was significantly effective only when the proportion of the PBLG-
b-PGlu copolymer was predominant over the PBLG-b-PEG one and this was confirmed by both
electrochemistry and AAS experiments. Moreover, both techniques showed that cisplatin release from
PBLG-b-PGlu nanoparticles was enhanced by the chloride containing PBS medium, as compared to
water. Finally, HAP binding of fluorescently labelled PBLG-b-PGlu nanoparticles could be shown by
both fluorescence and the voltammetry of microparticles approach. In conclusion, electrochemical
techniques showed to be innovative tools for the study of cisplatin-complexed PBLG-b-PGlu derivate
nanoparticles which provided further information about the different existing platine species.
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1. AAS for cisplatin determination
The instrument used for atomic absorption measurements was a Varian® SpectrAA GFAAS
(Australia) graphic furnace AA spectrophotometer (model 200Z) with Zeeman background correction
and equipped with an adapted autosampler, an ultrAA® platinum lamp and a pyrolytically coated
graphite tube (Varian® partition tubes (coated)-GTA, Part No. 63-100012-00). A platinum hollow-
cathode lamp was used as radiation source at 265.9 nm with a slit width of 0.5 nm. Lamp current was
set at 10.0 mA. The volume of automatic sample injection was 20 μL; the internal Argon flow rate was
3 L.min-1 and was stopped during atomizing. Details of the GFAAS heating program are listed in
table 1.
Table 1: Detailed heating program for AAS
Step Furnace
Temperature
(°C)
Ramp Time
(s)
Hold Time
Time (s)
Internal Gas
Flow (L.min-
1)
1 40 0 0.1 3 Drying2 120 55 0 3
3 600 10 5 3
4 1300 5 5 3
Ashing5 1300 0 0.5 0
6 2700 0.9 2 0 Atomizing
7 2850 1 0 3 Cleaning8 40 22 0 3
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2. TEM images of nanoparticles
PBLG-b-PGlu/PBLG-b-PEG 100/0 CDDP-PBLG-b-PGlu/PBLG-b-PEG 100/0
PBLG-b-PGlu/PBLG-b-PEG 80/20 CDDP-PBLG-b-PGlu/PBLG-b-PEG 80/20
PBLG-b-PGlu/PBLG-b-PEG 60/40 CDDP-PBLG-b-PGlu/PBLG-b-PEG 60/40
PBLG-b-PGlu/PBLG-b-PEG 40/60 CDDP-PBLG-b-PGlu/PBLG-b-PEG 40/60
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Figure 1: TEM images obtained at 120 kV of nanoparticles obtained from PBLG-b-PGlu/PBLG-b-PEG at
different proportions.
PBLG-b-PGlu/PBLG-b-PEG 20/80 CDDP-PBLG-b-PGlu/PBLG-b-PEG 20/80
PBLG-b-PGlu/PBLG-b-PEG 0/100
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3. DLS characterization of nanoparticles
Table 2: Characterization of PBLG-derivate nanoparticles by DLS
Nanoparticles Size (nm)
± SD a
PI ± SD
(nm)
ζ Potential
(meV) ± SD a
PBLG-bnz 47 ± 1.1 0.16 ± 0.0081 -37 ± 2.5
PBLG-dansyl 58 ± 0.9 0.12 ± 0.0077 -45 ± 1.5
PBLG-b-PGlu/PBLG-b-PEG 100/0 53 ± 0.82 0.13 ± 0.010 -46 ± 0.20
PBLG-b-PGlu/ PBLG-b-PEG 80/20 45 ± 0.45 0.14 ± 0.0012 -49 ± 2.48-
PBLG-b-PGlu/ PBLG-b-PEG 60/40 39 ± 0.26 0.099 ± 0.011 -45 ± 0.78
PBLG-b-PGlu/ PBLG-b-PEG 40/60 51 ± 0.39 0.13 ± 0.0005 -48 ± 2.08
PBLG-b-PGlu/ PBLG-b-PEG 20/80 38 ± 0.78 0.16 ± 0.0016 -48 ± 0.44
PBLG-b-PEG 38 ± 1.7 0.13 ± 0.005 -31 ± 0.86
After CDDP complexing
PBLG-b-PGlu/PBLG-b-PEG 100/0 53 ± 1.7 0.13 ± 0.016 -39 ± 0.66
PBLG-b-PGlu/ PBLG-b-PEG 80/20 45 ± 0.74 0.14 ± 0.025 -50 ± 4.6
PBLG-b-PGlu/ PBLG-b-PEG 60/40 45 ± 1.4 0.15 ± 0.013 -43 ± 0.47
PBLG-b-PGlu/ PBLG-b-PEG 40/60 56 ± 0.82 0.16 ± 0.023 -49 ± 8.6
PBLG-b-PGlu/ PBLG-b-PEG 20/80 49 ± 0.31 0.17 ± 0.013 -44 ± 1.2
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Résumé
Des nanoparticules multifonctionnelles ont été obtenues par auto-assemblage de polymères issus d’une
minilibrairie de dérivés du poly(glutamate de benzyle) (PBLG). Ces nanoparticules ont été conçues de
manière à cibler l’'hydroxyapatite, car il s’agit d’un composant très spécifique de l'os. Pour cela, une
série de nanoparticules décorées par deux ligands de l'hydroxyapatite, l'alendronate et/ou le poly(acide
glutamique) a été préparée par une méthode versatile de nanoprécipitation, ce qui a permis la
modulation précise des propriétés d'attachement in vitro à l'hydroxyapatite. Des études de distribution
conduites in vivo dans la structure complexe de l’os ont montré que certains types de nanoparticules
pouvaient s’accumuler à différents degrés dans ce tissu, sans relation directe avec la présence de
ligands ostéotropes. En revanche, l’examen de la microdistribution dans la structure complexe de l’os
a montré que la présence d’alendronate ou de poly(acide glutamique) en surface des nanoparticules
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favorisait leur immobilisation sur les surfaces minéralisées osseuses, en accord avec les études ex vivo
de fixation sur l'os. Grâce à leur ostéotropicité et à la possibilité de les adresser précisément dans l’os,
ces nanoparticules multifonctionnelles constituent donc des vecteurs prometteurs pour le traitement de
maladies squelettiques.
Abstract
Bone targeted polymeric nanoparticles may be a valuable option in view of the treatment of different
skeletal diseases. Multifunctional osteotropic nanoparticles were obtained by the self-assembly of
poly(gamma-benzyl-L-glutamate) derivates, which could be decorated by alendronate and/or
poly(glutamic acid) moieties intended for hydroxyapatite targeting. The nanoparticles were prepared
by a versatile nanoprecipitation method which allowed precise tuning of in vitro hydroxyapatite
binding properties. In vivo studies showed that both osteotropic and non osteotropic nanoparticles
could attain bone tissues, be distributed into the bone and bound to mineralised bone surfaces, in
coherence with ex vivo bone binding results. Detailed microdistribution studies showed for
alendronate nanoparticles and poly(glutamic acid) ones an enhanced in vivo bone binding, constituting
promising carriers for the treatment of skeletal diseases.
1-Introduction
Bone diseases such as osteoporosis, Paget's diseases, osteopenia, osteogenesis imperfecta or bone
cancer constitute an increasingly major public health problem in our society. As an example of this, it
is estimated that in 2020 more than one of two Americans over 50 years will risk or actually develop
osteoporosis in any part of the skeleton [1].
Active targeting nanoparticles have attracted much attention during the last decade, as a way of
increasing drug delivery to the target reducing side effects. Various approaches can be foreseen in
view of increasing specific delivery. In the case of cancers various approaches attempt to target the
over expressing receptors of tumor vasculature or cells. However, these receptors do in fact exist in
healthy cells and vasculature, driving to not so specific distributions in the body [2] and only few
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approaches are based on the targeting of truly specific targets. Bone, composed of 50-70% of
hydroxyapatite, (Ca10(PO4)6(OH)2), which is specific of bone tissue and is only present also in teeth
and pathological calcifications, offers a highly specific target for the engineering of nanoparticles. The
targeting of nanoparticles to bone extracellular matrix is a promising emerging approach [3-5] where
nanoparticles could constitute a drug reservoir for intra tissue delivery.
There are several identified bone targeting moieties, among which biphosphonates and acidic
oligopeptides have been largely used to impart drug osteotropicity [6]. Biphosphonate compounds are
analogous of the endogenous pyrophosphate, where the labile P-O-P linkage has been substituted by
the hydrolysis resistant P-C-P structure. The O-P-C-P-O backbone is responsible for the strong affinity
of calcium ions. Acidic rich domains of bone acidic non collagenous proteins were identified and
opened the way to the use of acidic oligopeptides, such as (Asp)6 and (Glu)6, as bone targeting
moieties [7]. Both binding moieties have been shown to have differential in vitro and in vivo bone
binding properties [8].
Here, we report the development of a library of osteotropic poly(benzylglutamate) (PBLG) polymers
that self-assemble to produce a series of novel bone targeted nanoparticles with tuned surface
properties. In vitro bone binding properties could be modulated depending on the osteotropic ligand
attached to nanoparticles. Bone histological and microdistribution studies showed that alendronate and
poly(glutamic acid) PBLG decorated nanoparticles could reach the mineralized surfaces. They showed
good in vivo long-term bone binding for five types of nanoparticles with alendronate and
poly(glutamic acid) PBLG nanoparticles being the most promising carriers for intra-tissue controlled
drug release in long-term therapeutics of bone skeletal diseases.
2- Materials and Methods
2.1- Materials
Dimethylformamide (DMF) (99.8 %) Extradry Acroseal and cisplatin were purchased from Acros, γ-
benzyl-L-glutamate-N-carboxyanhydride (BLG-NCA) was provided by IsoChem and used as
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received. Trifluoroacetic acid (TFA) (99 %), dansylcadaverin (≥99%), hexylamine (puriss ≥99.5%),
Palladium on carbon (Pd/C) were provided by Sigma Aldrich. All other reagents used were of
analytical grade. α-N-hydroxysuccinimide-ω- alkyne-poly(ethylene glycol) (NHS-PEG-alkyne)
(Mw=3000 Da) and α-azide-ω-amine poly(ethylene glycol) (N3-PEG-NH2) (Mw= 3317 Da) were
bought from Iris Biotech and Rapp Polymers respectively and dried overnight under vacuum at 40 °C
prior to use.
2.2- Synthesis of poly(γ-benzyl-L-glutamate) (PBLG) polymers
2.2.1- General polymerization procedure
A mini library of polymers based on a constant PBLG block has been prepared by ring opening
polymerization of the corresponding N-carboxyanhydride (NCA). Polymerization reactions were
carried out under inert pure argon atmosphere. Briefly, 1.5 g of BLG-NCA were weighed in a glove
box under inert atmosphere (pure argon) and were dissolved in DMF at a concentration of 0.5 M . The
solution was stirred for 10 minutes and a solution of the initiator in DMF was added with an argon-
purged syringe. The solution was stirred at 30 °C during 5-7 days. Then, the mixture was poured into a
large excess of cold diethylether (DEE) and the precipitate filtered and dried under vacuum. The
extent of the reaction was controlled by infrared analysis, by checking the disappearance of BLG-NCA
and the appearance of the PBLG bands. Polymers were analyzed by proton nuclear magnetic
resonance (1H NMR) in CDCl3 15 % trifluoroacetic acid (TFA) and for the PBLG-b-PEG copolymers
molecular weight of the PBLG block could be determined in function of the relative intensities of the
benzyl groups of the PBLG and the ethylene protons of the PEG.
2.2.2- Synthesis of PBLG-b-PEG-alendronate
The synthesis of PBLG-b-PEG-alendronate was achieved by a combination of ring-opening
polymerization initiated by N3-PEG3k-NH2 (Mw= 3317 Da), click chemistry with an alendronate-
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PEG3k-alkyne block and carbodiimide approach to synthesize the alendronate-PEG-alkyne block. The
chemical scheme is detailed in Supplementary Data.
The synthesis of alendronate-PEG-alkyne block was achieved in the following conditions. Briefly, 2
mmoles of alendronate trihydrate were dissolved in 30 mL of water with 3.5 meq of triethylamine
(TEA) and added to 0.2 mmoles of NHS-PEG-alkyne. The reaction mixture was stirred at 50 °C
overnight and rotavapor was used to remove TEA. The solution was dialyzed with dialyze membranes
of molecular cut off of 3500 Da over 72 hours and lyophilized to obtain a white powder. The structure
of alendronate-PEG-alkyne block was confirmed by 1H NMR. The presence of alendronate was
confirmed and quantified by 31P NMR and by phosphorus elemental analysis.
Synthesis of N3-PEG-PBLG block was achieved by ring opening polymerization using a DMF
solution of N3-PEG3k-NH2 (Mw= 3317 Da) at a concentration of 4.4 mM as initiator as described in
section 2.2.1 and its molecular weight was determined by 1H NMR in deuterated chloroform (CDCl3)
+ 15 % TFA, using the relative intensities of the protons belonging to the benzylic groups of the
PBLG and the ethylenic protons of the PEG. Click reaction between azido-PEG-PBLG and
alendronate-PEG-alkyne was performed in DMF at 55 °C for 72 hours. In a typical experiment azido-
PEG-PBLG (2 µmol) and alendronate-PEG-alkyne (10 µmol, 5 equiv) were dissolved in 1 mL of
anhydrous DMF. The mixture was stirred for 10 minutes and degassed prior to the addition of a DMF
solution containing pentamethyldiethylenetriamine (PMDETA) (10 equiv) and copper(I) bromide
(CuBr) (5 equiv). The block copolymer was recovered by precipitation in water after a dialysis
purification step against water during 5 days (SpectraPor, molecular weight cut off: 12-14000 Da) to
remove the excess of alendronate-PEG-alkyne, and was lyophilized. The efficacy of the click reaction
was determined by 1H NMR based on the relative intensities of the protons belonging to the benzylic
groups of the PBLG and the ethylenic protons of the PEG
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2.2.3- Synthesis of PBLG-b-poly(glutamic acid) (PBLG-b-PGlu) copolymer
A PBLG-b-PGlu copolymer was synthesized by a modified method previously described [9]. The
synthetic scheme for this copolymer is detailed in SD.
First, PBLG3k-bnz was synthesized by ring opening polymerization of γ-benzyl-L-glutamate-N-
carboxylic anhydride (BLG-NCA) as previously described in section 2.2. This polymer was analyzed
and its molecular weight determined by 1H NMR in CDCl3 + 15 % TFA by using the ratio of the
integrations of the peaks corresponding to CH3-NH2 from hexylamine and benzylic peaks from PBLG,
respectively.
Then, the benzylic groups were eliminated by catalytic hydrogenation. Briefly, 1.6 mg of hexyl-PBLG
were dissolved in 27 mL of anhydrous DMF and 10 % of Pd/C was added to the solution. After
purging three times with argon, the reaction mixture was stirred for 3 days at room temperature under
overpressure of hydrogen (4 mbar). Then, the solution was centrifuged at 25 °C, 4000 rpm for 10
minutes and was further filtered over 0.22 µm filters in order to eliminate the Pd(black). It was then
precipitated into a large excess of DEE, filtered and the precipitate dried in under vacuum at 40°C
overnight. The completion of the reaction was analyzed by 1H NMR in deuterated dimethyl sulfoxide
(DMSO (d6)).
Finally, the synthesis of PBLG-b-PGlu was achieved by ring opening polymerization of γ-benzyl-L-
glutamate-N-carboxylic anhydride (BLG-NCA) as described in section 2.2. using a solution of hexyl-
PGlu in DMF at a concentration of 3,1 mM as an initiator.
2.2.4- Synthesis of PBLG-dansyl
The synthesis of PBLG-dansyl was achieved by ring polymerization of γ-benzyl-L-glutamate-N-
carboxylanhydride (BLG-NCA) using dansylcadaverin as an initiator. The polymerization reaction
was made in the conditions described above. The resulting product was further washed three times
with methanol (MeOH).
Chapitre V: Osteotropicity and microdistribution in bones of
self-assembled multifunctional PBLG nanoparticles
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
155
2.2.5- Synthesis of other PBLG-derivates
The synthesis of PBLG-benzyl (PBLG-bnz), PBLG- fluorescein isothiocyanate (PBLG-FITC) and
PBLG-b-PEG was achieved as previously described [10] and following the general method described
in section 2.1.
2.3- Characterization of PBLG copolymers
2.3.1- Nuclear magnetic resonance (NMR)
1H NMR spectra were recorded on a Bruker AC 300 spectrometer in CDCl3 + 15% TFA. The role of
the acid is to disrupt helix, rendering PBLG in a random coil conformation.
2.3.2- Fourier transform infrared spectroscopy (FTIR)
FTIR spectra of the polymers were performed on a Fourier Transform Perkin-Elmer 1750 infrared
spectrometer using an attenuated total reflection system (ATR) to confirm the absence of NCA auto-
polymerization, to follow the evolution of the polymerization reactions and to study the secondary
structure of the polymers.
2.3.3- Size exclusion chromatography (SEC)
Size exclusion chromatography (SEC) was used to determine the molar mass of PBLG-b-PGlu. SEC
system was equipped with two PLgel 5µm MIXED-D (7.5mm ID x 30.0cm L) and a PLgel 5µm guard
column (guard column 7.5mm ID x 5.0cm L), a refractive index detector (Jasco 1530-RI) and a UV
detector (Jasco 875-UV). DMF with 1g/L of LiBr was used as a diluent at a flow of 0.8 ml/minute and
linear polystyrene samples were used as calibration standards.
2.3.4- Quantification of alendronate in PBLG-b-PEG-alendronate
Quantitative NMR spectroscopy using coaxial inserts containing monopotassium phosphate (KH2PO4)
solution as a reference standard was used to quantify the concentration of alendronate in alendronate-
PEG-alkyne. Details of the methods can be found in SD. Phosphorus elemental analysis of
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alendronate-PEG-alkyne was also performed. The alendronate content in PBLG-b-PEG-alendronate
was determined considering the efficacy of the click reaction yielded by 1H NMR.
2.4- Nanoparticle preparation
Nanoparticles were prepared following nanoprecipitation method previously described in our group
either single or different mixtures of PBLG copolymers, with varying ratios (expressed in wt%).
Briefly, 7.5 mg of the different PBLG derivates were dissolved in 2.5 mL of tetrahydrofuran
(THF)/MeOH 75/25 at 40 °C without magnetic stirring. Once dissolved they were added by dripping
to an aqueous solution containing two equivalents of sodium hydroxide (NaOH) per equivalent of
carboxylic acid (COOH) and magnetically stirred for 10 minutes. Solvents were eliminated by a
standardized protocol under vacuum at 40 °C and nanoparticles were added with poloxamer
(Pluronic® F68) to a final concentration of 0.1 % .
2.5- Morphological characterization of nanoparticles
Nanoparticle size and zeta potential were determined by dynamic light scattering (DLS) using a
Zetasizer 4 (Malvern Instruments). Nanoparticles were observed by means of a Transmission Electron
Microscopy (TEM) at 120 kV after negative coloration. 3µL of the diluted nanoparticle suspension
were deposited on a formvarcarbon film previously coated on a copper grid of 400 meshes and
phosphotungstic acid 1% w/w used as a negative coloration staining.
2.6- Nanoparticle interaction with hydroxyapatite (HAP)
2.6.1- In vitro HAP binding assay
One mL of multifunctional nanoparticles containing a fluorescent PBLG derivate, PBLG-dansyl, and
an osteotropic PBLG derivate in poloxamer (Pluronic® F68) 0.1 % w/v were incubated in 3 mL of
phosphate buffer saline (PBS) containing 0.4 g of HAP at a pH of 7.4 during 18 hours at 25 °C. The
suspensions were centrifuged at 5000 rpm for 5 minutes, washed and vortexed three times with
poloxamer 1% in PBS 7.4 and observed under UV light at 365 nm. Supernatants were quantified by a
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Perkin Elmer Luminescence spectrometer LS 50B at room temperature (λ excitation =340 nm . λ emission =
472 nm) so as to determine the amount of nanoparticles not bound to HAP.
2.6.2- Kinetics binding assay
0.25 mL of multifunctional nanoparticles containing a fluorescent PBLG derivate, PBLG-dansyl, and
an osteotropic PBLG derivate in poloxamer (Pluronic® F 68) 0.1 % w/v were incubated in 0.75 mL of
PBS containing 0.1 g of HAP at a pH of 7.4 at 25 °C different times. Suspensions were centrifuged at
5000 rpm for 5 minutes and washed three times with poloxamer 1% in PBS 7.4 with the subsequent
centrifugation step. Supernatants were quantified as described in section 2.6.1.
2.6.3- pH- dependent dissociation of nanoparticle-HAP complexes
Nanoparticle-HAP complexes were washed with poloxamer 1% /PBS 1/1 at several consecutive pH
5.5, 4.5 and 3.5, three times for each pH, centrifuged at 5000 rpm for 5 minutes and supernatants
obtained were quantified as described in section 2.6.1.
2.7- Bone binding assay
Femurs were obtained from specific pathogen-free BALB/cByJ mice and were embedded in
ethanol/water 70/30 and stored for two weeks prior to use. 3 mL of multifunctional nanoparticle
suspensions containing a fluorescent PBLG derivate, PBLG-FITC, and a PBLG derivate in 0.1 % of
poloxamer (Pluronic® F 68) were incubated with one femur overnight at 37 °C under rotary stirring.
Nanoparticles were removed and femurs were washed three times with poloxamer 1%. Images were
acquired using a CCD camera (Apogée Alta U 47). The images were analyzed with the public-domain
ImageJ software (US National Institutes of Health, Bethesda, MD). The average fluorescence intensity
was determined for each bone diaphysis using the same threshold settings (low threshold: 400, high
threshold: 20,000). Data are reported as the average channel fluorescence of bone diaphysis and
expressedas relative units after background subtraction.
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2.8- In vivo distribution studies
Male, 5-week-old, specific pathogen-free BALB/cByJ mice were purchased from Charles River
Laboratories. Mice were kept in accordance with the institutional guidelines of the French Ethical
Committee. Xylenol orange tetrasodium was injected subcutaneously at a dose of 40 mg/Kg in order
to label bone formation sites. Three days after, 200 µL of the different nanoparticle suspensions at a
concentration of 4.3 mg/mL, labelled with FITC, containing 0.2 % of poloxamer 188, and diluted in
0.9% wt NaCl, were injected via the tail vein and animals were euthanized by intraperitoneal injection
of sodium pentobarbital after 24 hours and 5 days (n=3 for each group).
Ex vivo fluorescence imaging
Liver, spleen, femurs and kidneys were extracted after euthanasia of the animals for isolated organ
imaging to estimate the tissue distribution of the fluorescently labelled nanoparticles with a CCD
camera (Photon Imager, Biospace). The fluorescence intensity was quantified using M3Vision 2.2.1
(Biospace Lab) after determination of regions of interest for each organ. Results were expressed as
photon per steradian per second per square centimeter (ph/sr/s/cm2).
Histological studies
For fluorescence analysis, the left femurs were excised for undecalcified tissue embedding. Briefly,
bones were fixed in 70% ethanol and dehydrated progressively in graded concentrations of ethanol and
embedded in methyl methacrylate. 10 µm sections were obtained with a Leica microtome (SM2500S)
(Wetzlar, Germany) and the distribution pattern of PBLG-derivate nanoparticles was analyzed under
microscopy (Microvision). Bone formation surfaces labelled with the different PBLG-FITC
nanoparticles were quantified by the Parfitt method [11] in both cortical and trabecular bones. The
simple labelled surfaces (FITC-Nanoparticles) and the double labelled surfaces (Xylenol orange and
FITC-Nanoparticles) were quantified with respect to the total bone using the objective eyepiece Leitz
intergratepaltte II.
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3- Results and discussion
3.1- Synthesis and characterization of PBLG polymers
Several PBLG polymers bearing different functionalities could be synthesized by ring opening
polymerization. Two osteotropic copolymers bearing alendronate or poly(glutamic acid) were
synthesized. Alendronate belongs to the family of biphosphonates and with poly(glutamic acid) are
well known to have affinity to HAP and have been used to impart osteotropicity to drugs [12-15]. The
synthesis of PBLG-b-PEG-alendronate copolymer was achieved by a combination of carbodiimide
and click chemistry. Alendronate content was quantified by a combination of NMR and elemental
analysis and it could be estimated that 31% of the PBLG-b-PEG-alendronate polymeric chains
contained an alendronate molecule. PBLG-b-PGlu copolymer could be synthesized by a living
polymerization approach. The PGlu block was composed of 16 repetitive units of glutamic acid, as
estimated by 1H NMR and theoretically 100 % of PBLG-b-PGlu chains contained a PGlu
macromolecule. Structures were characterized by 1H NMR and infra-red spectroscopy. Molar masses
were estimated using SEC as shown in table 1. Detailed procedures and characterization of the PBLG
copolymers are described in SD.
PBLG-polymers DPn a, b, Mn(g/mol)c PIc DPn c
PBLG-bnz 136 31727 1.14 144
PBLG-dansyl 91 25944 1.10 117
PBLG-b-PEG 228 65513 1.27 276
PBLG-b-PGlu 137 24436 1.75 102
PBLG-b-PEG-alendronate 228 52816 1.54 214
PBLG-FITC 228 52647 1.17 238
Table 1: Molecular weight (Mn), degree of polymerization (DPn) and polymolarity index (PI) of the
polymers (a): theoretical (b): of the PBLG block (c): determined by SEC
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3.2- Morphological characterization of nanoparticles
PBLG polymers were shown to self-assemble into nano-objects following a simple nanoprecipitation
method previously described in our group. Interestingly, different PBLG polymers could assemble to
form multifunctional nanoparticles, where surface properties could be precisely tuned.
Table 2: Morphological data obtained by TEM measurements of nanoparticles (n= 100). a: nanoparticles
containing 33% w/w of the PBLG-dansyl derivate except for PBLG-dansyl nanoparticles which contained
100 % of it. b; nanoparticles containing 25 % w/w of the PBLG-FITC derivate. c; ratio w/w PBLG-b-
PEG/PBLG-b-PGlu. c; ratio PBLG-b-PEG-alendronate/PBLG-b-PGlu
Nanoparticles Dlongitudinal
(nm) ± SD a
Daxial
(nm) ± SDa
Aspect
ratio
Dequivalent
(nm) ± SD
PBLG-dansyl a 43 ± 8.6 32 ± 6.5 1.4 39 ± 7.3
PBLG-bnz a 53 ± 10 34 ± 5.1 1.6 46 ± 8.5
PBLG-b-PEG a 41 ± 7.2 25 ± 3.5 1.6 35 ± 5.1
PBLG-b-PEG-alendronate a 43 ± 5.3 29 ± 4.3 1.5 37 ± 4.2
PBLG-b-PGlu a 46 ± 10 34 ±5.0 1.4 41 ± 7.8
PBLG-b-PEG-alendronate/
PBLG-b-PGlu (1/3) a,c
44 ± 8.4 32 ± 5.1 1.4 39 ± 6.6
PBLG-b-PEG/ PBLG-b-PGlu
(1/3 ) a,d
48 ± 9.1 30 ± 4.6 1.6 41 ± 6.7
PBLG-bnz b 66 ± 19 31 ± 5 2.1 51 ± 11
PBLG-b-PEG b 51 ± 13 26 ± 4 2.0 41 ± 8.0
PBLG-b-PEG-alendronate b 48 ± 9 31 ± 5 1.6 41 ± 6
PBLG-b-PGlu b 62 ± 20 32 ± 7 1.9 49 ± 13
PBLG-b-PEG-alendronate/
PBLG-b-PGlu (1/3) b,c
58 ± 16 30 ± 6.5 1.9 46 ± 10
PBLG-b-PEG/ PBLG-b-PGlu
(1/3) b,d
62 ± 19 32 ± 6 1.9 50 ± 12
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Nanoparticles presented an oblate spheroid form with aspect ratio ranging from 1.4 to 2.1 and their
longitudinal diameter being smaller than 70 nm (Table 2). Different osteotropic monofunctional and
multifunctional nanoparticles were prepared as well as other non osteotropic nanoparticles, as controls.
3.3- In vitro HAP binding
The in vitro HAP binding assay (Figure 1) showed the capability of alendronate and poly(glutamic
acid) to impart HAP binding ability to nanoparticles. Hence, the four types of nanoparticles containing
an osteotropic ligand could bind specifically to HAP whereas no binding occur for the negative control
nanoparticles, not bearing an osteotropic ligand except for bnz nanoparticles where ~ 20 % of binding
appears, which might be attributed to non specific binding.
Figure 1: Degree of binding expressed in percentage of nanoparticles bound to HAP after 18 hours.
Nanoparticles at a concentration of 1.5 mg/mL in 0.1 % w/v poloxamer were incubated with 0.4 g of HAP
suspension in 3 mL of PBS buffer (n=3).
Probably, the efficiency of binding depends on the efficiency of the binding ligand presentation on the
nanoparticle surface. This is likely to be very effective due to the rigidity of the assembled PBLG
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hydrophobic block, which makes unlikely the hindrance of hydrophilic moieties in the core of the
particles, but on the contrary induces their exposure onto nanoparticle surface (see chapter II).
The kinetics binding assay (Figure 2) showed a rapid binding with a full binding for the four types of
osteotropic nanoparticles after 2 hours. At shorter times, differential kinetics were observed depending
on the osteotropic ligand, with the following decreasing rate of binding: alendronate >
alendronate/poly(glutamic acid) > poly(glutamic acid) > poly(glutamic acid)/PEG nanoparticles. After
10 minutes, less than 55% poly(glutamic acid)/PEG nanoparticles, ~65% poly(glutamic acid) and
alendronate/poly(glutamic acid) nanoparticles and more than 80% alendronate nanoparticles were
bound to HAP. Nanoparticles binding to HAP is a time dependent process, as it has been already
described in the literature for alendronate and other osteotropic molecules [12, 16, 17]
Figure 2: Binding kinetics of nanoparticles to HAP (n=3).
The possible desorption of HAP-bound nanoparticles was studied at different acidic pH (Figure 3)
since the pH in the resorption lacunae is known to be acidic [18] and localized acidification, without
implying a true resorption, has been suggested to cause the release of bone bound biphosphonate. [19].
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Figure 3: Desorption of the different HAP-bound nanoparticles at the following consecutive pH: 5.5, 4.5
and 3.5 (n=3).
Desorption from HAP was negligible at pH 5.5 and 4.5 whatever the type of nanoparticle. However, at
pH 3.5, nearly 100 % of poly (glutamic acid) and poly (glutamic acid)/PEG nanoparticles were
desorbed whereas alendronate and alendronate/ poly (glutamic acid) nanoparticles resisted to
desorption. This assay also shows the differential HAP binding of alendronate and poly(glutamic acid)
decorated nanoparticles. Both kinetics and desorption studies suggest that for mixed alendronate/ poly
(glutamic) nanoparticles, it is the alendronate moiety which displays the HAP binding. In vitro bone
dissociation studies for alendronate (in the molecular state) have shown that 50% of alendronate
molecules are released at a pH of 3.5 [20]. In the present case, no desorption was observed for
alendronate nanoparticles. This difference can be attributed to the multivalency of alendronate
nanoparticles, which present several molecules of alendronate per nanoparticle, which is known to
increase dramatically the binding affinities (see chapter 2), as shown more specifically in the present
case for HAP at this pH. Finally, desorption from mineral is an important property that could be
influence the in vivo interaction within bone microenvironment. Obviously, once attained the
mineralized bone surfaces, the duration of their retention would depend on the balance between
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attachment and detachment, which is likely to affect further their microdistribution. Desorption from
mineral is an important property that influences in vivo interaction within bone
microenvironment. Once bound to bone, nanoparticles if they are prone to detachment, could
more easily interact with bone cells and they would be expected to have less skeletal retention
[21].
3.4- Ex vivo bone binding assay
Figure 4: Bone binding of the different PBLG-derivate nanoparticles using BALB/c femurs and
determined by fluorescence quantification.
Ex vivo bone binding studies were performed to determine the ability of nanoparticles to bind to the
bone (Figure 4). Surprisingly, all types of PBLG-derivate nanoparticles, osteotropic and non
osteotropic ones, where found to bind to bone. Bone is composed of 50-70% mineralised matrix, 20-
40% organic matrix, 5-10% water and 5% of lipids. The mineral phase consists of impure HAP
crystals whereas the organic matrix is mainly constituted of (~85-90%) type I collagen and also other
collagenous proteins and non collagenous proteins [22]. Moreover, synthetic and biological HAP are
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different in terms of hydroxylation degree, carbonate substitution and crystal size [23]. In view of the
results, it seems that PBLG nanoparticles themselves have an intrinsic affinity for bone mineral.
3.5- In vivo biodistribution studies
Nanoparticles ability to attain bone was determined by their biodistribution profile, which depends on
both anatomo-physiological characteristics of the organism and physico-chemical nanoparticle
characteristics. Ex vivo organ imaging using fluorescently labelled nanoparticles (25% of the PBLG-
FITC) was employed to estimate nanoparticles biodistribution in healthy mice following intravenous
administration. Figure 5 shows the biodistribution of the several types of nanoparticles 24 hours and 5
days post-administration.
Figure 5: Quantification of the fluorescence distributed in the organs 24 hours and 5 days after intravenous
administration of PBLG-derivate nanoparticles (n=3).
Nanoparticles were highly distributed to liver with different behaviours depending on the type of
nanoparticle. This behaviour is expected as the avoidance of the capture of nanoparticles by the
reticuloendotelial system (RES) is often difficult to achieve and due to the larger fenestrations of the
liver vasculature, that allows a transvascular flow up to 280 nm in mice [24]. Interestingly, the amount
of Bnz, PEG and AL nanoparticles distributed to liver increased between 1 and 5 days post-
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administration, suggesting a prolonged circulation in the bloodstream (i.e. stealth effect) whereas for
PGlu/PEG and AL/PGlu nanoparticles it diminished, suggesting a possible elimination by the Kuppfer
cells. No change was observed for PGlu nanoparticles. Nanoparticles were also considerably
distributed to bone, as evidenced by the bone/liver ratio, which ranges from 0.71-0.10 depending on
the type of nanoparticles and time. After 24 hours, the fluorescence intensity in bone decreased as
follows: PGlu> AL/PGlu> Bnz > PGlu/PEG> PEG> AL nanoparticles. After 5 days, the order was
different, being PGlu/PEG> AL/PGlu> PEG> PGlu> AL> Bnz.
For all nanoparticles the fluorescence intensity in bone diminished with time probably due to the
elimination by macrophages; the slightest diminution was seen for AL nanoparticles. This
considerable distribution to bone is likely to be due to the role of bone marrow as a RES organ. It is
known that the endothelium of bone marrow can remove non-endogenous macromolecules by phago-
endocytosis and upon transvascular release or spill over, be found in the interstitial bone marrow space
[24, 25]. Although less attention has been devoted to the bone marrow as a RES organ, some studies
have stressed its importance in the uptake of surface-modified nanoparticles [26]. It has been shown
that some poloxamer-coated nanoparticles could be highly distributed to bone marrow [27].
Nanoparticles should be stealth and small enough (around 60 nm) so as to be able to avoid liver RES
capture and be able to be endo-phagocytosed by the bone marrow endothelium [24]. In the present
experiments and whatever the type of PBLG nanoparticles, their size was smaller than 60 nm and an
adsorbed poloxamer-coating was added to render the nanoparticles stealth or bring to perfection the
coating of the nanoparticle surfaces with PEG blocks (where used), allowing the endo-phagocytosis by
the bone marrow endothelium. Logically, osteotropic ligands did not enhance accumulation in bone
since it is the capability of nanoparticles to be endo-phagocytosed by bone marrow endothelial cells
which would be the bottleneck to their delivery to mineral surfaces and finally would determine their
concentration in bone. In addition, bone mineralised surfaces are not readily next to the vessels.
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The present method was limited since quantification of nanoparticles was performed on the whole
bone and it did not allow distinguishing between distribution in the bone marrow from that in the
mineralized bone. Once nanoparticles have attained the bone microenvironment, there are still
important barriers to overcome so that they can attain bone mineralized tissue. Bone marrow contains
a large number of cells and is the site of production of 4.9 1011 cells per day as well as the site for
homing stem cells from the circulation [28]. Bone marrow produces stromal and hematopoietic cells,
including monocytes, granulocytes and bone marrow macrophages which are involved in the clearance
of nanoparticles [29]. In order to efficiently attain bone mineralized surfaces, nanoparticles should
penetrate through the bone marrow avoiding internalisation by these numerous cells. For this purpose,
stealthiness is again favourable. Once nanoparticles bound, nanoparticle desorption, if existing, might
also be considered. Nanoparticles more prone to detachment could interact more likely with bone cells
and could be more easily eliminated from the skeleton.
Bone histological experiments were therefore implemented so as to determine which type of
nanoparticle could attain more efficiently bone mineralized tissue and bone formation surfaces
(specifically labelled with xylenol orange) (Figure 6). Histological studies by fluorescence microscopy
revealed that most nanoparticles could attain mineralised tissue and remained bound to it (Figure 6).
Among them, alendronate nanoparticles were the most efficient nanoparticles in attaining bone
mineralized tissue at both 24 hours and 5 days even if they showed the lowest biodistribution to
overall bone. This could be in part due to the rapid bone binding kinetics, as evidenced by the HAP
binding assay. In trabecular bone after 5 days, PGlu nanoparticles were bound to mineralized surfaces
almost at the same degree as the alendronate ones. Bnz and PEG nanoparticles, although they lack an
active bone targeting moiety, could effectively bind to bone mineralized surfaces, in coherence with
the bone binding assay. Surprisingly, AL/PGlu nanoparticles, although they are found in the bone and
despite the efficient in vitro HAP and bone binding characteristics, did not appear to be able to bind to
bone mineralized surfaces in vivo.
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Figure 6: Histological semi-quantitative study of the single and double labelled mineralizing bone surfaces
in femurs 24 hours and 5 days after intravenous administration of PBLG-derivate nanoparticles. Single
labelled surfaces corresponds to fluorescently-labelled FITC nanoparticles (FITC-Np) whereas double
labelled surfaces corresponds to surfaces labelled with both the bone formation marker xylenol orange and
the fluorescently-labelled FITC nanoparticles (FITC-Np).
This might result from the complex multifactorial in vivo kinetic processes involved as indicated
above. This study underlines the difficulty to extrapolate results obtained with in vitro and ex vivo
methods to the in vivo fate of nanoparticles intended for bone targeting as others have evidenced [30]
4- Conclusions
We have prepared a series of bone-targeted multifunctional PBLG nanoparticles with tuned bone
targeting properties. In vitro HAP binding properties could be controlled by precise modulation of the
Chapitre V: Osteotropicity and microdistribution in bones of
self-assembled multifunctional PBLG nanoparticles
Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
169
type and amount of osteotropic moiety born on their surface and only nanoparticles bearing a bone
targeting moiety could bind to HAP. In vivo studies showed that all types of nanoparticles could also
be distributed to bone. Logically, biodistribution into the bone was not enhanced by the osteotropic
moieties since it is determined by the capability of trafficking and being endocytosed by bone marrow
endothelial cells. Most types of nanoparticles could attain bone surface and remain bound to it as
shown by the histological studies, exhibiting different microdistribution patterns. Among all,
alendronate nanoparticles showed enhanced in vivo bone binding, both in cortical and trabecular bone
and 1 and 5 days after injection. However, no benefit has been obtained from the combination of both
alendronate and glutamic acid on the nanoparticles. Binding of alendronate nanoparticles at
mineralizing surfaces may have a high potential for the long-term therapeutics of skeletal diseases.
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1. PBLG-b-PEG-AL copolymer: synthesis and characterization
1.1. Synthesis scheme for PBLG-b-PEG-alendronate
1.2. Quantitative 31P NMR spectroscopy in alendronate-PEG-alkyne
Quantification of alendronate in alendronate-PEG-alkyne was performed by a previously described
method with the use of coaxial inserts containing a KH2PO4 solution as a reference standard [1].
Because the specific condition for quantitative NMR that both the sample and the reference occupy the
same volume is violated, a first experiment was done so as to introduce a correction factor in function
of the ratio of volumes of both tubes, the insert and NMR sample tube. Values of volume
reference/volume tube (Vr/VT) were evaluated using two potassium phosphate solutions of same
concentration but differing in hydrogen ion concentration and thus in observed 31P chemical shift. To
prepare two potassium phosphate solutions of concentration as close as possible, a stock solution of
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KH2PO4 at a 0.1 g/mL concentration was prepared. Into a 5 mL flask, 2 mL of this solution, 1 mL of
deuterium oxide and 0.4 mL of NaOH 25% were added and diluted with water up to 5 mL. This
constituted the basic solution, confirmed by its basic pH of 13 where the form PO4-3 is predominant
and the 31P chemical shift is observed at 6.29 ppm. The acid solution of pH 5.5, was prepared
identically but without the addition of NaOH, where the predominant form is KH2PO4 and the
observed shift is at 1.26 ppm. To determine the Vr/VT ratio, they were analyze by quantitative NMR
where the basic solution was contained in the NMR tube and the KH2PO4 solution was introduced in
the coaxial insert tube (see Figure 1). Experiments were done by quadruplicate.
To determine alendronate concentration in the alkyne-PEG-alendronate macromolecule, and thus the
efficacy of the reaction, a water solution of alkyne-PEG-alendronate macromolecule was analyzed by
quantitative NMR using as a standard reference a solution of KH2PO4 in the coaxial insert (see figure
2). The relaxation times of both molecules were also checked prior to the experiment. The
concentration of alendronate was calculated with the following equation
Ct = Cr It Vr/Vt Ir
where Ct and Cr are the concentrations of the tube and reference, respectively It and Ir, the intensities of
the phosphorus signal of the tube and reference, respectively.
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Figure 1: 31P NMR spectrum for the correction factor calculation. In the NMR sample tube, a basic
solution containing PO4-3 and in the coaxial insert a mild acidic solution containing KH2PO4 at the same
concentration.
Figure 2: 31P NMR spectrum for the quantification of alendronate in alendronate-PEG-alkyne using a mild
acidic solution containing KH2PO4 in the coaxial insert as a reference standard.
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1.3. Quantification of alendronate in PBLG-b-PEG-alendronate
The quantitative NMR spectroscopy determined a phosphorus concentration of 31 mM and therefore
the efficacy of the reaction between alkyne-PEG-NHS and alendronate was found to be of 67 %. The
phosphorus concentration determined by elemental analysis was 1.40% and yielded an efficacy of
reaction of 71 %. The efficacy of the reaction between alkyne-PEG-alendronate and N3-PEG-PBLG
was found to be 46% and therefore 31 %. of the PBLG50-b-PEG-alendronate polymeric chains were
estimated to contain an alendronate molecule.
1.4. 1H NMR of PBLG-b-PEG-alendronate
Figure 3: 1H NMR of PBLG-b-PEG-alendronate
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2. PBLG-b-PGlu copolymer: synthesis and characterization
2.1. Synthesis scheme of PBLG-b-PGlu
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2.2. 1H NMR of PBLG-b-PGlu
Characteristic peaks were identified for hexyl- PBLG polymer. The molar mass of the polymer could
be determined by integration of the benzyl protons belonging to the PBLG block and the CH3 protons
of the hexylamine. The completion of the debenzylation reaction was checked by the absence of the
pics corresponding to the benzyl and aromatic protons. NMR spectra of the PBLG-b-PGlu copolymer
is shown below (see figure 4).
Figure 4: 1H NMR of PBLG-b-PGlu
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3. TEM images of nanoparticles
Figure 5: TEM images obtained at 120 kV and 20000 X screen magnification of nanoparticles containing
33% w/w of the PBLG-dansyl polymer except for PBLG-dansyl nanoparticles which contain 100 % w/w of
this derivate.
PBLG-b-PGlu/ PBLG-dansylPBLG-dansyl
PBLG-b-PEG-alendronate/PBLG-b-PGlu/PBLG-dansyl
PBLG-b-PEG-alendronate/PBLG-dansyl
PBLG-b-PEG/PBLG-dansyl
PBLG-b-PGlu/PBLG-b-PEG/PBLG-dansyl
PBLG-bnz/PBLG-dansyl
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PBLG-b-PGlu/PBLG-FITC
Figure 6: TEM images obtained at 120 kV and 20000 X screen magnification of nanoparticles containing
33% w/w of the PBLG-FITC polymer.
PBLG-b-PEG-alendronate/PBLG-FITC
PBLG-b-PEG-alendronate/PBLG-b-PGlu/PBLG-
FITC
PBLG-b-PGlu/PBLG-b-PEG/PBLG-FITC
PBLG-b-PEG/PBLG-FITCPBLG-bnz/PBLG-FITC
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4. Bone histological images 24 hours and 5 days after IV administration of nanoparticles
Figure 7: Bone histological images under fluorescent microscopy of trabecular bone of femurs after 24
hours (left) and 5 days (right) after IV administration of the FITC-labelled nanoparticles and further
undecalcified tissue embedding and inclusion procedure in methyl methacrylate.
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Figure 8: Bone histological images under fluorescent microscopy of cortical bone of femurs after 24 hours
(left) and 5 days (right) after IV administration of the FITC-labelled nanoparticles and further undecalcified
tissue embedding and inclusion procedure in methyl methacrylate
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GENERAL DISCUSSION
1- Introduction
Nanomedicine, which is the application of the nanotechnology to medicine, is promising for the
development of theranostic tools. The use of nanomedicine for cancer can improve current therapeutic
treatments; over two dozen nanotechnology based therapeutics have been approved for clinical use by
the FDA and more being in clinical trials [1].
A major attention has been devoted to active targeting of cancer over the past few years. The need
for safer treatments with enhanced efficacy are desired. The goal of this approach is to deliver
specifically the cytotoxic treatment to the malignant cells avoiding side effects in the healthy tissue
and cells. In order to achieve this goal, different targeting approaches can be designed such as
nanoparticles targeting cancer angiogenesis, cancer cell proliferation markers or cancer cells
themselves.
The skeleton is the third most common sites of metastasis. Prostate and breast cancer, which are
leading causes of cancer death, have a high tendency to metastasize to bone, and constitute more than
80% of cases of metastatic bone diseases. Bone metastases are infrequently silent and are associated
with a high morbidity involving pain, hypercalcemia, spinal cord compression or fractures. Although
no prevalence figures for people affected by bone metastases exist, it is estimated that more than
350.000 people in the United States die with bone metastases and thus there is an important need for
the development of effective treatments [2, 3].
Anatomy and physiology of bone tissues is complex in nature making difficult to design an efficient
targeting system. Indeed, we are demanding not only affinity for the target but also specificity, which
means that no interactions with other targets should occur during the distribution process following
delivery.
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The objective of this work was to design multifunctional nanoparticles derived from poly
(benzylglutamate) (PBLG) that could attain bone tissue and remain bound for a prolonged time period
in order to ensure intra-bone time-controlled delivery of anticancer drug. In this way, nanoparticles
could constitute anticancer drug reservoirs for long-term skeletal cancer treatments.
For this purpose, a small library of various PBLG copolymers bearing different functionalities have
been synthesised. We succeeded in assembling them into various proportions to form multifunctional
nanoparticles, whose bone binding affinity was evaluated in vitro, ex vivo and in vivo. An anticancer
agent was successfully associated to the nanoparticles in view of a bone anticancer application. This
discussion is divided into different sections and deals with the different steps needed to achieve these
bone targeted nanoparticles, from copolymer synthesis, nanoparticle preparation and in vitro
characterization of bone binding properties and anticancer agent association to in vivo binding
efficacy.
2- Synthesis of a mini-library of polymers with different functionalities
In order to prepare multifunctional nanoparticles, we proceeded to the synthesis of a mini-library of
PBLG polymers bearing various functionalities. These copolymers were intended to be self-assembled
together to form multifunctional nanoparticles. Polymerizations were achieved by ring opening
polymerization (ROP) of the α-aminoacid N-carboxyanhydrides (NCAs). It can basically proceed by
two main routes, the amine mechanism and the activated monomer mechanism. The amine mechanism
is a ROP where an amine attacks the carbonyl of a NCA molecule and in absence of side reactions the
polymer grows linearly with monomer conversion. Activated monomer mechanism consists of the
deprotonation of a NCA molecule, which becomes a nucleophilic molecule which in turn initiates the
polymerization by attacking the carbonyl of another NCA. It is important to remark that both
mechanisms can occur and can switch back and forth during a polymerization, one being the side
reaction for the other one. The nucleophilicity/basicity ratio of the initiating molecule will influence
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the preponderance of one or the other polymerization mechanism. Primary amines, being more
nucleophilic than basic, are good initiators in general for NCA polymerizations so as to proceed by the
normal amine mechanism. One inherent problem of conventional NCA polymerizations is that there is
no control on the reactivity of the growing polymer chain end and thus they are subjected to a variety
of side reactions. In order to circumvent such side reactions, developments have been made.
Developments in ROP includes the use of zerovalent metal complexes as initiators of well controlled
ROP that produce polypeptides with narrow chain length distributions PI < 1.2 and controlled
molecular weights. However, the active propagating species are generated from the first NCA
monomer and therefore no functionalities can be attached to polymers by this method [4].
Alternatively, functionalized precursors of amido-amidate nyckelacycles, that are transformed into
NCA initiators have been successfully synthesised. They allow to obtain C-ending functionalized
polymers [5]. Other recent developments include variations of the conditions of the reaction
(temperature and vacuum) as it is discussed below.
In this work, polymerization reactions were carried out by ROP of γ-benzyl-L-glutamate-N-
carboxylic anhydride (BLG-NCA) using primary amines as initiators without the use of any zerovalent
metal complexes. Optimising the conditions for polymerizations would have been interesting, above
all for the PBLG-b-PGlu initiated by the PGlu-NH2 that gave a too large polymolarity index. However,
due to technical difficulties, analyses with steric exclusion chromatography (SEC) could be only done
months after the synthesis and thus optimization could not be efficiently performed. Different
polymers bearing several functionalities are presented below.
PBLG-bnz
Different batches of PBLG-bnz with various molecular weights were synthesised using
benzylamine, a primary amine, as an initiator. These polymerizations were well controlled as indicated
by the comparison between theoretical and experimental molecular weightes and the low polymolarity
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indexes obtained by MALDI-TOF and SEC (For PBLG-bnz of a theoretic molecular weight of 30000
Da: PISEC = 1.14 and PI MALDI-TOF= 1.13).
PBLG-b-PEG
PBLG-b-PEG copolymers were prepared in view of conferring stealth properties to nanoparticles by
the introduction of PEG chains onto their surface. Different batches of PBLG50k-b-PEG5k of 50000
g/mol of molecular weight were synthesised. The molecular weight of the PEG block was chosen to be
5000 Da since in general terms it seems to be an appropriate length so as to reduce the adsorption of
opsonins [6]. Reaction was initiated by methoxy-PEG-NH2 and yielded polymers of a relatively low
polymolarity ( PISEC = 1.27 and PI MALDI-TOF= 1.23)
PBLG-b-PEG-alendronate
In order to provide nanoparticles with bone targeting properties, a PBLG copolymer bearing a
biphosphonate moiety was synthesised. In order to immobilize nanoparticles onto the bone,
hydroxyapatite (HAP) was chosen as a possible binding target. HAP is the main mineral component
that accounts for 50-70 % of the extracellular matrix. Within the body, HAP is very specific to bone,
although it is also found in teeth and pathological calcifications. There are some molecules that have
affinity for HAP such as tetracyclines, tetracycline derivates, biphosphonates, acidic oligomers or
poly(malonic acids). Among these compounds, biphosphonates are the most widely used drugs for the
therapeutics of skeletal diseases such as osteoporosis, metastatic bone disease or Paget's disease.
Biphosphonates are chemically stable analogues of inorganic pyrophosphate and it is the P-C-P moiety
which is responsible for their binding to HAP [7]. Among them, alendronate was chosen since it has a
primary amine on its structure and was therefore appropriate for coupling reactions with a PBLG
block. Different coupling strategies were assayed.
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PBLG-b-PEG-alendronate synthesised by the carbodiimide coupling approach
Two copolymers of different molar masses were prepared by a carbodiimide coupling approach:
PBLG50k-b-PEG6k-alendronate and PBLG10k-b-PEG6k-alendronate. To ensure that molecules of
alendronate could be exposed and available on nanoparticle surface, NHS-PEG6k-NHS was chosen for
the synthesis of the bone-targeting copolymers both as a spacer and to confer stealth properties to the
bone-targeted nanoparticles.
In order to synthesise an alendronate bearing polymer, the carbodiimide approach had been
previously carried out successfully in our group. However, many technical problems were encountered
during this synthetic approach. This approach was not optimal due to the use of an homofunctional
linker, NHS-PEG6k-NHS, that limits to 1 the [alendronate]/[ NHS-PEG6k-NHS] molar ratio in the
reaction between them so as to try to prevent the reaction of two molecules of alendronate with this
linker. Modifications were made to the original method proposed by Ozcan et al. [8], including
elimination of unreacted free alendronate and further activation of the carboxylate group. However,
this latter step might have provoked the activation of the phosphonate groups of the alendronate
molecule, which leaded finally to the formation of star-shaped polymers, which had to be eliminated
with a further purification process.
In spite of all the technical difficulties encountered during the chemical synthesis, bone targeted
nanoparticles could be obtained and were shown to display bone targeting properties using the HAP as
an in vitro model (see section 4). However, the low efficacy of this coupling reaction, (only 5,3 % of
the PBLG10k-b-PEG6k-alendronate chains beared an alendronate group) added technical difficulties to
further physico-chemical experiments carried out to determine the binding affinity with the divalent
calcium ions by isothermal titration calorimetry (ITC). These difficulties prompted us to look for an
alternative coupling method.
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PBLG-b-PEG-alendronate synthesised by a combination of click chemistry and carbodiimide
coupling approach
Due to the unsuitability of the coupling reaction pathway described above and despite the obtaining
of bone targeted nanoparticles, a new chemical synthetic approach was carefully designed involving
the click chemistry and carbodiimide approach. Two copolymers of different molar mass were
prepared by click chemistry: PBLG17k-b-PEG6k-alendronate and PBLG50k-b-PEG6k-alendronate. For
further clarification we will refer to this latter copolymer as alendronate PBLG copolymer (click). The
length of the PEG spacer was chosen to be of 6000 Da, similar to the one in the carbodiimide
approach.
The use of an heterobifunctional linker, NHS-PEG3k-alkyne, allowed us to improve the efficacy of
the reaction between alendronate and NHS-PEG3k -alkyne since the [alendronate]/[NHS-PEG3k -
alkyne] molar ratio could be enormously increased. The click chemistry reaction of PBLG-PEG3k -N3
and alendronate-PEG3k-alkyne proceeded with a high efficacy of reaction. The overall efficacy of both
reactions resulted in the fact that among the PBLG50k-b-PEG6k-alendronate chains, 69% were actually
PBLG-b-PEG chains (15% PBLG50k-b-PEG6k and 54 % PBLG50k-b-PEG3k) and 31 % consisted of
PBLG50k-b-PEG6k-alendronate chains. Polymeric chains bearing an alendronate molecule in the
PBLG50k-b-PEG6k-alendronate (click) were almost six times more abundant than for the PBLG10k-b-
PEG6k-alendronate (carbodimide) and more than 8.5 times higher if compared to the similar molecular
weight copolymer, PBLG50k-b-PEG6k-alendronate (carbodimide). Due to initial technical difficulties in
the synthesis of PBLG50k-b-PEG-alendronate, a lower molecular weight PBLG block, namely
PBLG17k-b-PEG6k-N3 was synthesised. Efforts were made to evidence the azide functionality of the
block PBLG17k-b-PEG3k-N3 by infrared spectroscopy techniques at 2100 cm-1 and its disappearance
after reaction with alendronate-PEG3k-alkyne. However, even with this shorter polymer, this band
could not be seen, probably due to the too high polymer molecular weight per azide group.
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PBLG-b-PGlu
Poly(glutamic acid) (PGlu) was chosen as a block with a double functionality. Firstly, bone affinity
of glutamic acid oligomers is largely known [9]. Secondly, its ability to complex metals, including
cisplatin, has been considered as a mean of associating such derivates and thus conferring anticancer
properties to the nanoparticles.
PBLG25K-b-PGlu2k polymerization was initiated by a hydrophilic PGlu2k-NH2 block previously
synthesised by us by a ROP of NCA and a further debenzylation by catalytic hydrogenation. The
method of debenzylation was chosen so as to reduce any possible polymer degradation and so as to
favour the presence of protonated carboxylic acids and to avoid carboxylate ions in the PGlu2k-NH2
block. Such a polymerization has been previously described [10]. However, it was not a well
controlled polymerization as depicted from the PISEC= 1.75. Efforts to obtain a MALDI-TOF spectrum
in various conditions were made but were unsuccessful. Despite this large polymolarity, nanoparticles
were rather homogeneous and not more polydisperse than nanoparticles made from other PBLG-
derivates.
In order to reduce polymolarity and side reactions, various alternatives for the polymerization
reaction are available such as the use of zerometal complexes or the use of low temperatures (0°C
degrees) [11] or a combination of low temperature and low pressure [12]. Problems associated to the
purity of PGlu-NH2 and to the availability of the amine in the initiator molecule PGlu2k-NH2 might
also account for this lack of control. Polymerizations carried out at 25 °C are known to proceed with
diverse side reactions which result in several end-groups, a common being the pyrrolidone ring [12].
Besides, the effect of the catalytic hydrogenation reaction on these issues should be studied.
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PBLG derivates with fluorescence properties
PBLG-dansyl:
A PBLG-dansyl fluorescent polymer was synthesised in view of preparing multifunctional
fluorescently labelled nanoparticles for in vitro experiments. The synthesis of PBLG-dansyl was
achieved by ROP of BLG-NCA using dansylcadaverin as an initiator. Dansylcadaverin has a primary
amine on its structure and no anions or groups that could interfere with the polymerization.
Figure 1: Structure of dansylcadaverin
As evidenced by MALDI-TOF (Mn of 19880 g/mol and PI of 1.15) and SEC (Mn of 25900 g/mol
and PI of 1.1) results, the synthesis was well controlled, which evidenced the good suitability of the
initiator. The initial molecular weight of PBLG-dansyl was chosen to be 22000 g/mol. It has a lower
molecular weight compared to the initially established one at 50000 g/mol. This was chosen to
increase the number of fluorophore molecules per gram of polymer and thus the fluorescence
detection.
PBLG-rhodamine
Efforts were made to synthesise a PBLG derivate bearing a rhodamine molecule to prepare
rhodamine-labelled nanoparticles. In order to achieve this goal, a ring opening polymerization of NCA
was carried out using a derivate of rhodamine possessing on its structure a secondary amine,
rhodamine piperazine, as showed below. This rhodamine derivate has been synthesised and provided
by Dr B. Le Droumaguet and Dr. J. Nicolas. However, even if this polymerization has been previously
reported [13], nanoparticles from this derivate could not be successfully achieved in our case. It is
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likely that problems encountered through the polymerization reaction were due to the use of a
secondary amine as an initiator having a counter-ion on its structure, which led to an heterogeneous
PBLG-rhodamine derivate that precipitated partially during the nanoprecipitation step.
Figure 2: Structure of the rhodamine-piperazine initiator for the attempt of PBLG-rhodamine synthesis
PBLG-FITC
A PBLG-FITC fluorescent polymer has been previously synthesised in our group and was directly
used. Its chemical synthesis has been carefully designed using fluorescein isothiocyanate (FITC), an
electrophilic group, as a chain terminating agent, as it has been previously shown [14]. Fluorescein
isothiocyanate isomer I (FITC), was introduced into the polymer structure by ending a ROP initiated
by benzylamine. This strategy allowed the functionalization of the N-terminal ends and the preparation
of a PBLG-FITC polymer with a well controlled molecular weight and a narrow polymolarity index
(PI MALDI-TOF = 1.14 and PI SEC=1.18 ).
Miscellaneous
Regarding the polymer molecular weight characterization technique, it is important to remark the
great concern that exists: only the 1H NMR technique in the case of the copolymers PBLG-b-PEG can
give an accurate molecular weight of the degree of polymerization but no polymolarity index is
provided. Molecular weight data obtained from both SEC and MALDI-TOF were obtained with
experimental errors, as shown in Table 1.
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Table 1:Molecular weight data of different PBLG polymers
PBLG-polymers DPna Mn
(g/mol)
PIb Mnc
(g/mol)
PIc
PBLG10k-bnz 45 8431c 1.16 - -
PBLG25k-bnz 136 23407c 1.13 31727 1.14
PBLG50k-bnz 228 39690 1.1 - -
PBLG40k-b-PEG5k 228 39366c
56465d
1.23 65513 1.27
PBLG40k-b-PEG5k 228 34512c
50425d
1.22 - -
PBLG40k-b-PEG6k -alendronate(carbodiimide)
228 42415c 1.17 - -
PBLG10k-b-PEG6k -alendronate(carbodiimide)
45 8711e - - -
PBLG25K-b-PGlu2k 137 - - 24436 1.75
PBLG20k-dansyl 91 19786c 1.19 25944 1.10
PBLG40k-FITC 228 36155c 1.14 52647 1.17
PBLG17k-b-PEG6k -alendronate(click)
78 - - 34171 1.17
PBLG50k-b-PEG6k -alendronate
(click)
228 - - 52816 1.54
(a) theoretical; (b) determined by MALDI-TOF; (c) determined by SEC; (d) determined by NMR; (e)
determined from PBLG10k-bnz
The MALDI-TOF technique has been reported to underestimate the molecular weight of polymers,
probably due to the molecular weight discrimination effect during ionization/desorption processes [15,
16] whereas the SEC measurements, lacking of an appropriate standard for the rod-like PBLG
polymer led to an overestimation of the molecular weight as reported by other authors [17].
3- Preparation of multifunctional nanoparticles
As shown in table 2, various types of multifunctional nanoparticles were prepared by
nanoprecipitation of the different polymers issued from the library described above, either alone or as
mixtures of two or more polymers. Because of the presence of the constant PBLG block, it was
expected that these different polymers could self-associate together, without segregation phenomena.
From a practical point of view, the nanoprecipitation protocol was modified in order to be able to
prepare nanoparticles containing the PBLG25k-b-PGlu2k copolymer.
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PBLG25k-b-PGlu2k nanoparticles
The previous nanoprecipitation method carried out in our group consisted in the nanoprecipitation in
water of a THF solution containing the PBLG derivate. A novel nanoprecipitation method allowed the
preparation of PBLG25k-b-PGlu2k nanoparticles. This method consisted of dissolving PBLG25k-b-
PGlu2k copolymer in THF/MeOH 75/25 at 40 °C and precipitating it in water containing two
equivalents of NaOH per equivalent of COOH contained in the PGlu moiety. The presence of NaOH
was essential so as nanoparticles did not aggregate. In absence of NaOH, nanoparticles aggregated
presumably through the formation of hydrogen bonds between adjacent nanoparticles. The aggregation
of nanoparticles was macroscopically appreciable as shown in figure 3 and confirmed by dynamic
light scattering (DLS) measurements, which yielded 150 nm objects while transmission electron
microscopy (TEM) measurements showed very small nanoparticles (typically 24 x 17 nm in size with
an aspect ratio of 1.4). Nanoparticles prepared in the basic nano-precipitating medium were 34 x 27
nm in size with an aspect ratio of 1.3.
Figure 3: PBLG25k-b-PGlu2k nanoparticle suspensions prepared from the novel nanoprecipitation
method: left: in presence of sodium hydroxide; right: in absence of sodium hydroxide
General Discussion
196 Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
Table 3: Size measured by TEM and DLS of PBLG25k-b-PGlu2k nanoparticles prepared in absence and
presence of NaOH.
PBLG25k-b-PGlu2k/PBLG derivate nanoparticles
Multifunctional nanoparticles obtained by the mixture of PBLG25k-b-PGlu2k copolymer and another
PBLG derivate could be obtained by the same nanoprecipitation method described above. The amount
of NaOH was adjusted to two equivalents of NaOH per equivalent of COOH, which was optimal and
did not provoke the precipitation of the other PBLG copolymers. For the PBLG17k-b-PEG6k-AL (click)
copolymer, the nanoprecipitation method had to be modified due to the solubility problems
encountered in THF/MeOH 75/25. So as to be able to prepare multifunctional nanoparticles together
with the PBLG25k-b-PGlu2k copolymer, the nanoprecipitation method needed DMF for dissolving the
different polymers before nanoprecipitation in water and further elimination of the DMF by dialysis.
Nanoparticle stabilization
In presence of ions and biological media, all types of nanoparticles precipitated, except those
obtained only from the PBLG25k-b-PGlu2k copolymer, which were further stabilized by the
electrostatic repulsion among the negatively charged carboxylate groups. In order to render
nanoparticles stable in ion containing and thus biological media, nanoparticles had to be stabilised
with poloxamer. The use of pluronic F68 ® in large excess at a concentration of 66 % (% w/w per
PBLG polymer mass) resulted in the obtaining of stable nanoparticles in physiological media.
Nanoparticles TEM DLS
PBLG25k-b-PGlu2k Dlongitudinal (nm) Daxial (nm) Aspect ratio Size (nm)
In absence of NaOH 34 27 1.4 150
In presence of NaOH 24 17 1.3 50
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4- Hydroxyapatite (HAP) binding nanoparticles
Alendronate and acidic oligopeptides are well known for their affinity to bone and have been used
to impart osteotropicity to many drugs [18, 19]. A small library of nanoparticles with modulated HAP
affinity were prepared from the alendronate copolymer (carbodiimide and click), poly(glutamic acid)
copolymer, a combination of them or a combination of non osteotropic and osteotropic polymers. The
nanoprecipitation technique was found to be a versatile tool to modulate precisely nanoparticle
surfaces, being able to modulate HAP targeting properties as well. It was likely that the efficient
presentation of the HAP targeting ligands was also favoured by the rigidity of the PBLG block, since
hindrances of these hydrophilic moieties inside the hydrophobic nanoparticle core were not likely to
occur.
First, alendronate decorated nanoparticles were prepared from the alendronate copolymer PBLG10k-
b-PEG6k -alendronate (carbodiimide) and interaction with HAP and divalent calcium ions was studied.
Interestingly, experiments showed that calcium-bound nanoparticles can still bind to HAP with the
same affinity, confirming that calcium is displaced and not interfering with HAP binding. This yields a
deeper understanding of potential in vivo fate of bone targeted nanoparticles.
Nanoparticles decorated with either alendronate or/and poly(glutamic acid) prepared from PBLG50k-
b-PEG6k -alendronate (click) or/and PBLG25K-b-PGlu2k copolymers showed differential targeting
properties, as shown by both the kinetics and desorption in vitro HAP assays. Interestingly, for
nanoparticles containing both osteotropic ligands, alendronate and PGlu, a low percentage of the
alendronate copolymer (click) (ratio alendronate/PGlu polymer of 0.34) was enough so that the
alendronate moieties, and not the poly(glutamic acid) were responsible for HAP binding.
Alendronate and acidic oligopeptides are known to present differential bone binding properties. In
vitro HAP binding affinity for the acidic oligopeptides (L-Asp)6 or (L-Glu)6 was found to be in the
order of ~ 102 lower than for the biphosphonates [20, 21]. This lower affinity could result in more
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chemical desorption and less skeletal retention but at the same time to more penetration into the
osteocyte network. Moreover, some studies with osteotropic HPMA polymers have shown differential
in vitro and in vivo interaction between alendronate and (Asp)6, (Asp)6 being distributed preferentially
to bone resorption sites whereas alendronate would be distributed to both formation and resorption
sites. This could be due to the lower affinity of (Asp)6 to HAP and to a more dependent binding on
HAP crystallinity, which is higher for resorption sites rather than for the newly formed bone.
Influence of cisplatin on hydroxyapatite (HAP) binding properties
Interaction of cisplatin-loaded PBLG25k-b-PGlu2k nanoparticles with HAP differed from PBLG25k-b-
PGlu2k nanoparticles free of cisplatin (see section 5 for cisplatin association to nanoparticles). In terms
of kinetics, the presence of cisplatin fastened the HAP binding reaction whereas the desorption assay
revealed an intermediate desorption degree of PBLG25k-b-PGlu2k-cisplatin nanoparticles. This is not
surprising since cisplatin is known to interact with HAP in such a manner that its release from HAP is
very slow and dependent on the chloride concentration [22, 23]. Therefore we could hypothesize that
the cisplatin involvement in HAP binding could account for the faster kinetics and for the lower
release of cisplatin-PBLG25k-b-PGlu2k nanoparticles at pH 3.5 compared to PBLG25k-b-PGlu2k
nanoparticles. In a coherent way, alendronate/PGlu-cisplatin nanoparticles displayed similar binding
properties as the alendronate ones.
Comparison of hydroxyapatite(HAP) binding properties of alendronate PBLG nanoparticles
(carbodiimide) and (click)
Both alendronate nanoparticles obtained either from PBLG10k-b-PEG6k-alendronate (carbodiimide),
synthesised by a double carbodiimide approach or from PBLG50k-b-PEG6k-alendronate (click)
obtained by a combined carbodiimide and click approach showed total binding to HAP, the kinetics
being much quicker for nanoparticles obtained from PBLG50k-b-PEG6k-alendronate (click). This could
be attributed to the increased number of alendronate molecules per polymer chains, although other
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factors such as aspect ratio, number of chains per nanoparticle or different degree of steric hindrance
caused by the different length of PEG could be involved and should be further studied.
Ex vivo bone binding properties
Ex vivo bone binding experiments using fluorescently labelled nanoparticles showed differences
compared to the in vitro HAP binding assay. It revealed that all types of nanoparticles (osteotropic and
non-osteotropic ones) presented similar bone binding.
Some hypotheses could explain this discrepancy between in vitro and in vivo experiments. First of
all, bone is composed not only by HAP, the major component of the mineralised tissue (50-70%), but
also by an organic phase consisting mainly of collagen type I and other proteins [24] to which
nanoparticles could also bind. Secondly, it has to be considered that synthetic and biological HAPs
differ substantially since biological HAPs have multiple substitutions and deficiencies at all ionic sites.
For example, cortical biological HAP contains 20 % hydroxyl groups compared to the stoichiometric
HAP [25], and carbonates substitutions (4-6% in weight) for the phosphate ion are present in
biological HAP.
Whether the observed amount of fluorescent nanoparticles bound to bone was high enough to be
considered as actually reflecting an interaction between nanoparticles and bone and whether the
stabilizing poloxamer could influence this interaction are the first questions to be solved. If we
consider that an interaction exist between poloxamer coated PBLG nanoparticles and bone, several
questions arise to understand the nature of this interaction, any of which would require further
experiments to confirm them.
Considering the nanoparticle, what is this interaction due to? Is it due to the poloxamer, to the
PBLG itself or more probably to complex interactions involving several components? Considering the
bone structure, is this interaction due to the biological HAP (whose composition and structure are
different from that of synthetic HAP) or rather due to the organic proteic components or other of bone
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or more likely to a combination of all of them? It could be not be ruled out that among these complex
interactions, peptide-protein interactions between type I collagen, which is constituted by three
polypeptide chains forming a triple-helix, and the poly(benzylglutamate) could also be involved.
Further experiments to explore interactions of nanoparticles with these components, and also with
collagen, which is the most abundant non mineralized component of the bone, would be necessary.
Moreover, a lot of research has been conducted on the adsorption of proteins onto the HAP
structures. Protein adsorption is known to be dependent on many factors such as surface charge,
composition (i.e. Ca/P ratio) or HAP crystallinity [26]. Some essential aminoacids have been shown to
bind to poorly crystallized HAP [27]. Moreover HAP chromatography is a common well-known
method for the separation of mitochondrial proteins [28]. In an elegant study, a library of peptides
were screened for interaction with human tooth. The authors discovered that peptides, free of acidic
aminoacid sequences did display affinity for teeth (and differently for dentin and enamel), opening a
new insight into the mechanisms involved in interactions with biomineral surfaces [29].
5- Bone binding nanoparticles for bone cancer applications: associating an anticancer agent to
PBLG derivate nanoparticles
When designing nanomedicines, whatever their nature, drug association is generally a challenge
concerning the need to associate and to vehicle sufficient drug amounts to the target, to trigger and
control the release kinetics. Different approaches have been foreseen during this work in order to
associate an anti-cancer drug to the bone binding nanoparticles.
5.1- pH labile polymeric prodrug
Cancers are known to present a mild extracellular pH due to an increased metabolic activity of
cancerous cells, which exports H+ to the extracellular space via a Na+/H+ exchanger. Thus, the pH in
cancer extracellular space was found to be 6.60-6.98 in various tumours [30]. Secondly, if
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nanoparticles are interacting and endocytosed by cells, they encounter acidic pH, since early
endosomes present a pH ranging from 6.0-6.8 while lysosomes are more acidic (pH 5.2-4.5) [31].
Moreover, in the specific case of bone, in the resorption lacunae created by osteoclasts, it exists an
acidic microenvironment, where pH is approximately 4-4.5 [32] since osteoclasts secrete protons
through the ruffled border via direct pumping or by fusions of acidic vesicles extracellularly into the
resorption lacunae that will dissolve the mineral content of the matrix, the HAP [33].
Taking advantage of these specific pH conditions, several pH labile linkers such as hydrazone,
acetal, have been described and used to deliver drugs from prodrugs depending on acidic pH. Efforts
to make a pH-sensitive polymeric prodrug of gemcitabine were made. Cis- aconityl was chosen as a
pH labile linker between the PBLG-derivate polymer and the anticancer drug gemcitabine.
Figure 4: Structure of cis-aconityl anhydride
However, it might not be an optimal approach since cis-aconityl prodrugs have shown an
incomplete release probably due to the formation of a trans isomer that cannot be cleaved [34].
Numerous conditions were assayed to couple cis-aconityl anhydride and gemcitabine. Reaction studies
using the aniline as a model drug led us to conclude that this approach was not feasible likely due to
the low nucleophilicity of the gemcitabine. The pH labile polymeric prodrug approach was therefore
discarded.
5.2- Paclitaxel physical entrapment
A first approach for physically associating an anticancer agent, paclitaxel, to PBLG nanoparticles
was assayed. Paclitaxel is an antineoplasic agent that belongs to the family of taxanes, and that has
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been approved by the FDA for some types of cancers, including prostate and breast cancers. These two
types of cancer have both a high incidence of bone metastasis with 73% and 68% occurrences found
respectively at post-mortem studies [35]. Two methods for physically entrapping paclitaxel were
tested using PBLG50k-bnz as the nanoparticle forming polymer since whatever the nanoparticle type,
the PBLG block remained constant and formed the hydrophobic core.
First, a tetrahydrofuran (THF) solution of paclitaxel and PBLG50k-bnz polymer was precipitated in
water in view to form paclitaxel-loaded nanoparticles. No controlled release was achieved by this
method: 82.5% of total paclitaxel was released within 90 minutes. A second strategy implementing a
cosolvency method using 1/10 dichloromethane(DCM)/THF instead of THF was tested in view of
delaying the release kinetics. Paclitaxel and PBLG-bnz polymer were dissolved in 1/10 DCM/THF
and further precipitated in water. However, no improvement in the control of paclitaxel release was
achieved: 86% of total paclitaxel was released within the first 70 minutes.
In both methods paclitaxel was not efficiently encapsulated but probably rather adsorbed onto the
surface of nanoparticles or forming nanocrystals (that maybe could have been evidenced by TEM
within the nanoparticle suspension) since no control on the release of paclitaxel from nanoparticles
was achieved. In any case, the impossibility to obtain satisfying release kinetics evidenced the failure
of this strategy.
5.3- Cisplatin association
Cisplatin (Figure 4) is an antineoplasic agent used for the treatment of different types of cancers,
such as ovarian, testicular, bladder, cervical, head and neck, esophageal and small cell lung cancers
[36]. It is also used in combined chemotherapy for advanced prostate cancer. Cisplatin is rapidly
distributed throughout the whole body upon administration and thus gives rise to side effects such as
the nephro, neuro, oto and hepatotoxicity among others, as well as to drug resistance. In order to
improve its pharmacokinetics and reduce side effects, many efforts have been focused on the
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development of nanoparticulate carriers, some of them undergoing preclinical or clinical development,
such as Prolindac®, LipoPlatin® or Nanoplatin® [37-39]. Cisplatin has the following structure:
Figure 5: Structure of cisplatin
Due to its aqueous solubility and considering the hydrophobicity of the core of the PBLG
nanoparticles, cisplatin encapsulation into these nanoparticles was not investigated due to the poor
expected results.
5.3.1- Cisplatin-PGlu complex encapsulation
Cisplatin-PGlu complexes were prepared and attempts to physically encapsulate these complexes in
PBLG nanoparticles were made. The similarity in the structure of poly(glutamic acid) and
poly(benzylglutamate), two polypeptides, was expected to favour its encapsulation. However, this was
not the case and the encapsulated payload was found to be negligible.
5.3.2- Cisplatin association to preformed PBLG25k-b-PGlu2k nanoparticles
A novel approach was conceived to associate cisplatin to preformed bone targeted PBLG25k-b-
PGlu2k nanoparticles through cisplatin complexation to the carboxylates of the PGlu block. These
nanoparticles were able to associate cisplatin with a drug loading content of approximately 6 % when
a [CDDP]/ [COO-] ratio of 1.25 was used. It would be very interesting to deepen into the mechanism
of interaction of cisplatin with PBLG25k-b-PGlu2k nanoparticles. At higher [CDDP]/ [COO-] ratios, the
1:1 stoichiometry is thought to be more favoured vs the 1:2 one than at lower [CDDP]/ [COO-] ratios,
but both can occur. In the case of 1:2 stoichiometry, it could be interesting to study if intra-chain and
inter-chain crosslinking could be possible, which one would be favoured and the effect of shell-
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crosslinking on nanoparticle properties. Theoretical chemistry studies and molecular modelling could
be useful to deepen into this issue. Regarding cisplatin release, this was surprisingly slow in a PBS
media with absence of any burst release. This type of almost zero order release kinetics confirmed that
cisplatin is coordinated to the carboxylate groups of PGlu and not physically entrapped in the
nanoparticle PBLG core. As it has been previously stated in the literature, the presence of chloride
ions is essential for cisplatin release from PGlu complexes due to a ligand exchange reaction where
chloride ions would substitute the Glu residues from the PBLG25k-b-PGlu2k nanoparticle, due to good
leaving properties of Glu residues [40]. Other ions such as acetates or phosphates are also likely to
play a minor role in cisplatin release. Moreover, the release of cisplatin from carboxylate complexes
have been shown to be enhanced in mild acidic pH [41]. It should be studied in the case of cisplatin
PBLG25k-b-PGlu2k nanoparticles how the pH affects the cisplatin release. The release of small amounts
of cisplatin in distilled water medium was observed but was very slow compared to the one in
physiological medium. However, others have found no release at all for cisplatin complex [42-44] and
cisplatin-loaded micelles [40, 45]. The possible role of impurities or hypothetically poloxamer
(although a priori it should not be involved) should be studied. Cisplatin release from PBLG25k-b-
PGlu2k nanoparticles is mainly dependent on the concentration of chloride ions. The proton
concentration has been also shown to play a role as it has been previously commented above. In the
case of bone targeting nanoparticles for the therapeutics of bone cancer, this is important in two ways.
First, cancers, due to an enhanced metabolic activity of cancer cells are known to present a mild
acidic extracellular pH (pH 6.60-6.98 in various tumours) [30] and nanoparticles if endocytosed
encounter an acidic pH.
Secondly, in the case that nanoparticles bind to the bone mineralized surface and remain there, the
osteoclast mediated resorption could induce the release of cisplatin. Osteoclast pump chloride ions into
the resorption lacunae creating an acidic microenvironment with a high concentration in chloride. It
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might happen that in these conditions the release of cisplatin could be enhanced. Further experiments
should be done so as to confirm these hypothesis:
5.3.3- Cisplatin association to PBLG25k-b-PGlu2k / PBLG40k-b-PEG5k nanoparticles
Cisplatin association studies carried out with multifunctional nanoparticles made of different
proportions of PBLG25k-b-PGlu2k/PBLG40k-b-PEG5k showed that such nanoparticles had to be formed
by at least 60% of PBLG25k-b-PGlu2k so as to be able to complex cisplatin in significant quantities. It
was observed that nanoparticles made from 40% of PBLG25k-b-PGlu2k could hardly complex cisplatin.
This was likely due to the steric hindrance caused by the PEG chains that makes more difficult or
inhibits cisplatin access to the carboxylate groups. It could also be related to the fact that in the
assembling of PBLG25k-b-PGlu2k/PBLG40k-b-PEG5k nanoparticles, the chains of PBLG25k-b-PGlu2k are
not adjacent anymore but intercalate between the other PBLG40k-b-PEG5k chains; this might influence
cisplatin complexation. Molecular modelisation studies as stated above would be of high utility to
yield deeper insight into this issue. Also, similar experiments of associating cisplatin to nanoparticles
made from different proportions of PBLG25k-b-PGlu2k and a PBLG derivate not containing PEG chains
might contribute to clarify this issue.
5.3.4- In vitro antitumor properties
Aquation or hydrolysis of cisplatin in the body is a preliminary step before adduct formation with
DNA, which are partly responsible for the cytotoxic effect of the drug.
It results from a series of equilibria, depending on the concentration of water and chloride ions, as
shown in figure 6. In extracellular fluids, where the concentration of chloride is above 100 mM, the
hydrolysis of cisplatin is not favoured and it mainly remains on its neutral state. Once it has entered
cells, where the chloride concentration is between 2-30 mM, hydrolysis or aquation of cisplatin
occurs, one or two chlorides being replaced by water molecules, forming the cationic mono and
diaquacisplatin, [Pt(H2O)Cl(NH3)2]+ and [Pt(H2O)2(NH3)2]2+, which are very reactive towards
General Discussion
206 Nanoparticules multifonctionnelles de PBLG destinées au ciblage et à la délivrance
d’anticancéreux aux tissus osseux.
Laura de Miguel- Université Paris-Sud- 2013
nucleophilic centers, including DNA, RNA and proteins, mainly because of the good leaving
properties of water.
Figure 6: Species resulting of the hydrolysis of cisplatin. Adapted from [46].
The interaction with DNA involves reaction with the N7 atoms of the imidazole rings of guanine
and adenosine. It is believed that the hydrolysis reaction is the rate limiting step for DNA binding.
Monoadducts are first formed when one chloride is substituted by one water molecule. Most of the
monoadducts (90%) subsequently react to form bifunctional adducts, most of them being intrastrand
rather than interstrand crosslinks. The most abundant intrastrand crosslink has been shown to be 1,2-
intrastrand crosslinks involving two adjacent guanines. Adducts involving DNA-protein crosslinks
have also been reported [47-49].
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Figure 7: Platinating species adducts on DNA. Figure adapted from [47].
The cytotoxic mechanism of cisplatin involves the binding of cisplatin to DNA and non-DNA
targets inducing cell death through apoptosis and/or necrosis [50]. The cytotoxicity of cisplatin-loaded
PBLG-PGlu nanoparticles was evaluated by two methods: MTS test and trypan blue exclusion assay
in three different cell lines that have the potential to metastasize to bone [51]. Cisplatin-loaded
PBLG25k-b-PGlu2k nanoparticles exhibited less cytotoxicity compared to cisplatin in solution whatever
the experimental method used. The IC50 of cisplatin-loaded PBLG25k-b-PGlu2k nanoparticles was 2-11
times higher than for cisplatin solution. Differences were observed depending on the testing methods,
trypan blue determining higher IC50 as reported by other authors [52, 53]. Other methods to evaluate
cytotoxicity based on ATP or DNA measurements would be useful to determine which is the most
accurate method in our experimental conditions (type of cells, treatment). Interestingly, blank PBLG-
PGlu nanoparticles were hardly toxic.
As evidenced by electrochemistry experiments, the platin species released from nanoparticles
previously incubated in PBS were able to interact with DNA. At a sodium chloride (NaCl) aqueous
concentration of 0.150 mM these species consist probably mainly of cisplatin, although a small
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fraction exists as mono(aqua) species [54]. This mono(aqua) species can interact with DNA. Cisplatin
bound to DNA will shift the equilibrium, generating more monoaqua species that are able to interact
with DNA. It could also occur a slow interaction with dichlorodiamineplatinum (II) via a ligand
exchange mechanism. These two mechanisms are considered to account for the interaction of
extracellular cisplatin with the head groups of the phospholipids of the membranes [55]. Another
hypothesis would be the direct interaction of the cisplatin born by the PBLG25k-b-PGlu2k-cisplatin
nanoparticles and that would be in equilibrium with the released cisplatin since in addition carboxylate
groups are good leaving groups.
5.3.5- Protection of cisplatin associated to PBLG25k-b-PGlu2k nanoparticles during transport in
blood and extra-cellular fluids
Once administered in the body, cisplatin is readily attacked by proteins with exchange of one or two
chloride to form protein-cisplatin complexes. Approximately, one day after rapid intravenous
administration, 65-98 % of platinum in blood plasma is protein bound, particularly to those proteins
containing thiol groups such as albumin [56]. This results in reduced concentrations of freely
diffusible drug to the tumoral cells and thus reduced therapeutic efficacy. Further, it contribute to
some side effects. In order to reduce protein binding and thus side effects, Pt(IV) prodrugs are
promising alternatives [57, 58]. Pt (IV) is more inert than Pt (II) thus avoiding more efficaciously
interaction with proteins and others and thus side reactions. This Pt (IV) prodrugs can be reduced extra
or intracellularly (ideally) to Pt(II), taking advantage of the reducing tumour environment, and could
interact with DNA [59].
Interestingly, it can be speculated that cisplatin association to PBLG25k-b-PGlu2k nanoparticles could
counterbalance unfavourably protein binding by masking a significant amount of cisplatin molecules
during the distribution process, as far as it is not released in biological media. From this point of view,
it should be remarked that the low release kinetics was favourable to the transport of large platin
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amounts to the targeted organs with minimal exposure of cisplatin to proteins binding. However,
because some of the cisplatin molecules are likely to be exposed on the outer shell of the nanoparticles
and therefore their interactions with proteins should be further evaluated.
6- In vivo fate of bone targeted nanoparticles
The in vivo fate of nanoparticles following intravenous administration is a complex issue that
involves different kinetic processes and that will determine their biodistribution. Clearly, the
biodistribution of drugs and nanomedicines can be considerably modified in diseased organisms, with
considerable modifications of the efficacy of different barriers in the body. For example, it is well
known that the permeability of the vasculature of solid tumors may be considerably increased, leading
to the so-called enhanced permeation and retention (EPR) effect. Local metabolism or pH
modifications are other examples. However, in the present work, it has been decided to investigate the
fate of the bone targeted nanoparticles in a physiological model rather than a pathological model, as it
was primarily necessary to understand the ability of the nanoparticles to reach bone tissues and the
relationship with their composition and structure, not only for antitumoral delivery but also in a
general purpose.
The biodistribution properties of nanoparticles are determined by anatomo-physiological
characteristics and physico-chemical properties of nanoparticles. As a rule of thumb, the main
parameter that determines nanoparticle biodistribution is their recognition by the reticuloendothelial
system (RES), which often lead to their capture and their consequent elimination. In general, for active
targeted nanoparticles, stealthiness is required in order to have long plasma half-lives so that targeted
nanoparticles can progressively attain their target.
Another essential parameter that should be taken into account is the whole body microvasculature.
Liver capillary microvasculature consists of reticuloendothelial sinusoids with open fenestrae vessels
that allow transvascular flow of nanoparticles up to 180 nm in humans and rabbits and up to 280 nm in
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mice and rats. Spleen consists of sinusoidal non reticuloendothelial microvasculature in the terminal
splenic red pulp arterial blood capillary that allows a transvascular flow of particles up to 5 µm [60].
Information regarding the microstructure of myeloid bone marrow microvasculature remains
controversial. Literature mentioning that bone marrow sinusoids are fenestrated capillaries with pores
up to 80 nm [8, 61-64] is extensive. However, others have revisited these data in more recent reviews
and state that bone marrow sinusoids are formed by a continuous endothelium [60, 65]. A recent
review by Sarin et al. [60] stated that myeloid bone marrow sinusoids are reticuloendothelial blood
capillaries with macula occludens interendothelial junctions that determines a transvascular flow for
lipid insoluble particles limited to 5 nm. Considering this approach, non endogenous macromolecules
smaller than 60 nm that could evade phagocytosis by hepatic Kuppfer cells and splenic red pulp
macrophages, could remain in the bloodstream a sufficient time so as to be phagocytosed by the
capillary wall of the reticuloendothelial cells.
Figure 8: Schematic depictions of the capillary wall ultrastructure in different blood capillary
microvasculature. Left: liver; center: bone marrow; right: kidney glomerulus. Green pillars represent the
individual mucopolysaccharide fibers of glycocalyx; orange hatched region represents the collagenous
basement layer. Schema adapted from [60]
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Nanoparticles once endo-phagocytosed by the bone marrow reticuloendothelial cells, and upon
transvascular release or spill over (saturation of the reticulo-endothelial cells of the bone marrow)
could accumulate in the bone marrow interstitial spaces [60].
In the case of bone targeted nanoparticles, it has to be considered that in absence of an enhanced
permeability effect, no pathological modification would increase favourably biodistribution to bone.
For both theories of bone microvasculature the rational approach would be the development of small
nanoparticles (around 60-80 nm, depending on the theory, this is not clear) with highly stealth
properties. However, we should take into account that due to the whole body microvasculature (blood
flow and much larger fenestrations of liver and spleen) and the eventual RES capture, nanoparticles
might still be importantly distributed to liver and spleen. It has also been shown that specific coatings
could favour the biodistribution of nanoparticles to the bone marrow [66, 67]. It was suggested for
example, that poloxamer- 407 coated nanospheres could accumulate in bone marrow mediated by
plasma components or cellular adhesion molecules [66]. In our study, PBLG-derivate nanoparticles
have been shown to also distribute to bone, and this might be due both to their small size (under 60
nm) and to the stealthiness provided by the poloxamer coating (and by the PEG chains in the case of
pegylated nanoparticles).
Once nanoparticles have attained bone microenvironment, mineralized bone surfaces are not readily
next to the vessels. There is still an important barrier to overcome which is the high number of cells
present in the bone marrow and specifically macrophages. Bone marrow homes the production of a
large variety of cells derived from the hematopoietic stem cells (HSC) or mesenchymal stem cells
(MSC) and giving rise to erythrocytes, platelets and leucocytes in the first case and to chondrocytes,
adipocytes, osteoblast, fibroblast or myocytes in the second case. In the case of HSC cells it has been
shown the existence of different niches, the vascular one, next to the sinusoids, involved in the
differentiation and further mobilization through the endothelium via specific interactions [68, 69].
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Nanoparticles could interact with these cells and thus less number of nanoparticles would be available
to attain the bone mineralized tissue. At this level, stealthiness of nanoparticles would be again very
favourable so as to avoid interaction of nanoparticles with cells. If we take into consideration all the
intra-bone barriers to attain bone mineralized surfaces, it should be considered that the amount of
nanoparticles that has overcome all these barriers and could attain bone mineralized surfaces is
probably low. Indeed, the amount of nanoparticles able to bind to the mineralised tissue would be the
result of the different kinetic processes: the main ones being: penetration of nanoparticles within the
bone marrow, interaction with macrophages and other cells and binding to the extracellular matrix.
Figure 9: Nanoparticle interaction in the bone microenvironment once extravasated into the bone
tissue. Nanoparticles can interact with different cell types and extracelullar matrix domains present in the
bone microenviroment: 1- bone marrow cells, including phagocyting cells 2- low crystallized HAP
corresponding to bone formation sites 3- osteoblasts 4-osteoclast 5- highly crystallized HAP corresponding
to bone resorption sites. Once attached to the bone surface nanoparticles could: 6-detach from it, being
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available to interact with bone cells or to reattach to the bone surface; 7-being resorbed by osteoclast 8-
being embedded within the osteoid
Once nanoparticles have attained the bone mineralized surfaces, a retention mechanism that would
prevent them from returning to the bone marrow (and interacting with macrophages and other bone
cells) and from being cleared from the organism would be very useful. This is the reason why HAP
binding properties have been conferred to nanoparticles either by coupling alendronate or/and
poly(glutamic acid) moieties onto nanoparticle surface. The advantage of bone binding nanoparticles
would be the reduced clearance of nanoparticles and thus a prolonged time of residence within the
bone.
Whatever the type of HAP targeting nanoparticles, their binding to HAP in the PBS medium was a
very rapid process, total binding was achieved in less than 20 minutes except for poly(glutamic acid)
and poly(glutamic acid/PEG PBLG nanoparticles, for which it took approximately 45 minutes. This
fast kinetics is in favour of a rapid immobilization of nanoparticles into the bone mineralised matrix
when they attain this microenvironment. However, the in vivo bone binding kinetics is unknown and is
likely to be dependent on the nanoparticle surface characteristics after circulation in the bloodstream
and on their possible protein corona formed by plasma protein adsorption [70]. Moreover, kinetics of
other processes involved at this stage: mainly penetration and interaction with bone marrow cells are
unknown. Therefore, the in vivo fate of nanoparticles is impossible to predict or to attribute to any
property. So as to be able to predict in a more accurate way in vivo fate of nanoparticles in bone, bone
matrix could be used as a model instead. It would be very interesting to study these two main kinetic
processes: uptake by macrophages and binding to the bone matrix to predict in vivo fate of
nanoparticles in bone microenvironment. In order to evaluate this, an in vitro co-culture of
macrophages and bone matrix forming osteoblasts would be highly valuable, although the feasibility
of this model should be evaluated. Moreover, direct capture of decorated nanoparticles by the different
cell types were out of the scope of this work. But unexpected effects are not excluded since
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biphosphonates are currently used in the treatment of bone pathologies and malignancies. Finally,
biodistribution modelling for the prediction of the in vivo fate of nanoparticles in the bone
microenvironment is an appealing but very difficult task since the rates as well as extensive
knowledge of these processes are ignored.
Once nanoparticles are bound to bone, they are subjected to chemical or biological detachment.
Detachment is inversely related to affinity. Higher affinity binders would result in less detachment and
more reattachment to the bone surface [20]. If we compare the different PBLG derivate nanoparticles
and based on literature findings, poly(glutamic acid) and poly(glutamic acid/PEG PBLG nanoparticles
would be more prone to chemical desorption than alendronate decorated PBLG nanoparticles.
Moreover, the influence of the multivalency displayed by nanoparticles (nanoparticles can be
decorated by a variable number of bone binding moieties on their surface) on the binding affinity
should be evaluated for all types of nanoparticles.
As shown by the histological experiments of femurs after IV administration of nanoparticles, all
types of nanoparticles can attain bone mineralized surfaces to a certain degree although alendronate
nanoparticles showed an enhanced biodistribution to these surfaces. Alendronate nanoparticles were
the most efficiently bound, even if they showed the lowest biodistribution to overall bone. This could
be in part due to the rapid bone binding kinetics, as evidenced by the HAP binding assay. Bnz and
PEG nanoparticles, although they lack an active bone targeting moiety, could effectively bind to bone
mineralized surfaces, in coherence with the bone binding assay. Interestingly, alendronate/poly
(glutamic acid) nanoparticles did not display in vivo bone binding in spite of the effective in vitro
binding properties to HAP and ex vivo to bone, probably as a result of the complex processes involved
as indicated above.
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Discrepancy between bone uptake visualized by in vivo imaging and histological examination
Results concerning in vivo bone uptake obtained by in vivo imaging and by histological examination
of bone slices differs substantially. This is completely coherent. In vivo imaging results give us a
relative biodistribution of nanoparticles in bone, including the bone marrow, whereas for the
histological examination we have focused on the relative microdistribution of nanoparticles in the
bone mineralized tissue. The first is determined by the biodistribution of nanoparticles, including the
bone marrow and its role as a RES system. The second consist of the ability of nanoparticles that have
been distributed into the bone organ to attain bone mineralized surfaces and relies on all factors
discussed above. It would be very interesting to study the biodistribution of the different types of
nanoparticles within the bone and bone marrow microenvironment, to determine if some types have
more interaction with the bone marrow cell types or others are rather located in the bone mineralized
tissue and to determine the parameters involving this.
Diseased state: bone cancer pathology
In the case of a bone cancer pathology, the biodistribution of nanoparticles within in the bone will
be favoured by the EPR effect [71]. Again, nanoparticles with stealth properties are desired to avoid
the main RES organs, liver and spleen, and to be distributed into the tumour site. Cancers are known
to have leaky vasculature. This is derived from the abnormality of endothelial cells which do not form
a monolayer barrier but are rather disorganised and irregularly shaped. Endothelial cells have trans-
endothelial cell fenestrations, caveolae and vesiculo-vacuolar vesicles and loose interendothelial
junctions, which are likely to be responsible for much of the vessel leakiness [72, 73]. Besides, they
produce high amounts of vascular permeability factors [71]. However, EPR effect has been often
overestimated, should be evaluated for each type of cancer and is subjected to inter-individual
variation. Interestingly, in a specific animal model of bone metastasis, the enhanced permeability
effect could be evidenced [74].
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As stated in the previous section, HAP targeted nanoparticles could result in an enhanced
accumulation in the bone if they can attain and remain bound to the bone mineralised surfaces. Indeed,
it would not increase nanoparticle arrival into the bone, which is determined by the ability of
nanoparticles to be endocytosed and release by the bone marrow endothelial cells. In case of a bone
cancer pathological microenvironment, tumours are generally located before bone mineralized
surfaces and nanoparticles might not be able to overcome the tumour to attain the mineralised matrix
due to difficulty in tumour penetration. However, some studies have shown that biphosphonate
decorated PLGA and PIBCA nanoparticles present an enhanced biodistribution to bone [74-76].
Indeed, this is a global effect that could be due to other properties, including the enhanced
internalisation of the zoledronate nanoparticles by breast cancer cells as authors evidenced [74].
Biphosphonates are approved for the treatment of bone metastases and therefore the issue of a non
identified active targeting of bone cancer cells by these nanoparticles could be raised. Recent studies
suggest that these effects are likely to be due to the effect in host cells and bone microenvironment and
not to a direct effect on bone cancer cells [77]. In any case, as it has been evidenced by Chaudhari et
al. that zoledronate nanoparticles are indeed more rapidly internalised that those without zoledronate
[74].
Once in the bone, nanoparticles are subjected to interaction with macrophages and other bone cells
as well as with metabolically active cancerous cells. If nanoparticles attained mineralized tissue, they
could constitute a drug reservoir for intra-bone delivery and drug could be either released in the
extracellular media or after desorption, being able to interact with bone cancer and other cells.
Therefore, intra-bone toxicity derived both from the lack of targeting of bone cancer cells (a priori)
themselves could not be excluded.
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7- Conclusion
Bone targeted nanoparticles were foreseen for the treatment of various bone pathologies, including
bone metastasis. This approach involves the retention of nanoparticles within the bone tissue to
constitute drug reservoirs for intra-skeletal delivery. The main objective of this work was to
investigate (i) the feasibility of bone targeted nanoparticles, (ii) their biodistribution and their possible
bone affinity and finally (iii) their possible application for cisplatin delivery in view of treatment for
bone metastasis.
In this work, various types of bone targeted PBLG nanoparticles were conceived, one type of them
could exhibit both potential bone targeting and sustained anticancer properties. In vivo studies in a
healthy animal model carried out with the blank PBLG25k-b-PGlu2k nanoparticles were encouraging.
They showed in vivo bone targeting properties and retention for at least five days. These nanoparticles
were able to interact with HAP in vitro and in vivo and thus could potentially act as local reservoirs
within bone tissue, releasing loaded drugs locally.
However, quantitative biodistribution of both nanoparticles and loaded drug should be further
evaluated since the drug delivery potential of these nanomedicines depends on the amount of
nanoparticles distributed at the right localization as well as on the amount of drug delivered at the right
localization.
The bone targeted nanoparticle approach might be useful to some extent in some bone disease states
such as bone cancer where the EPR effect would favour an improved biodistribution in the tumour and
locally in the bone environment. Therefore, treatment of bone metastasis was identified as a possible
application for these osteotropic nanoparticles. Their ability to encapsulate appreciable amounts of
cisplatin (up to 6% w/w) and to sustain its delivery on a time-scale compatible with long-term skeletal
durations have been shown.
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For the bone metastasis application, if we consider the in vivo situation of a bone cancer not only
localisation on the bone mineralized surfaces but rather a direct internalisation of the nanoparticles by
the metastatic cancer cells should be foreseen. Biphosphonate-decorated nanoparticles could be
favourably internalized in tumoural cells due to the biphosphonate moiety present on nanoparticle
surface, as it has been shown for zoledronate-decorated nanoparticles. Consequently, PBLG40k-b-
PEG6k-alendronate/ PBLG25k-b-PGlu2k nanoparticles could eventually constitute a better approach in
this case. Besides, acidic environment might trigger cisplatin release, which would be very favourable
to enhance both tumour extracellular and intracellular cisplatin delivery.
Biodistribution and efficacy studies in an animal model of bone metastatic tumour should be
performed as well as in vitro internalisation studies, which would confirm which type of nanoparticle,
PBLG25k-b-PGlu2k or PBLG25k-b-PGlu2k / PBLG50k-b-PEG6k-alendronate could be a more suitable
approach. Therefore, cisplatin loaded-PBLG-derivate nanoparticles remain as a promising approach
for the treatment of bone metastasis.
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L’objectif de ce travail a consisté à concevoir des nanoparticules possédant un tropisme
pour l’os, en vue du traitement ciblé de diverses pathologies osseuses. Pour cela, nous avons
réalisé: (i) la conception, (ii) la préparation et la caractérisation de nanoparticules possédant
un tropisme pour l’os, (iii) l’étude de leur biodistribution dans les tissus osseux et finalement
(iv) la mise en œuvre de ces nanoparticules en vue de transporter et délivrer de manière
contrôlée du cisplatine aux métastases osseuses. Ce travail a été mené à deux niveaux, avec en
premier lieu la problématique d’essayer de comprendre les mécanismes de la distribution de
nanoparticules vers et dans les tissu osseux puis, en second lieu, avec l’objectif de mettre en
œuvre ces particules dans le cadre du traitement des métastases osseuses.
Ainsi, des nanoparticules multifonctionnelles ont été préparées par autoassemblage de
divers dérivés fonctionnalisés du poly(gamma-benzyl–L-glutamate), préalablement
synthétisés et caractérisés. Ces nanoparticules sont qualifiées de multifonctionnelles
puisqu’elles ont été dotées simultanément : (i) de molécules d’alendronate ou de poly(acide
glutamique), toutes les deux utilisées comme ligands de reconnaissance de l’os (notamment
via leurs interactions avec l’hydroxyapatite) et (ii) de poly(acide glutamique) à nouveau,
permettant l’association de quantités importantes de cisplatine (jusqu’à 6%) et un contrôle
prolongé dans le temps et très efficace de sa libération, déclenchée par un pH acide et/ou la
présence d’ions chlorure, (ii) de groupements PEG dans certains cas, destinés à diminuer les
phénomènes de reconnaissances non spécifiques dans l’organisme et d’élimination précoce
par le système réticuloendothélial, sans oublier (iv), les entités fluorescentes nécessaires à
l’imagerie des nanoparticules.
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Des études de distribution des différents types de nanoparticules préparées ont été menées
chez l’animal sain et ont montré des résultats encourageants puisque les nanoparticules
décorées par les ligands ostéotropes (alendronate ou poly(acide glutamique) ont été retrouvées
dans les tissus osseux et que leur rémanence a été mise en évidence jusqu’à 5 jours après leur
administration intraveineuse grâce à leur capacité d’interagir avec l’hydroxyapatite. Plus
précisément, des études histologiques ont permis d’établir que les nanoparticules portant de
l’alendronate en surface avaient un tropisme net pour les surfaces en cours de minéralisation
dans l’os, très certainement en raison de l’affinité vérifiée de ce biphosphonate pour
l’hydroxyapatite. Au total, ces nanoparticules possèdent donc un tropisme osseux intéressant
qui pourrait donc leur permettre de constituer localement un réservoir de principe actif et
qu’elles pourraient libérer progressivement dans cet environnement, en concentrations plus
élevées et soutenues dans le temps.
Clairement, la biodistribution de ces nanoparticules mériterait d’être mieux comprise,
notamment en utilisant des modèles animaux pathologiques, afin de pouvoir sélectionner les
nanoparticules possédant la microdistribution dans les tissus osseux la mieux adaptée à
l'application thérapeutique. De ce point de vue, le traitement des foyers métastatiques osseux,
fréquemment disséminés, constitue un objectif extrêmement intéressant au plan thérapeutique
mais qui nécessite aussi de poursuivre ces travaux afin de mieux comprendre les mécanismes
de la distribution dans les tissus osseux métastatiques. Il s’agira tout particulièrement de
mieux comprendre le trafic des particules dans ces tissus extrêmement complexes, leur
microdistribution, les modalités de leur éventuelle capture par les cellules tumorales, afin
d’être finalement capables de multifonctionnaliser efficacement ces nanoparticules et qu’elles
atteignent au mieux leur objectif.
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RESUME
Des nanoparticules multifonctionnelles polymères, préparées par auto-assemblage de plusieurs dérivés du
poly (L-glutamate de gamma-benzyle) (PBLG), ont été conçues afin d’assurer le ciblage des tissus osseux et
la libération contrôlée de molécules actives. Des propriétés d'attachement aux tissus osseux leur ont été
conférées par la présentation en surface de différents ligands ostéotropes, l'alendronate et l' acide
poly(glutamique), seuls ou en combinaison. Leur affinité pour les tissus osseux a été évaluée in vivo ainsi que
leur distribution fine dans ces tissus. Par ailleurs, des propriétés anticancéreux ont été conférées aux
nanoparticules grâce à un mécanisme originale d’association du cisplatin par complexation. Le procédé mis en
œuvre permet d’obtenir des cinétiques de libération très progressives de dérivés actifs du platine et déclenchée
par la présence des ions chlorure. Enfin, leur cytotoxicité a été mesurée. Cette stratégie constitue donc une
approche prometteuse en vue d’améliorer le traitement des métastases osseuses.
MOTS-CLES:: nanoparticules, ciblage de l'os, délivrance du principe actif, poly(glutamate de benzyle),
alendronate, poly(acide glutamique), cisplatine.
ABSTRACT
Multifunctional bone targeted polymeric nanoparticles prepared by self-assembly of several
poly(gamma-benzyl-L-glutamate) (PBLG) derivates have been developed. Their bone binding
properties were provided by two different osteotropic moieties, alendronate or/and poly(glutamic
acid) exposed on the nanoparticle surface. Their affinity for bone tissues has been evaluated in vitro,
ex vivo and in vivo, including their detailed distribution in bone tissues structures. Further, in view of bone
cancer therapeutics, nanoparticles were provided with anticancer properties thanks to the complexation of
cisplatin, which leaded to very well controlled release properties. Finally, cytotoxicity were studied.
Therefore, this strategy constitute a promising approach for the improvement of bone cancer therapeutics.
KEYWORDS: nanoparticles, bone targeting, drug delivery, poly(benzylglutamate), alendronate,
poly(glutamic acid), cisplatin, hydroxyapatite.
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